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ABSTRACT
Colorectal cancer represents the second most common form of malignancy in the 
Western World and with over 20,000 deaths in the UK each year this disease 
represents a major health problem. The genetic component of this malignant disease 
has received much attention over the past few decades and it is now becoming clear 
that development of colorectal cancer is a muti-stage process and that a number of 
genes are involved at various stages of the process.
Central to any malignant disease is the question of why the immune system allows a 
tumour to grow given that under the correct conditions the host immune system is 
capable of mounting an immune response. Central to the modulation of the immune 
response is a family of cytokines termed the tumour necrosis factors (TNFa, 
Lymphotoxin-a (LTa) and LT(3). Low levels of TNFa have been shown in 
colorectal tumours and it has been suggested that the constant exposure of tumour 
cells to low levels of TNFa may result in the cells becoming desensitised to the 
cytotoxic activity TNFa. Why such low levels of TNFa production should occur are 
however unclear.
Recently a number of polymorphisms have been identified within the region of the 
TNF genes and a number of studies have demonstrated a link between specific 
alleles of these polymorphisms and a number of autoimmune and non-autoimmune 
diseases and a possible genetic predisposition to either over- or under-production of 
TNFa.
The genotypes at six of the TNF polymorphism (TNFa, TNFc, TNFd, TNFe, -308 
TNFa, LTa Ncol) loci of 100 individuals with clinically defined colorectal cancer 
were compared to those of 115 normal non-malignant control individuals. The data 
presented in this thesis clearly identifies that alleles of the TNF polymorphisms are
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markers of not only the presence of colorectal cancer but also the aggressiveness of 
the disease. In particular alleles of the TNFa, TNFd and TNFe microsatellites seem 
to be associated with the presence (TNFa3 and al 1; TNFd3; TNFe3) or absence 
(TNFal, a5, a9 and al3; TNFe2) of colorectal cancer whilst an extended genotype 
involving the LTa Nco\ RFLP and the -308 TNFa RFLP may also be involved. 
Similar data is observed in a small study of 23 gastric adenocarcinoma patients.
An examination of the relationship between these polymorphisms and Dukes' 
staging also suggests that these markers may be involved in the aggressiveness of 
this malignant disease with alleles of both the RFLPs and the microsatellites 
showing associations with different Dukes' stages, whilst an association is also 
shown with the presence or absence of secondary disease.
It is still unclear whether these polymorphisms are functional or whether they 
represent markers for a near-by gene which is involved in the process of colorectal 
tumourigenesis. The possible reasons for these associations are discussed and future 
strategies for determining the role of these polymorphic markers in the 
carcinogenesis of colorectal cancer are suggested.
3
TABLE OF CONTENTS
ABSTRACT..............................................................................................................................................2
TABLE OF CONTENTS......................................................................................................................... 4
LIST OF TABLES....................................................................................................................................9
LIST OF FIGURES................................................................................................................................. 11
DECLARATION.................................................................................................................................... 17
DEDICATION........................................................................................................................................ 18
ACKNOWLEDGMENTS.......................................................................................................................19
INTRODUCTION.............................................................................................................................. 21
1.1 C o lo rec ta l  Ca n c e r ..................................................................................................................................................22
1.1.1 Epidemiology......................................................................................................................................................... 22
1.1.2 Aetiology.................................................................................................................................................................. 23
1.1.3 Clinical risk factors .............................................................................................................................................2 7
1.1.3.1 Genetic risk factors...........................................................................................................................27
1.1.3.2 Pre-existing disease..........................................................................................................................30
1.1.4 The progression to malignancy...................................................................................................................... 32
1.1.5 Screening for disease.......................................................................................................................................... 34
1.1.6 Biomarkers o f disease development and progression ........................................................................... 37
1.1.7 Molecular events in disease development..................................................................................................39
1.1.7.1 Normal mucosa to hyperproliferative epithelium............................................................................ 39
1.1.7.2 DNA hypomethylation.................................................................................................................... 42
1.1.7.3 The ras family of oncogenes........................................................................................................... 43
1.1.7.4 LOH on chromosome 18................................................................................................................. 44
1.1.7.5 p53 and the malignant cell cycle..................................................................................................... 44
1.1.7.6 nm23.................................................................................................................................................45
1.2 Th e  h o st  /  tu m o u r  in t e r a c t io n ..........................................................................................................................48
1.2.1 T-cells.................................................................................................................................................................... 49
4
1.2.2 Macrophages.................................................................................................................................. 50
1.2.3 The major histocompatibility complex.........................................................................................52
1.2.3.1 The MHC and malignancy.............................................................................................................. 53
1.3 T um o u r  N ecro sis Factor  a n d  Ly m ph o t o x in .............................................................................................. 57
1.3.1 Biological function......................................................................................................................... 57
1.3.2 TNF and human malignant disease..............................................................................................62
1.3.3 The TNF genes................................................................................................................................ 64
1.3.3.1 The TNF-a gene...............................................................................................................................64
1.3.3.2 The LT-a gene..................................................................................................................................65
1.3.3.3 The LT-(3 gene..................................................................................................................................65
1.3.4 Polymorphisms within the TNF locus...........................................................................................67
1.3.4.1 LT-a £coRI RFLP............................................................................................................................67
1.3.4.2 LT-a Ncol RFLP..............................................................................................................................68
1.3.4.3 -308 TNF-a RFLP............................................................................................................................70
1.3.4.4 The AspHl RFLP..............................................................................................................................71
1.3.4.5 -238 TNFa RFLP.............................................................................................................................71
1.3.4.6 TNF microsatellite polymorphisms................................................................................................. 72
1.3.5 TNF polymorphisms and human disease......................................................................................74
1.4 A im s o f  this p r o je c t ..................................................................................................................................................80
SUBJECTS...........................................................................................................................................82
2. l C o lo rectal  ad en o c ar cino m a  pa tien ts..........................................................................................................83
2.1.1 Epidemiology.................................................................................................................................. 83
2.1.2 Pathology........................................................................................................................................87
2.1.3 Survival analysis............................................................................................................................. 90
2.1.4 Metastatic disease..........................................................................................................................92
2 .2  Co ntrol  in d iv id u a l s .............................................................................................................................................93
MATERIALS AND METHODS........................................................................................................94
3.1 Iso lation  o f  genom ic  D N A ................................................................................................................................. 95
5
3.1.1 Collection o f peripheral venous blood.........................................................................................95
3.1.2 Isolation o f PBLs from peripheral venous blood.........................................................................96
3.1.3 Isolation o f full-length genomic DNA from whole cells..............................................................96
3.2  C o nfirm a tio n  of  integrity  of  geno m ic  D N A .............................................................................................. 98
3.3 G e n o t y pe  d eterm ination  at  th e  -308 T N F a  RFLP L o c u s ....................................................................98
3.3.1 PCR primers....................................................................................................................................98
3.3.2 PCR amplification..........................................................................................................................99
3.3.3 Nco-1 restriction endonuclease digestion o f PCR products......................................................100
3.3.4 Polyacrylamide gel electrophoresis (PAGE) o f PCR products............................................... 100
3 .4 Ge n o t y pe  d eterm ination  at  the L T a  N c o -I  RFLP L o c u s ..................................................................103
3.4.1 PCR primers..................................................................................................................................103
3.4.2 PCR Amplification........................................................................................................................ 103
3.4.3. Nco-I restriction endonuclease digestion o f PCR products.....................................................104
3.4.4 Agarose gel electrophoresis o f PCR products........................................................................... 104
3.5 G en o t y pe  determ ination  a t  the four  T N F m icrosatellite polym orphism  l o c i ..................107
3.5.1 PCR primers..................................................................................................................................107
3.5.2 PCR amplification........................................................................................................................107
3.5.3 Polyacrylamide gel electrophoresis o f micro satellite PCR products...................................... 108
3.5.3.1 Production o fy^2p labelled lObp ladder............................................................................... 108
3.5.3.2 Non-denaturing PAGE ............................................................................................................. 109
3.5.3.3 TNF allele sizes......................................................................................................................... 110
3 .6  Statistical  A n a l y sis ...............................................................................................................................................116
RESULTS...........................................................................................................................................117
4. l  A sso cia tio n s  betw een  alleles o f  po lym o rphism s a t  th e  T N F lo cus a n d  th e  pr ese n c e  o f
COLORECTAL CANCER........................................................................................................................................................ 118
4.1.1 -308 TNFa RFLP analysis.......................................................................................................... 118
4.1.2 LT-a Nco-I RFLP analysis.......................................................................................................... 124
4.1.3 TNF microsatellite polymorphism analysis............................................................................... 125
6
4.1.3.1 TNFa microsatellite 126
4.1.3.2 TNFc Microsatellite.......................................................................................................................127
4.1.3.3 TNFd microsatellite........................................................................................................................128
4.1.3.4 TNFe microsatellite........................................................................................................................129
4.1.3.5 Family analysis...............................................................................................................................130
4 .2  A sso cia tio n  betw een  alleles a t  th e  TN F lo cus a n d  D u k es' stag in g  in  colo rectal  
ADENOCARCINOMA............................................................................................................................................................. 143
4.2.1 -308 TNFa RFLP and Dukes' stage...........................................................................................143
4.2.2 LTa Nco-I RFLP and Dukes' stage............................................................................................144
4.2.3 TNF microsatellites and Dukes' stage........................................................................................145
4.2.3.1 TNFa microsatellite........................................................................................................................145
4.2.3.2 TNFc microsatellite........................................................................................................................145
4.2.3.3 TNFd microsatellite........................................................................................................................146
4.2.3.4 TNFe microsatellite........................................................................................................................147
4 .3 A sso cia tio n  betw een  alleles at  the  TNF locus a n d  d ise a se  prog ression  in co lo rectal
ADENOCARCINOMA..............................................................................................................................................................156
4.3.1 -308 TNFa RFLP and disease progression............................................................................... 156
4.3.2 LTa Nco-I RFLP and disease progression................................................................................ 157
4.3.3 TNF microsatellite polymorphisms and disease progression.................................................. 158
4.3.3.1 TNFa microsatellite........................................................................................................................158
4.3.3.2 TNFc microsatellite........................................................................................................................159
4.3.3.3 TNFd microsatellite........................................................................................................................159
4.3.3.4 TNFe microsatellite........................................................................................................................160
4 .4  E x t e n d e d  g eno ty pes o f th e  five  T N F p o l y m o r p h ism s ........................................................................169
4.4.1 Extended genotypes involving the two RFLPs........................................................................ 169
GASTRIC CANCER.........................................................................................................................174
5.1 Gastric  c a n c e r ..........................................................................................................................................................175
5 .2  G astric  ca nc er  a n d  T N F ......................................................................................................................................176
7
5 .3  TNFa p o ly m o r p h ism s .............................................................................................................................................176
5.4 L T a N C O l RFLP....................................................................................................................................177
DISCUSSION....................................................................................................................................188
REFERENCES................................................................................................................................. 215
8
LIST OF TABLES
Table 2.1. Clinical data on the 100 colorectal cancer patients examined in this study.
Page 84-6
Table 2.2. Comparison of the original Dukes' staging system for colorectal
Table 4.1 Complete genotypes at the six TNF polymorphisms in a) the colorectal
Table 4.2. Breakdown of the allelic frequencies and associated Chi-square values of 
the 13 TNFa alleles in the normal and colorectal cancer populations.
Page 137
Table 4.3. Breakdown of the allelic frequencies and associated Chi-square values of 
the 7 TNFd alleles in the normal and colorectal cancer populations.
Page 140
Table 4.4. Breakdown of the allelic frequencies and associated Chi-square values of 
the 3 TNFe alleles in the normal and colorectal cancer populations.
Page 142
Table 5.1 Complete genotypes at the TNFa microsatellite polymorphisms and the LT 
a  Ncol RFLP in the 25 gastric adenocarcinoma cancer patients. Page 179
Table 5.2. Breakdown of the allelic frequencies and associated Chi-square values of 
the 13 TNFa alleles in the normal and gastric cancer populations. Page 181
malignancy with the AJC/UICC classification system. Page 89
cancer patients, and b) the normal control individuals. Page 119-23
9
Table 5.3. Breakdown of the allelic frequencies and associated Chi-square values of 
the 13 TNFa alleles in the colorectal and gastric cancer populations.
Page 183
Table 6.1. Comparison of the allelic frequencies at the TNFa and TNFc loci of the 
normol control individuals with 6 published populations. Page 193
10
LIST OF FIGURES
Figure 1.1. Concordant increase in the incidence of colorectal cancer, at various 
sites, from the second to the seventh decade. Page 24
Figure 1.2. Diagramatic representation of the histological stages of the adeno­
carcinoma sequence of colorectal cancer. Page 33
Figure 1.3. Model of mutational events in the development and progression of 
colorectal carcinogenesis. Page 40
Figure 1.4. A number of factors can result in the inactivation of the normal function 
of p53 in malignant and premalignant cells. Page 46
Figure 1.5. Diagramatic representation of the TNF locus showing the position of the 
TNFa, LTa and LT(3 genes and there intron/exon arrangement and the relative 
position of the TNF polymorphisms. Page 66
Figure 2.1. Kaplan-Meir survival curve for 68 patients for whom complete follow up 
data was available. Page 91
Figure 3.1. Polyacrylamide gel showing the three possible -308 TNFa RFLP 
genotypes. Page 102
Figure 3.2. Agarose gel showing the three possible LTa AfccTRFLP genotypes.
Page 106
Figure 3.3. Section from a representative polyacrylamide gel showing a range of the 
possible TNFa microsatellite alleles. Page 112
11
Figure 3.4. Section from a representative polyacrylamide gel showing the two 
possible TNFc microsatellite alleles. Page 113
Figure 3.5. Section from a representative polyacrylamide gel showing a range of the 
possible TNFd microsatellite alleles. Page 114
Figure 3.6. Section from a representative polyacrylamide gel showing a range of the 
possible TNFe microsatellite alleles. Page 115
Figure 4.1. Histogram showing the distribution of the 3 possible -308 TNFa RFLP 
genotypes in the normal and colorectal cancer populations. Page 132
Figure 4.2. Histogram showing the distribution of the 2 possible -308 TNFa RFLP 
alleles in the normal and colorectal cancer populations. Page 133
Figure 4.3. Histogram showing the distribution of the 3 possible LTa Ncol RFLP 
genotypes in the normal and colorectal cancer populations. Page 134
Figure 4.4. Histogram showing the distribution of the 2 possible LTa Ncol RFLP 
alleles in the normal and colorectal cancer populations. Page 135
Figure 4.5. Histogram showing the distribution of the 13 TNFa microsatellite alleles 
in the normal and colorectal cancer populations. Page 136
Figure 4.6. Histogram showing the distribution of the 2 TNFc microsatellite alleles 
in the normal and colorectal cancer populations. Page 138
Figure 4.7. Histogram showing the distribution of the 7 TNFd microsatellite alleles 
in the normal and colorectal cancer populations. Page 139
12
Figure 4.8. Histogram showing the distribution of the 3 TNFe microsatellite alleles
in the normal and colorectal cancer populations. Page 141
Figure 4.9. Histogram showing the distribution of the three possible -308 TNFa 
RFLP haplotypes in the four Dukes' stage groups. Page 148
Figure 4.10. Histogram showing the distribution of the two possible -308 TNFa 
RFLP alleles in the four Dukes' stage groups. Page 149
Figure 4.11. Histogram showing the distribution of the three possible LTa Ncol 
RFLP haplotypes in the four Dukes' stage groups. Page 150
Figure 4.12. Histogram showing the distribution of the two possible LTa Ncol RFLP 
alleles in the four Dukes' stage groups. Page 151
Figure 4.13. Histogram showing the distribution of the 13 TNFa microsatellite 
alleles in the four Dukes' stage groups. Page 152
Figure 4.14. Histogram showing the distribution of the 2 TNFc microsatellite alleles 
in the four Dukes' stage groups. Page 153
Figure 4.15. Histogram showing the distribution of the 7 TNFd microsatellite alleles 
in the four Dukes' stage groups. Page 154
Figure 4.16. Histogram showing the distribution of the 3 TNFe microsatellite alleles 
in the four Dukes' stage groups. Page 155
13
Figure 4.17. Histogram showing the distribution of the three possible -308 TNFa
RFLP haplotypes in the 2 years clear and metastatic/local recurrence individuals.
Page 161
Figure 4.18. Histogram showing the distribution of the two possible -308 TNFa 
RFLP alleles in the 2 years clear and metastatic/local recurrence individuals.
Page 162
Figure 4.19. Histogram showing the distribution of the three possible LTa Ncol 
RFLP haplotypes in the 2 years clear and metastatic/local recurrence individuals.
Page 163
Figure 4.20. Histogram showing the distribution of the two possible LTa Ncol RFLP 
alleles in the 2 years clear and metastatic/local recurrence individuals.
Page 164
Figure 4.21. Histogram showing the distribution of the 13 possible TNFa 
microsatellite alleles in the 2 years clear and metastatic/local recurrence individuals.
Page 165
Figure 4.22. Histogram showing the distribution of the 2 possible TNFc 
microsatellite alleles in the 2 years clear and metastatic/local recurrence individuals.
Page 166
Figure 4.23. Histogram showing the distribution of the 7 possible TNFd 
microsatellite alleles in the 2 years clear and metastatic/local recurrence individuals.
Page 167
14
Figure 4.24. Histogram showing the distribution of the 3 possible TNFe 
microsatellite alleles in the 2 years clear and metastatic/local recurrence individuals.
Page 168
Figure 4.25. Histogram showing the distribution of the 4 possible extended RFLP 
haplotypes in the normal and colorectal cancer populations. Page 171
Figure 4.26. Histogram showing the distribution of the 4 possible extended RFLP 
haplotypes in the four Dukes' stage groups. Page 172
Figure 4.27. Histogram showing the distribution of the 4 possible extended RFLP 
haplotypes in the two years disease free clear and the metastatic/local recurrence 
individuals. Page 173
Figure 5.1. Histogram showing the distribution of the 13 TNFa microsatellite alleles 
in the normal and gastric cancer populations. Page 180
Figure 5.2. Histogram showing the distribution of the 13 TNFa microsatellite alleles 
in the colorectal and gastric cancer populations. Page 182
Figure 5.3. Histogram showing the distribution of the three possible LTa Ncol RFLP 
haplotypes in the normal and gastric cancer populations. Page 184
Figure 5.4. Histogram showing the distribution of the two possible LTa Ncol RFLP 
alleles in the normal and gastric cancer populations. Page 185
Figure 5.5. Histogram showing the distribution of the three possible LTa Ncol RFLP 
haplotypes in the colorectal and gastric cancer populations. Page 186
15
Figure 5.6. Histogram showing the distribution of the two possible LTa Ncol RFLP 
alleles in the colorectal and gastric cancer populations. Page 187
16
DECLARATION
I declare that the work presented within this thesis has been carried out solely by 
myself, except where indicated below. The sample preparation from the colorectal 
patients and the polymorphism analysis for both the normal control individuals and 
the colorectal cancer patients was carried out by myself.
The work of Hui- Hui Oh, who was an undergraduate student within the department 
of Surgery during the academic year 1993-1994, contributed significantly to the 
preliminary study of the polymorphisms in Gastric cancer, although this work was 
performed under my supervision.
The normal control DNA was a kind gift from I Galbraith of the Tissue Typing Unit, 
Glasgow Royal Infirmary.
17
DEDICATION
To Olive
18
ACKNOWLEDGMENTS
I am extremely grateful to Dr. Grant Gallagher, who both as a supervisor and friend 
has helped me through the three and a half years of my study for the Degree of PhD. 
His encouragement, support and enthusiasm for all of the work which his group 
undertakes has provided me with a stimulating environment in which to develop as 
an independent researcher, and my commitment to continued collaboration and 
friendship with Grant will continue for many years to come.
I am also grateful to the Head of the Department, namely Professor T.G. Cooke, who 
not only funded my three years of study, but also gave me much encouragment 
during my time within his unit.
I am also indebted to Professor C.S. McArdle, Professor of Surgery within Glasgow 
Royal Infirmary, who supplied me with the majority of patient material and data for 
this study.
I would like to take this opportunity to thank the clinical and nursing staff attached 
to the University Department of Surgery for there support. In particular I would like 
to thank Heather, Liz and Patricia, the units research nurses, who assisted with the 
collection of blood and follow up data from the cancer patients.
I must also thank the staff of the Tissue Typing Laboratory, within the Royal 
Infirmary, and in particular Ian Galbraith and Nancy Henderson who supplied me 
with the DNA samples for the normal control individuals.
I am also grateful for the support of all of the secretarial and academic staff within 
the University Department of Surgery, Glasgow Royal Infirmary. I especially wish 
to acknowledge the support of Mrs. W. Hughes who as the Professors secretary has
19
assisted me greatly during my time within the department. The assistance of Mr. R. 
Wright who as the laboratory manager helped me during those unexpected and often 
frought periods when materials failed to arrive, is also acknowledged.
I would like to thank the remainder of the Post Docs., laboratory staff and students - 
whose list of names would seem endless - who assisted me in numerous ways and 
who have made my time within the department a pleasure. I wish them all sucess in 
the future.
I would last but not least like to thank my family and my wife Olive for their support 
and encouragment.
20
Introduction
21
1.1 Colorectal Cancer
Recent data now supports the idea that colorectal cancer is a multi-stage disease, 
which primarily afflicts the elderly. A number of rare familial syndromes have 
recently been identified in which colorectal cancer presents atypically. Through the 
study of these familial syndromes, the genetic processes that cause colorectal 
adenocarcinoma have begun to be unravelled. The influence that the environment 
has on the development of colorectal cancer is also unclear; scientists have been 
unable to identify any major high risk factors to date. Therefore the story remains 
incomplete and new studies are required to examine the fine details of the 
interactions between the genetic and environmental factors.
1.1.1 Epidemiology
Colorectal cancer represents the second most common form of malignancy in the 
western world, second only to lung cancer, and represents a major health problem. 
Annually this disease accounts for over 20,000 deaths in the United Kingdom and 
over 70,000 deaths in the United States of America. Despite an improvement in the 
five-year survival rate over the last 50 years, the incidence of this disease has risen 
and thus the mortality rate has changed little in the same period of time.
The general population risk, in the UK, of developing colorectal cancer is calculated 
at 1 in 50 but a recent analysis of the Scottish incidence data demonstrate that the 
actual life time risk is 1 in 23 for men and 1 in 33 for women, with a mortality rate 
of 1 in 50 for men and 1 in 65 for women (Dunlop, MG., 1992). Almost 20% of all 
incidence of colorectal cancer can be attributed to a genetic predisposition and thus, 
the life-time risk for members of the families of these patients increases 
dramatically. The life time risk for an individual with one relative affected is 
estimated at 1 in 17, with one first-degree and one second-degree relative affected
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this rises to 1 in 12, with one relative under 45 years old affected the risk is 1 in 10, 
increasing to 1 in 6 with two first degree relatives affected and finally reaching 1 in 2 
in individuals with a dominant family history (Houlston, R. S., et. al., 1990).
The age-specific incidence of colorectal cancer rises progressively from the second 
to the seventh decade (Figure 1.1), whilst men have more incidence of cancer of the 
rectum than women the sexes are represented almost equally in respect to incidence 
of colorectal cancer (McArdle, C. S., et. al., 1990).
1.1,2 Aetiology
A number of recent studies have suggested that both genetic and environmental 
factors have an influence in the development of colorectal cancer. The role of 
genetic factors in the predisposition to colorectal cancer will be discussed later in 
this chapter, however it is worth noting that the interaction between environmental 
and genetic factors is unclear, but the influence of these factors is not mutually 
exclusive.
To date, no major risk factors have been identified which correlate with the 
development of colorectal cancer. Factors such as diet are becoming the major 
focus of attention as the general public are becoming aware of the influence of diet 
on the development of a number of common cancers. In countries where diseases 
associated with dietary factors are common, such as coronary heart disease, which is 
associated with a low fibre and a high fat diet, it has been shown that there is a 
concordant increase in the incidence of colorectal cancer (Trichopoulou, A., et. al., 
1992).
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Figure 1.1. Concordant increase in the incidence of colorectal cancer, 
at various sites, from the second to the seventh decade. (Adapted from 
McArdle, C.S. et. al., 1990).
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The hypothesis that fibre intake is associated with the incidence of colorectal cancer 
has been based on observations from studies in the third world; however, two major 
studies by Drasar and Irvine (1973) and Armstrong and Doll (1975) have found no 
association between dietary fibre and the geographical incidence of colorectal cancer. 
Burkitt, in 1971, first proposed that increased stool bulk produced by high fibre 
intake reduces the time taken for the bolus to transit through the large bowel and thus 
reducing the potential exposure time of colonic mucosa to carcinogens. To date, 
however, there is no clear evidence to suggest that high fibre content of the stool 
shortens large bowel transit time.
Increased intake of aryl-hydrocarbon hydroxylases has also been suggested as an 
alternative explanation to the fibre hypothesis. These compounds, such as those 
found in cabbage, have been shown to inactivate noxious chemicals in the gut, and 
in animal studies these same compounds have been found to prevent experimentally 
induced tumours in rats (Wattenberg, L. W., & Loub, W. D., 1978).
The opposing theory to the fibre hypothesis is that decreased animal fat intake may 
lessen the risk of developing colorectal cancer. A study, in 1975, by Wynder of the 
incidence of colorectal cancer in 21 countries showed a clear relationship between 
high animal-fat diets and the incidence of this disease. Wyder suggested that people 
with a high animal fat intake showed elevated levels of bile acids and neutral 
steroids in their faeces. Reddy and Wynder (1977) subsequently showed that 
colorectal cancer patients do have higher levels of bile acids and neutral steroids in 
their faeces than normal controls. The bacterium Clostridium paraputrificum 
present in faecal material is known to dehydrogenate steroids to produce carcinogens 
(Hill, M. J .,et. al., 1975).
A number of other studies have attempted to examine more precisely the agents 
which may cause the development of colorectal cancer.
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1). Fecapentaenes, are a family of potent mutagenic compounds detectable in 
human faeces. Levels of these compounds in the stool have been correlated 
with the incidence of colorectal cancer in high and low risk populations in 
South Africa (Ehrich, M., et. al., 1979), whilst Bruce (1987) has recently 
demonstrated a positive association with fecapentaene levels and the 
incidence of colon polyps.
2). 3-Ketosteroids, are a breakdown product of cholesterol and have been 
shown to induce mutagenesis in vitro and in vivo (Susuki, K., et. a l , 1986; 
Smith, LL., 1981).
3). Pyrolysis products, such as benzo[a]pyrene, are produced by frying meats at 
high temperatures and have been shown to be carcinogenic in experimental 
animals (Weisburger, J.H., et. al., 1986).
4). Bile acid, levels are directly related to the intake of fat and are thought to 
induce the proliferation of cells lining the gut lumen (Suzuki, K., and Bruce, 
WR., 1986).
5). Dietary calcium, has been shown in experimental animals, to be able to 
modulate the damage caused by free bile acids by forming insoluble bile salt 
complexes (Bird, RP., et. al., 1985). Garland et. al., (1985) have shown, in a 
19-year prospective study of men with colorectal cancer, that men tend to 
have a lower intake of calcium than do health control individuals.
6). Alkaline pH is known to allow the accumulation of abnormal levels of free 
bile acids and other potential mutagens (Van Dokkum, W., et. al., 1983). 
Studies in both South Africans and Americans have also revealed a
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correlation between high faecal pH and the incidence of colorectal cancer 
(Garland, C., et. al., 1985;Walker, ARP., and Walker, AJ., 1986).
The primary prevention of colorectal cancer is an attractive proposition and with the 
belief that diet forms such a major factor in the development of this malignant 
disease, a variety of dietary controlled intervention therapies have been postulated 
and tried in the clinic. A number of case control and population studies have shown 
that increased intake of fibre in the diet is of benefit, whilst studies in Nebraska, 
Hawaii, and of Seventh-Day Adventists have confirmed that increased dietary intake 
of fat and cholesterol can be associated with increased risk of colorectal cancer.
With the advent of numerous biomarkers of colorectal cancer, such as colonic-crypt­
cell proliferation index, faecal occult blood and the markers proposed in this study it 
is tempting to suggest that identification of those in the general population at 
elevated risk of developing colorectal cancer may benefit from a controlled "anti­
cancer" diet.
1.1.3 Clinical risk factors
A number of risk factors have now been determined for colorectal cancer and these 
can be split into two broad groups.
1.1.3.1 Genetic risk factors
Although there are a number of hereditable syndromes associated with high risk of 
colorectal cancer the two most important of these are familial adenomatous 
polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC).
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Although FAP is an extremely rare condition (accounting for only 1 % of colorectal 
cancer patients), without clinical treatment all affected individuals develop 
colorectal cancer (Lipkin, M., et. al., 1980). FAP affected individuals develop pan­
colonic adenomatous polyps which are not present at birth. By the age of 
adolescence more than 1,000 individual polyps may be seen throughout the entire 
length of the colon.
The gene responsible for the development of FAP, and also the related Gardner's 
syndrome (Gardner's syndrome consists of polyposis coli, osteomas and desmoid 
tumours), was initially localised to human chromosome 5q (Herrera, L., et. al.,
1986), and subsequent linkage analysis by Vogelstein and colleagues (1988) 
confirmed this localisation. Initial analysis of this region on chromosome 5q showed 
four genes within this region (FER, MCC, TB2 and APC). Analysis of the sequence 
of the FER gene has now shown that it produces a 94-kDa polypeptide that exhibits 
protein tyrosine kinase activity (Hao, Q.L., et. al., 1989; Feller, S.M. and Wong, 
T.W., 1992).
The "mutated in colorectal carcinoma" (MCC), TB2 and the adenomatous polyposis 
coli (APC) genes all map within a 200 kb fragment of 5q21. The MCC gene encodes 
a 829 amino acid polypeptide with a 19-residue stretch showing homology to the G 
protein-coupled m3 muscarinic acetylcholine receptor (Groden, J., et. al., 1991).
This region also exhibits putative sequences which specify G-protein specificity. 
MCC is therefore thought to be involved in the Ca++ / phosphoinositide cell 
signalling pathway, possibly as a negative receptor. Initial data on the MCC gene 
showed the existence of an number of point mutations within this gene resulting in 
non-conservative amino acid changes (Kinzler, K.W. 1991). Analysis of 90 FAP 
kindreds however failed to reveal any germline mutations.
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The APC gene is predicted to encode for a 2843 amino acid polypeptide of which 
25% of the N-terminus shows sequence homology to myosins, intermediate 
filaments, and plakoglobin (the cytoplasmic component of gap junctions) and 75% 
of the C-terminus shows short region homology with the yeast RA12 gene which is 
thought to play a role in ras regulation (Peifer, M., & Weischaus, E., 1990; Fukui, 
Y., et. a l,  1989). Loss of heterozygosity (LOH) studies have demonstrated a loss of 
5q in 20% - 50% of patients with sporadic colorectal cancer (Solomon, E., et. al., 
1987; Vogelstein, B., et. a l, 1988; Miki, Y., et. al., 1991). Studies of FAP patients 
have failed to demonstrate allelic loss of the APC gene (Okamoto, M., et. a l, 1988; 
Vogelstein, B., et. a l, 1988) suggesting that a single gene mutation may be enough 
to allow polyp development, whilst loss of the normal allele is required for 
carcinoma formation.
Two other forms of inherited colorectal cancer have recently been identified. These 
syndromes (termed Lynch type I and Lynch type II) are collectively referred to as 
hereditary nonpolyposis colorectal cancer (HNPCC; Fitzgibbons, R.J., et. a l, 1987). 
HNPCC accounts for between 4% and 13% of colorectal cancer cases (FAP accounts 
for approximately 1%). It is impossible to clinically distinguish the difference 
between HNPCC patients and cases of sporadic colorectal cancer as neither show the 
pan-colonic polyposis seen in FAP. HNPCC families are generally defined as those 
in which a minimum of three relatives in two generations have been diagnosed with 
colorectal cancer and with at least one of these relatives having been first diagnosed 
at less than 50 years of age (Vasen, H.F.A., et. a l, 1991). It has also been 
demonstrated that as well as malignancy of the colon, HNPCC patients can have 
malignancies of the endometrium, stomach, biliopancreatic system and urinary tract 
(Lynch, HT, et. a l 1991).
Genetic changes in the tumour cells of patients with HNPCC are characterised by 
instability of short di- and tri-nucleotide repeats, and the accumulation of a large
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number of other mutations throughout the cells genome (Aaltonen, L.A., et. al.,
1993; Thibodeau, S.N., et. al., 1993; Ionov, Y., et. al., 1993). Initial linkage analysis 
mapped the gene predisposing to HNPCC to human chromosome 2 (Peltomaki, P., 
et. al., 1993). Analysis of the tumours from HNPCC patients demonstrated that 
there was no loss of heterozygosity in 14 tumours examined and only 1 of 46 
tumours from individuals with sporadic colorectal cancer showed loss of 
heterozygosity. The gene (hMSH2) on chromosome 2pl6-15, responsible for the 
predisposition to HNPCC, has now been characterised and shows a high degree of 
homology to the MSH2 gene in yeast. In yeast, mutations in either the MLH1,
MSH2 or PMS1 genes (which are involved in DNA mismatch repair) results in a 
100- to 700-fold increase in genome instability (Strand, M., et. al., 1993).
More recently a number of other human mismatch repair homologues have been 
identified. Theses include a gene located on chromosome 3p21.3-23 which shows a 
high degree of homology with the yeast gene MLH1, and has thus been termed 
hMLHl. Chromosome 3-linked HNPCC shows the characteristic microsatellite 
instability of chromosome 2-linked HNPCC (Lindblom, A., et. al., 1993). Mutations 
in the hMLHl gene have now been identified and in particular the H6 tumour cell 
line, which has no mismatch repair activity, has no wild-type hMLHl(Papadopoulos, 
N., et. al., 1994).
1.1.3.2 Pre-existing disease
A number of diseases are now shown to be associated with increased risk of 
developing colorectal cancer. In particular, in patients with an inflammatory bowel 
disease there is a well recognised 30-fold increase in their risk of developing 
colorectal cancer.
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Specific inflammatory bowel diseases, such as ulcerative colitis (UC), show an 
increased risk of developing colorectal malignant disease concordant with the level 
of bowel involvement, age of onset, disease severity and duration of disease (Mir- 
Modjlessi, S.H., et. al., 1986). Although only about 1% of patients diagnosed with 
colorectal cancer have a history of inflammatory bowel disease, Ekbom et. al. (1990) 
found that the incidence of colorectal cancer in patients with UC was 5.7 times 
greater than the expected general population risk.
Crohn's disease is also known to confer an increase in risk of developing colorectal 
cancer (Hamilton, S.R., 1989). Although Crohn's disease is not associated with 
colorectal cancer as frequently as ulcerative colitis, atypical presentations of bowel 
adenocarcinomas are often seen at a younger than normal age (Kirsner, J.B. & 
Shorter, R.G., 1987). The bowel tumours in these patients may arise at the site of 
the inflammatory bowel disease or may occur at sites of previous bowel surgery 
(Weedon, D.D., et. al., 1973).
People who have previously presented with malignant disease of the large bowel are 
also at an elevated risk of developing a second colorectal tumour. The possibility of 
developing a second primary tumour either coincident with the initial tumour or 
subsequently is increased at least three-fold (Morson, BC., 1976). It is interesting 
that clustering of adenocarcinomas of the breast, ovary, colon and rectum in the 
same patients has also been identified and are similar to those patterns observed in 
familial adenocarcinoma syndromes (Burbank, F., 1971).
Previous surgical interventions such as cholecystectomy and ureterosigmoidostomy 
have been reported to have an increased risk of developing large bowel cancers, 
though the mechanism by which this may occur is unclear.
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It is now well recognised that there is a progression from adenoma to carcinoma 
involved in the development of cancers of the large bowel (See later). Large villous 
adenomas are 8 to 10 times more likely to contain malignant foci than small tubular 
adenomas (Muto, T., et. a l, 1975) and as expected the larger the number of 
adenomas a patient has the greater the risk of subsequently developing colorectal 
cancer (McDermott, F.T., et. a l, 1981).
1.1.4 The progression to malignancy
The hypothesis that there is a progressive shift from a non-malignant disease, 
normally a neoplastic polyp or adenoma, to the development of a malignant 
adenocarcinoma of the colon and rectum was first suggested by Morson (Morson, 
B.C., 1974), and the idea of an "adenoma-carcinoma sequence" is now widely 
accepted. It is proposed that normal intestinal epithelial cells pass through three 
histologically identifiable, precancerous stages between normal epithelium and 
histological colorectal cancer (Figure 1.2).
A histological examination of 1961 colorectal tumours by Muto and colleagues 
(Muto, T., Bussey, H.J.R., Morson, B.C., 1975) showed that over 14% of the 
tumours had some degree of non-malignant adenomatous tissue present. In the same 
study the authors report that 60% of the tumours confined to within the submucosa 
had an adenomatous component, whilst this was reduced to 20% in those infiltrating 
into the bowel wall, and only 7% in tumours infiltrating into the extramural fat. 
Although this study does not, in itself, provide overwhelming evidence for the 
adenoma-carcinoma sequence it does suggest that a number of adenocarcinomas do 
develop from a premalignant stage. Data from autopsy studies in the USA, where 
there is a high incidence of colorectal cancer, have shown that at over the age of 
fifty-five, 58% of males and 47% of females have one or more adenoma present at 
the time of death.
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Figure 1.2. Diagramatic representation of the histological stages of 
the adeno-carcinoma sequence of colorectal cancer. Arrows represent 
the flow through increasing malignant potential. (Adapted from, 
Introduction to the cellular & molecular biology of cancer: second edition. 
Ed. Franks, LM., and Teich, NM., Oxford University Press, 1991).
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It is clear, however, that the presence of an adenoma is not necessarily a 
predisposing factor to the development of colorectal cancer. The histological type, 
size of the adenoma, degree of dysplasia and number of polyps all contribute to the 
malignant potential associated with adenomas. Between 60%-70% of adenomas are 
tubular, 10% are villous and 20%-30% are tubulovillous upon histological 
examination. Muto et. al. (1977) report that the occurrence of malignancy in tubular 
adenomas is 5%, this figure rises to 22% for the intermediary tubulovillous 
adenomas and rises to a high of 40% in villous adenomas. Malignant change is also 
more common in larger villous adenomas. Muto et. al. (1977) as well as reporting 
the association with histological type of adenoma, also reported an association with 
size of adenoma. The authors reported that of adenomas less than 1 cm in diameter, 
over 1% showed any sign of malignancy, whilst over 45% of those over 2 cm in 
diameter had a malignant component. It is interesting that a recent study by De 
Benedetti showed a higher level of APC mutations in tubulovillous and villous 
adenomas than in tubular adenomas (De Benedetti, L., et. al., 1994).
Although both histology and size of an adenoma correlate with malignant potential, 
the degree of epithelial dysplasia seen within adenomas has also been shown to 
correlate with the malignant potential. Studies have also correlated the number of 
polyps present within the bowel with the development of malignant disease. The 
risk of developing a subsequent adenoma a number of years after the initial detection 
of the first adenoma rises with the number of adenomas initially detected, whilst the 
risk of developing malignant disease rises concurrently (Bond, J.H., 1993).
1.1.5 Screening for disease
It is clear that there is an necessity to try and develop techniques by which the 
premalignant stages of the adenoma to carcinoma process of colorectal 
tumourigenesis can be detected and it is now widely accepted by clinicians that
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detecting premalignant changes in the colon and rectum can facilitate the 
improvement of the mortality rate of colorectal cancer.
There are a number of methods available for the clinical screening of patients at risk 
from developing colorectal cancer. The classic physical examinations such as 
'digital rectal examination', rigid sigmoidoscopy or flexible sigmoidoscopy result in 
a level of discomfort for the patients and also vary in their level of sensitivity.
Digital rectal examination has been part of the normal physical examination in a 
number of countries for sometime, however the sensitivity of this technique is low.
Rigid sigmoidoscopy remains the least popular examination with patients, and even 
though it is an inexpensive procedure its usefulness is severely limited to the short 
length of the bowel which can be covered. However a study by Hertz et. al. (1960) 
showed that of 26,000 patients over the age of 45 screened, 58 had asymptomatic 
cancer which resulted in a cure rate of 90%.
Flexible sigmoidoscopy remains the standard test for the examination of the bowel 
for the presence of asymptomatic or pre- malignant disease. The longest of the 
scopes, of about 45cm, will allow the easy detection of almost 65% of neoplastic 
polyps and small cancers. Atkin et. al. (1993) suggest that once-only sigmoidoscopy 
between the age of 55-60 years could prevent approximately 19% of colorectal 
cancers in this age group in the UK.
Recently there has been a search for more sensitive techniques for the detection of 
the premalignant stages in the development of colorectal cancer. One such 
technique which may facilitate this is the process of detection of "aberrant mucosal 
crypt cell production rate" (CCPR; Rooney, P.S., et. al, 1993). This process 
involves the examination of non-neoplastic rectal biopsy material taken during
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endoscopy. Biopsy material is incubated, in vitro, in vincristine to induce metaphase 
arrest. The resultant samples are then examined to determine the number of crypts 
in metaphase arrest and these figures compared with biopsy samples from either 
adenoma negative controls or from a group of vegetarian control volunteers. Rooney 
et. a l showed a clear association with high numbers of crypt cells in metaphase in 
patients with adenomas compared to both the normal and vegetarian controls.
At the opposite end of the scale is the non-invasive technique of faecal occult blood 
(FOB) testing or "Haemoccult". This process involves the sampling of faecal 
material to detect small quantities of blood that could be predictive of neoplastic or 
malignant changes in the bowel, and is based upon three systems.
1) Guaiac impregnated paper slides which detects the presence of 
haemoglobin in the faecal material by the colourimetric determination of its 
peroxidase activity (Mandel, J.S., et. al. 1989).
2) The HemoQuant test (SmithKline Diagnostics) which detects faecal 
haemoglobin content by the conversion of heme to fluorescent porphyrins 
(Ahlquist, D.A., et. al. 1984).
3) The immunodetection of faecal haemoglobin using an antibody based 
system (Saito, H., et. al. 1985).
The standard Haemoccult test fails to detect occult blood when it should in 1 in 
every 5 test performed (a false negative rate of 20%). This failure rate can be 
improved by increasing the number of tests a patient is given but this increase in 
sensitivity produces a highly unacceptable high false positive rate. There is still no 
conclusive evidence to support the use of this technique as a routine method of 
screening for colorectal cancer.
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1.1,6 Biomarkers of disease development and progression
Of all the identifiable biomarkers of malignant disease several of these antigens have 
been suggested as useful markers in colorectal cancer. In 1969 it was first shown 
that CEA was elevated in the plasma of 35 out of 36 patients with colorectal cancer 
and that the plasma titre fell after "successful" surgery whilst levels equivalent to 
normal were found in patients bearing non-colorectal tumours or in patients with 
benign disease (Thompson, et. al. 1969). Carcinoembrionic antigen (CEA
is a 200 kD glycoprotein expressed on the cell-surface) was originally identified in 
the foetal liver, intestine and pancreas during the first six months of development, 
however, it is now clear that CEA can be found, in adults, in malignant diseases of 
the liver, colon and pancreas but cannot be found in normal or benign tissues.
The largest study of this antigen to date has been a cumulative study of 35,000 
samples from 10,000 patients and controls (Hansen, H.J., et. al. 1974). In this study, 
of 1425 non-smoking healthy individuals, 98.7% had CEA levels below the value of 
5.0 ng/ml, however of 857 normals with a history of smoking, CEA was elevated in 
33%. In a further 576 patients who had no clinical evidence of cancer, 23 were 
subsequently demonstrated to have colorectal cancer by barium enema and CEA 
levels of greater than 2.5 ng/ml were found in 18 of the 23. The authors also 
suggesting a correlation with CEA and stage of disease. CEA levels of greater than 
5 ng/ml was found in 4% of Dukes' A disease patients, 25% of Dukes' B disease 
patients, 45% of Dukes' C disease patients and 65% of patients with clinically 
detectable metastatic disease at time of initial surgery (Hansen, H.J., et. al. 1974). It 
is clear that CEA lacks the specificity required to be used successfully in screening 
or diagnosis of colorectal cancer since it lacks both disease and stage specificity; 
elevated levels of CEA have also been found to have varying degrees of usefulness 
in breast cancer and in one study CEA was seen to be elevated in 60% of women
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with metastatic breast cancer (Schwartz, M.K., 1987). The lack of specificity is 
confirmed by Sandler et. al. (1984) who suggest a false-negative rate of 24%.
The mucin-type glycoproteins have been suggested to have limited use in the 
screening for colorectal cancer. These antigens include CA 19-9, CA 195 and TAG 
72. CA 19-9 is derived from a colon tumour cell line, but is not elevated in the 
serum of many patients with colorectal cancer. In one study CA 19-9 was found to 
be elevated in only 42% of colorectal cancer patients compared to a 72% rise in 
CEA (Koprowski, H., et. al. 1981). Levels of the CA 195 antigen (an antigen 
similar to CA 19-9) have been shown to be elevated in 72% of patients with active 
colorectal cancer compared with 57% with raised CEA and 61% with raised CA 19- 
9. The final antigen in this family, termed TAG 72, is a high molecular weight 
glycoprotein and is reported to be elevated in 54% of patients with advanced colon 
cancer and 55% of patients with advanced gastric cancer.
The clinical usefulness of these antigens in the analysis of disease development and 
progression is questionable. A number of studies have used CEA levels to direct 
surgery for local recurrence. In a retrospective study of 22 patients with elevated 
CEA, 86% of the patients were observed to have recurrent disease at laparotomy, 
however only 27% of these patients had a resectable tumour (Martin, E.W., et. a l, 
1977). In all the studies which have examined the usefulness of CEA in directing 
surgery to recurrent disease, tumour was found in between 78%-100% of patients, 
however like the study of Martin et. al., the resectability rate in these patients is low 
suggesting that CEA may be a marker for late disease, at least in recurrent tumours. 
The specificity of the mucin-type glycoproteins is also questionable. Studies have 
shown that both CA 19-9 and CA 195 are elevated in individuals with benign 
disease.
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1.1.7 Molecular events in disease development
The molecular changes involved in the development of colorectal cancer are 
complex, and involve the alteration of the normal balance between oncogenes and 
tumour suppressor genes. Although its is becoming clear that these genetic changes 
are fundamental to the development of tumours, its is still accepted that these 
changes cannot be considered in isolation of environmental factors. It is now widely 
accepted that most tumours arise due to a combination of both environmental and 
genetic factors.
A number of genes have been now been identified that play a role in the 
development of both sporadic and familial colorectal cancer. Figure 1.3 shows a 
diagramatic representation of the mutational events that occur during the 
development of colorectal cancer.
1.1.7.1 Normal mucosa to hyperproliferative epithelium
The earliest event in the development of any tumour is a change which allows 
normal cells to escape from the cell-cycle to become hyperproliferative. The normal 
cell cycle is now well characterised, however the reason why premalignant cells 
escape the stringent control of the cell cycle is unclear.
Genetic instability is a common factor to both solid and leukaemic tumours. The 
recent identification of alterations in a number mismatch repair genes in both 
sporadic and hereditary non-polyposis colorectal cancer (HNPCC), suggests that 
early changes in genomic stability may be primary in the development of cancer. In 
an article in Nature, which was published concordantly with the reports describing 
the initial identification of mismatch repair errors in HNPCC, Vogelstein suggested
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Figure 1.3. Model of mutational events in the development and 
progression of colorectal carcinogenesis. (Adapted from Fearon and 
Vogelstein, 1990).
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that alterations in the function of mismatch repair genes could result in the genetic 
changes commonly associated with colorectal tumourigenesis; such as those seen in 
APC. (For a fuller description of the HNPCC associated genes please see section 
1.1.3.1.)
A number of other genes have been shown to be altered at this early stage of tumour 
development. The myc gene, located on chromosome 8q24, is the cellular homolog 
of the transformation gene of avian myeloblastosis virus. This gene produces two 
polypeptides of 62 kD and 64 kD in size, and although the natural function of these 
two polypeptides is unknown, structure analysis has implicated them either in the 
regulation of transcription or as accessory factors for DNA polymerase. Increased 
levels of both myc mRNA and the p62 and p64 peptides have been identified in 
colorectal cancer (Finley, G.G., et. a l, 1989). It has now been shown that up to 50% 
of colorectal tumours with elevated myc expression have an associated deletion 
within the region of APC, whilst those tumours with no APC deletions show no 
overexpression of myc (Erisman , M.D., 1989). The reason for this interaction 
between myc and APC is unknown. The result of expression of myc by cells is now 
known to be dependent on the coexistence of growth factors within the cell's 
microenvironment. If growth factors are present within the cells microenvironment 
then the cell is prevented from entering the Go phase of the cell cycle and continues 
to proliferate, however if growth factors are absent, then the cell selects a path 
towards programmed cell death.
The adenomatous polyposis coli (APC) gene has been widely studied in colorectal 
cancer due to its recent identification as the cause of FAP. Recent studies have 
shown that alterations in APC are an early event in the development of the majority 
of colorectal cancers, with recent LOH studies demonstrating a loss of 5q in between 
20% and 50% of patients with sporadic colorectal cancer (Solomon, E .,et. al., 1987;
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Vogelstein, B., et. al., 1988; Miki, Y., et. al., 1991). For a more detailed description 
of FAP and APC please see section 1.1.3.1 of this thesis.
The MCC gene is also located on chromosome 5q21. This gene was initially 
thought to be the gene responsible for FAP (Kinzler, K.W., et. al., 1991), however it 
is now accepted that there are no genetic mutations in MCC associated with FAP. 
Studies of MCC in sporadic colorectal cancer have shown that the gene is mutated in 
at least 15% of patients (Nishisho, L., et. al., 1991), whilst LOH studies have 
suggested that allelic loss occurs in over 40% of patients (Ashton-Rickardt, P.G., et. 
al., 1991; Miki, Y., et. al., 1991). The role this loss plays in colorectal 
tumourigenesis is unclear as all three of these studies were performed prior to the 
identification of APC within such a close proximity, and it is possible that deletions 
within this region cover both APC and MCC.
1.1.7.2 DNA hypomethvlation
Methylation of genomic DNA is a normal event in both prokaryotes and eukaryotes 
where it appears to be involved in the control of gene expression and chromosome 
condensation. The methylation status of DNA from non-malignant polyps and 
colorectal adenocarcinoma specimens has been shown to differ from that observed in 
normal colonic mucosa. A decreased or hypo-methylation status has been observed 
in both colonic polyps and adenocarcinomas suggesting that this reduction in DNA 
methylation is an early event which precedes the development of malignancy (Goelz, 
S.E., et. al., 1985). It is possible that loss of methylation of specific genes such as c- 
erbB-2 and myc may confer growth advantage to preneoplastic cells (Holzmann, K., 
et. al., 1992; Sharrad, R.M., et. al. 1992).
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1.1.7,3 The ras family of oncogenes
Numerous studies have examined the role of ras expression in colorectal cancer.
The ras family consists of three genes (H-ras, K-ras and N-ras) which encode a 
series of 21 kD guanine nucleotide-binding proteins which are expressed on the 
cytoplasmic side of the cell membrane (p21ra5). The most common alterations of 
ras in colorectal cancer involve the K-ras gene, whilst H-ras and N-ras mutations 
are rare (Bos, J.L., 1989). Vogelstein et. al. (1988) reported that ras mutations occur 
in only 9% of adenomas of less than 1 cm in size, compared to 58% in larger 
adenomas and 41% in primary adenocarcinomas. Mutations in ras have been 
reported to be similar in both sporadic adenomas and tumours and in adenomas and 
tumours of patients with FAP (Sasaki, M., 1990) suggesting that ras mutations may 
indicate a common pathway of development of both sporadic and familial colorectal 
cancer.
Recently attempts have been made to associate ras mutations with stage of disease. 
In 1991, Oudejans et. al., reported an increase in mutations of both K-ras and N-ras 
in patients with either liver or lung metastases (50% and 57% respectively) whilst 
only 37% of patients with "non-metastatic" Dukes' B tumours showed mutations in 
ras. Recently Moerkerk et. al. (1994) have reported a difference in the type of 
mutation in codon 12 of K-ras and the association with metastatic propensity of 
Dukes' B and C colorectal tumours.
Although gene transfer studies have failed to show that mutations in ras alone are 
capable of inducing a complete transformed phenotype (Sager, R., et. al., 1983) there 
is some evidence to suggest that ras can result in partial transformation and an 
increase in proliferation of primary epithelial cells (Bums, J.S., et. al., 1993).
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1.1.7.4 LOH on chromosome 18
The putative tumour suppressor gene termed DCC ("deleted in colorectal cancer") 
has now been localised to chromosome 18q. Allelic loss of DCC has been shown to 
be a rare event in small early adenomas, but is observed in over 50% of late stage 
adenomas (Vogelstein, B., et a l , 1988) and over 70% of colorectal 
adenocarcinomas (Vogelstein, B., et al., 1989) and is thus thought to be a late event 
in colorectal tumourigenesis (Fearon, E.R., et a l , 1990). The DCC gene encodes a 
transmembrane protein which shows sequence homology with members of the Ig 
supergene family, and in particular the neural cell adhesion molecule (N-CAM; 
Edelman, G., 1988). Studies using antisense DCC mRNA, transfected rat fibroblasts 
have shown that if expression of DCC is inhibited then cells can acquire a 
tumourigenic phenotype, but also grow in vitro as suspension rather than as a 
monolayer (Narayanan, R., et. al, 1992). This suggested that DCC is involved in 
cell-matrix interactions rather than cell-cell adhesion. The loss of DCC may be 
important in promoting a more invasive phenotype in an already transformed cell.
1.1.7.5 p53 and the malignant cell cycle
The gene for p53 maps to human chromosome 17pl3.1. The gene encodes a 53 kD 
nuclear protein which shows almost pan-expression and shows a high level of 
conservation across species (Jenkins, J.R., et a l 1988). p53 was originally thought 
to be the product of a dominant oncogene due to its ability to transform a number of 
cell lines (Jenkins, J.R., et a l, 1984). Recent evidence has suggested that the initial 
transformation studies were flawed in that they used mutant p53 clones rather than 
the wild-type. It is thought that, in some cases, mutant p53 is capable of binding to 
wild type p53 and thus inactivating the wild-type molecule. A number of recent 
studies have now shown that p53 can revert transformed human cancer cell lines,
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including colon and bladder, to an untransformed phenotype (Baker, S.J., et. al., 
1990; Chen, P.L., et. al., 1990).
The function of p53 is not entirely clear. Emerging evidence suggests that p53 may 
be be important in the control of the cell-cycle of stressed cells (Lane, DP., 1992) 
and that p53 may function to control the passage from Gj to S-phase in cells with 
damaged DNA (Hartwell, L., 1992; Lane, DP., 1992). Expression of p53 in cells 
with damaged DNA may allow the cell time to repair their DNA by causing cell- 
cycle arrest, if this repair subsequently fails then the cell can be pushed into 
apoptosis (Lane, D.P., 1992). A number of factors can result in the disruption of the 
normal function of wild-type p53. Figure 1.4 shows a diagramatic representation of 
the ways in which such inactivation may occur. The most common form of mutation 
in human tumours, including colorectal tumours, is a missense mutation in one 
allele of p53 followed by a deletion of the second allele (Baker, S.J., et. al. 1990).
A number of studies have attempted to correlate p53 overexpression with disease 
prognosis in colorectal cancer. Starzynska et. al., (1992) report a significant 
association with p53 overexpression and clinical outcome with a progressive 
increase in levels of p53 associated with Dukes' staging and an association between 
high levels of p53 and early reccurence of disease. Remvikos et. al. (1992) also 
report an association between p53 and clinical outcome but failed to show any 
association with Dukes' staging.
1.1.7.6 nm23
Reduced expression of the nm23 gene has been identified in metastatic breast cancer 
and has been associated with a poor prognosis (Barnes, R., et. al., 1991). The gene 
encoding nm23 has now been mapped to human chromosome 17p21 and encodes a 
nucleoside diphosphate (NDP) kinase (Gilles, A-M., et. al., 1991) which is thought
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Figure 1.4. A number of factors can result in the inactivation of the 
normal function of p53 in malignant and premalignant cells.
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to play an important role in the formation of p2 1 ra*yGTP complexes (Ruggieri, R., 
and McCormick, F., 1991).
Reduced expression has also been observed in colorectal cancer. Cohn et. al. (1991) 
have reported an association with allelic loss of nm23-Hl and distant metastases in 
colorectal cancer. In this study 73% of patients with deletions in nm23 had clinical 
evidence of matastases after 25 months of follow-up, compared to only 20% who 
had no evidence of nm23 deletions. The true role of nm23 in metastasis is still 
unclear, however studies have shown that transfection of nm23 results in the loss of 
metastatic phenotype in a number of animal models (Leone, A., et. a l, 1991).
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1.2 The host / tumour interaction
In parallel to the expansion of the tumour cell population, solid tumours develop a 
stromal component, which varies in proportion with the malignant cells depending 
on the tumour type. This stromal component consists of new blood vessels, a 
fibrotic reaction and an inflammatory cell infiltrate (Dvorak, H.F., 1986). 
Interactions between the stromal component and the malignant cells form an 
important part of the modulation of the growth of solid tumours.
It has always been difficult to define the role which the host immune system plays in 
the prevention, control and eradication of malignant cells. Numerous studies, 
including the transplantation of chemical induced syngeneic rodent tumours (Foley, 
E.J., 1953; Prehn, R.T., & Main, J.M., 1957), have demonstrated the ability of the 
host immune system to recognize and reject malignant cells. Burnet's theory of 
immunological surveillance (Burnet, F.M., 1970) proposed that a major function of 
the immune system was the detection and elimination of cells which became 
disparate from the host due to some form of somatic mutation (e.g. tumour cells). 
Rygaard and Povlsen (1976), however, demonstrated that athymic nude mice did not 
develop spontaneous tumours at a higher rate than immunologically intact mice, and 
Prehn (1976) demonstrated that in some cases host T-cells could be seen to 
potentiate the growth of immunogenic transplanted syngeneic tumours. These 
studies provided a conflicting view of the role of the host immune system in the host 
/ tumour interaction in the 1970s.
With the advent of advanced techniques in molecular and cellular immunology a 
number of the initial questions regarding the host / tumour interaction have been 
answered. Burnet's theory of immune surveillence now seems at least in part to be 
correct. It is now clear that immune system evolved to provide a mechanism for the 
control of viral infections and that T-cells are central to this response (Zinkernagel,
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R.M., & Doherty, P.C., 1979). T-cells, however, still have an important role in the 
control of malignant disease. Epstein-Barr virus-induced (EBV) B-cell lymphomas 
are seen with increased frequency in patients that have undergone specific T-cell 
depletion (Moss D.J., et. al. 1977; Thorley-Lawson, D.A., et. al. 1977; Thorley- 
Lawson D.A., et. al. 1980) whilst UV-induced squamous cell cancers occur with 
high frequency in renal transplant patients (Hardie, I.R., et. a l 1980) suggesting that 
in a number of cases T-cells can control the development of a malignant phenotype.
1.2.1 T-cells
It is clear that tumour cells can express potentially immunogenic antigens on their 
surface in that it is possible to direct an immune response against tumours by the in 
vitro enrichment of lymphocytes (see below). The failure of T-cells to detect these 
determinants is probably due to an ineffective antigen presentation mechanism either 
by the tumour cells themselves or by professional antigen presenting cells (APC) 
which results in T-cell anergy by failing to provide the required costimulatory 
signals (Mueller,D.L., et. al., 1989). Others have suggested that rapidly proliferating 
tumours result in the induction of a suppressor T-cell phenotype (Fujimoto, S., et. 
al., 1976; Gorelik, E., 1983), however the idea of a suppressor T-cell subset has lost 
favour over the last few years. A final hypothesis as to the inability of T-cells to 
respond to tumours in vivo, is the idea that the effector T-cells cannot clonally 
expand at a sufficient rate to control tumour growth (De Boer, R.J., et. al., 1985).
Cytotoxic T-cells were originally perceived to recognise integral membrane proteins. 
It is now clear, from the analysis of the mechanism of recognition by CD8+ve 
cytotoxic T-cells (Tc) of virally infected cells, that Class-I restricted Tc recognise 
intracellular proteins that are synthesised and degraded in the cytoplasm before 
translocation to the endoplasmic reticulum to be inserted into the cleft of the Class-I 
MHC molecule and finally transported through the Golgi resulting in the expression
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on the cells surface in association with the MHC (Bjorkman, P.J., et. a l, 1987a,b; 
Nuchtern, J.G., et. al., 1989).
Studies by Rosenberg have shown that it is possible to to augment the function of T- 
cells by treatment of lymphocytes with high doses of interleukin-2 (IL-2) in vitro. 
This results in the development of a population of cells exhibiting non-specific 
lymphokine activated killer function (LAK cells) which can be reinfused into the 
patient with or without concurrent infusion of IL-2. This form of adoptive 
immunotherapy does however carry a significant toxicity.
Studies in humans and experimental animals have shown that T-cell clones isolated 
from tumour infiltrating lymphocyte (TIL) preparations can be expanded in tissue 
culture to produce a large number of T-cells exhibiting a unique specificity against 
the initial tumour (Chapdelaine, J.M., et. al., 1979; Belldegrun, A., et. a l, 1989).
The treatment of patients with malignant melanoma, by such a method, can result in 
a response to the therapy in over 40% of patients (Rosenberg, S. A., et. al., 1988)
1.2.2 Macrophages
Although T-cells constitute a sizable fraction of the total white cell infiltrate into 
tumours, numerous other cell types are present. Undoubtedly the most important 
cell, next to T-cells, is the tumour-associated macrophage (TAM).
Derived from bone marrow promonocytes, and passing through a blood-borne 
monocyte phase, macrophages (M(j>) represent a large part of the tissue bound 
mononuclear phagocytic population. This phagocytic population is found 
throughout the bodys' connective tissue and surrounding the basement membrane of 
small blood vessels, but is particularily concentrated in areas such as the lung
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(alveolar M(|)), the liver (Kuppfer cells) and the lining of the spleen sinuosoids and 
lymph node medullary sinuses.
It is thought that TAMs are recruited from blood-bome monocytes by the production 
of a number of compounds, including monocyte chemotactic factor (MCP; Martinet, 
N., 1992). This recruitment requires the production of a concentration gradient from 
the secreting malignant cell to the blood vessels (Keller, H.V., 1977). A number of 
studies have now identified the existance of compounds such as MCP within the 
vicinity of tumours and this model of recruitment is now well accepted (Martinet,
N., 1992).
A number of the functions of macrophages, such as the clearance of obsolete red 
blood cells (RBC), are continuous processes. However, their participation, in the 
defence against tumours requires the recruitment and subsequent specific activation 
of the cell (for review see Fidler, I.J., & Poste, G., 1982).
TAMs exhibit a wide range of functions, including the sectretion of:
1) cytotoxic factors, e.g. tumour necrosis factor (TNF;see later)
2) angiogenic factors, e.g. fibroblast growth factor (FGF; Polvemi, P.J et. 
a l, 1984)
3) lytic enzymes, e.g. plasminogen activator (PA; Mussoni, L., et. a l, 1988)
4) immunomodulatory factors, e.g. prostaglandin E2  (PGE2 ; Varesio, L., 
et. al., 1979)
5) acute phase-response proteins, e.g. interleukin 6 (IL-6; Erroi, A., et. al., 
1989).
The role these M<))-derived factors play in the host / tumour interaction remains 
unclear in that a number of the factors produced can have pro- and anti-tumourigenic
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activities. The swing from the protumourigenic to antitumourigenic activity of M(J) 
will depend on the interactions of the individual compounds produced by the cell, 
which in themselves will be controlled by the level of activation of the M<|>.
Immunohistichemical analysis of a number of human tumours including breast 
(Gottlinger, H.G., et. al., 1985), colon (Allen, C., & Hogg. N., 1985) and skin 
(Broker, E.B., et. al., 1988) have demonstrated the presence of M(J) in the stromal 
compartment of these tumours. Allen and Hogg (1987) have demonstrated that 
Dukes' C colonic cancers have a larger M<|) infiltrate than than less advanced 
tumours.
The presence of TAM in solid tumours makes them an attractive target for 
therapeutic agents. The results of a number of rodent studies are hopeful in that they 
demonstrate that activated M<J) express an anti-tumour phenotype, however this 
response is only noticible with a high macrophage to tumour cell ratio (Allavena, P., 
et. al., 1987). It would be futile to attempt to describe the fine details of the 
interaction between host tumour cells and TAMs. Relevent to this thesis is the 
central role of the M(|) in the production of TNF and this will be discussed in more 
detail in a subsequent section of this thesis.
1.2.3 The major histocompatibility complex
The major histocompatibility complex (MHC) is located on the short arm of 
chromosome 6, within the band 6p21.3 (Lamm, L.U., & Olaisen, B., 1985), and 
consists of three linked gene clusters. These gene clusters are termed the MHC class 
I (class I), MHC class II (class II) and MHC class HI (classIH) regions and contain a 
series of highly polymorphic genes which encode for a series of cell surface and 
secreted peptides.
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The class I region containes at least 17 highly related genes including the classical 
transplantation antigens HLA-A, HLA-B and HLA-C (Strachan, T., 1987). These 
antigens are expressed as 43 kD peptides non-covalently linked to the 11 kD 
molecule p2 -microglobulin. The class I genes are now known to be central to the 
recognition of viral or foreign antigens by CD8+ cytotoxic T-cells (CTLs).
The class II region, commonly termed HLA-D, is subdivided into four subregions 
containing the genes for the a  and p domains for HLA-DP, HLA-DZ / DO, HLA- 
DQ and HLA-DR (Trowsdale, J., 1987). The products of the class II genes are 
found mainly on cells of the immune system (specifically on B-cells, M(() and 
dendritic cells) and are involved in antigen presentation to CD4+ T-cells and B-cells.
The class III region of the MHC contains a number of seemingly unrelated genes 
(Dunham, I., et. al., 1987; Browning, J.L., et. al., 1993) including the second and 
fourth components of the complement system (C2 and C4), the steroid 21- 
hydroxylase (21-OHase), the heatshock protein 70kD (HSP-70) family and the 
tumour necrosis factor genes (TNF-a, LT-a and LT-p; see section 1.3).
1.2.3.1 The MHC and malignancy
The majority of studies examining the role of the MHC in malignancy have been 
performed on experimental animal models with the studies on human material being 
confined to in vitro experiments or to immunohistochemical analysis of biopsy 
material. Studies of animal models have shown that a number of tumour systems 
show a significant down regulation of specifically MHC class I (or H-2 in the 
mouse) expression on the tumour cells, others show an up regulation of specific 
molecules of the MHC whilst other tumours show the development of novel class I 
molecules due to recombination or mutation (for review please see Doherty, P.C., et. 
al., 1984).
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In the majority of tumours down regulation of class I molecules is associated with a 
concordant loss of p2 -microglobulin expression, however in colon tumours the 
down regulation may be due to a loss of p2 -microglobulin expression (Garrido, F.,
& Ruiz-Cabello, F., 1991). Loss of class I expression is seen in approximately 14% 
of human primary colorectal adenocarcinomas (Ruiz-Cabello, F., et. al., 1991), 
compared to 10% of human melanomas (Lopez Nevot, M.A., et. al., 1987), and 20% 
of carcinomas of the lrynx (Esteban, F., et. al., 1989).
A number of studies have attempted to correlate loss of class I expression with a 
high metastatic propensity. Altered expression of class I on the surface of circulating 
"metastatic" cells may allow them to escape from detection by the host immune 
system. In 1987 Durrant, et. al., demonstrated a large variation in the expression of 
class I and class II MHC on the surface of colorectal cancer cells, but failed to 
demonstrate any association with MHC expression and clinical outcome or 
pathological staging. Goepel, et. al., (1991) report a partial or complete loss of 
monomorphic determinants in 60% of primary colorectal tumours, whilst two 
respective lymphnode metastases showed a reduce level of expression relative to 
their primary tumour and four showed increased expression. The authors also 
examined the specific loss of HLA-A2 and report a partial or complete loss of this 
polymorphic determinant in all of the tumours examined with a similar loss in the 
associated metastases.
Epithelial cells rarely express class II MHC molecules, however over 50% of 
colorectal tumours express HLA-DR (Durrant, L.G., et. al., 1987). The pattern of 
staining was consistantly associated with the most poorly differentiated tumours, 
however in the majority of tumours the level of staining was poor (Durrant, L.G., et. 
al., 1987, Rognum, T.O., et. al., 1983). The loss of class II has also been reported on 
the metastases from colorectal tumours although the figures vary from 50% to 100% 
(Durrant, L.G., et. al., 1987, and Thompson, J.J., et. al., 1982, respectively).
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It has been suggested that expression of HLA-DR on the surface of primary tumours 
is capable of increasing the tumours immunogenicity (Fossati, G., et. al., 1984). 
However a study of metastatic melanoma cells demonstrated that cells expressing 
high levels of HLA-DR antigens have the potential to inhibit the immune response 
of autologous T-cells (Taramelli, D., et. al., 1984). This is in conflict with the view 
of Durrant et. al. (1987) who suggest that in colorectal cancer the metastatic cells are 
absent of Class II on their surface. It may be that in the melanoma model the 
excessively high levels of class II MHC result in the induction of tolerance to the 
target antigen.
ylFN has the ability to upregulate the expression of HLA-DR antigens ( and HLA-A, 
B and C) on a number of cell types, including tumour cells (Durrant, L.G.,1987). 
Durrant et. al. (1987) demonstrate that 2/4 secondary tumours express the HLA-DR 
antigen, however they also demonstrate that young dividing cells, when grown in 
vitro, show consistent negative staining for HLA-DR. On treatment of these cells 
with ylFN upregulation of the MHC molecule can be observed. This would be 
consistent with the idea that metastases are produced from MHC negative or MHC 
down regulated cells which can easily evade the immune system.
The true function of the MHC in colorectal tumourigenesis is unclear, with a number 
of reports showing conflicting degrees of expression. It is of course widely accepted 
that tumours represent a heterogeneous population and it may be this fact that results 
in the discrepancies seen between studies. However it seems safe to say that the 
MHC plays an extremely important part in the host / tumour interaction. Any factor 
or factors that can affect the expression of the MHC will have major implications on 
the intricate interactions which occur between host and the tumour. It is clear that 
loss of expression of HLA antigens is of benefit to tumours in that it allows them to 
evade the immune system. However studies in experimental animals have also
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demonstrated that an increase in class-I expression is associated with a decrease in 
natural killer (NK) cell sensitivity (Stem, P., et. al., 1980).
There are very few studies which have examined whether specific MHC antigens are 
involved in the predisposition to malignancy. A number of MHC haplotypes have 
been associated with lung cancer including Aw 19 and B5 which seem to confer 
resistance to the progression of bronchogenic carcinoma (Rogentine, G.N., et. al., 
1977), whilst more recently HLA-DR7 has been suggested to confer resistance to 
lung cancer (Romano, P.J., et. al., 1991). Other tumours such as nasopharyngeal 
cancer, which has been associated with Bw40 ( Simons, M.J., et. al., 1975,) and 
eosophageal cancer, which has been associated with B40 (Simons, J.M., et. al., 
1977), all show associations with class I antigens although only in specific ethnic 
groups. Recently, however, an association has been demonstrated between specific 
HLA-DR and DQ antigens and the susceptibility to papillomavirus-type specific 
cervical carcinoma (Apple, R.J., et. al., 1994). In this study the authors report an 
association with with DRB*1501 and DRQB 1*0602 with HPV 16-type specific 
cervical cancer whilst DR 13 exerts a strong protective effect. This result suggets 
that perhaps specific MHC haplotypes can influence the way in which a tumour is 
seen by the immune system with certain MHC haplotypes allowing for good tumour- 
specific antigen recognition and others resulting in poor antigen presentation.
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1.3 Tumour Necrosis Factor and Lvmphotoxin
In the late 19^ Century Dr WB Coley (1891) attempted to treat a number of patients 
who presented with sarcomas, to the Memorial Sloan-Kettering Cancer Center, with 
a preparation of killed Gram-negative bacteria, which he termed Coley's toxin. On 
treatment with this toxin these patients tended to show a remarkable (although 
generally short lived) regression of their tumours. It was almost a century later 
before a group from the same centre became the first to describe a factor distinct 
from bacterial endotoxin which could induce haemorraghic necrosis of transplanted 
murine tumours, and thus proposed the existance of tumour necrosis factor or TNF 
(Carswell, E.A., et. al., 1975).
Today the tumour necrosis factors (TNFs) are a closely related family of compounds 
which are individually refered to as tumour necrosis factor alpha (TNFa), 
lymphotoxin alpha (LTa; previously TNFp) and lymphotoxin beta (LTp). These 
three compounds are members of the rapidly growing group of compounds, 
commonly termed cytokines.
Although the initial studies examined the role of TNFa in the host response to 
malignant disease, this compound has now been demonstrated to be important in the 
host response to numerous other, non-malignant, diseases. Recent advances in 
recombinant technology have allowed a greater understanding of the function of this 
compound and within the last few years major advances have been seen in the use of 
this compound as a therapeutic agent.
1.3.1 Biological function.
Tumour Necrosis Factor was originally described in the middle of the 1970's. 
Carswell et. al. (1975) originally described a soluble factor which could be identified
57
in the sera of animals treated with reticuloendothelial stimulators, bacterial 
endotoxins or lipopolysaccharide (LPS). Mannel et. al. (1981) subsequently 
described the macrophage as being the principal source of TNFa and that this same 
molecule was an important effector molecule in the non-specific tumouricidal 
activity of macrophages. TNFa appeared to be a preferential mediator of 
cytotoxicity for tumour and transformed cells and received its name due to its ability 
to cause haemorrhagic necrosis of subcutaneous tumours in mice. Thence came the 
expectation that TNFa could provide a major key to therapy of malignant disease.
The cloning of the two original forms of TNF (TNF-a and LT-a (Lymphotoxin)) in 
1984 by Gray et. al. and Pennica et. al. and the expression of these genes in E. coli. 
allowed further work to be performed using this recombinant source of the protein. 
Sugerman et. al. (1985) showed that TNFa was capable of stimulating proliferation 
of normal cells, Dayler et. al. (1985) showed that TNFa could stimulate collagenase 
production whilst Bertolini et. al. (1986) showed that TNFa could cause bone 
resorption. A review by Aiyer and Aggarwal (1987) describes a number of other 
activites of TNFa on normal cells including effects on the metabolism of fibroblasts, 
neutrophils, hepatocytes and leucocytes. Tracey et. al. (1986) first suggested that 
TNFa had the ability to induce similar effects to those resulting from endotoxin- 
induced shock and Beutler et. al. (1985), claim that TNFa is the primary mediator in 
endotoxin-induced shock. However in the experiments of Beutler et. al. (1985), the 
authors fail to show a complete block of the shock following administration of anti- 
TNFa antibodies, suggesting that other mediators are also important.
Numerous studies have examined the ability of TNFa to induce tumour necrosis in 
vivo or tumour cell lysis in vitro. Carswell et. al. (1975) were the first to show that 
serum from mice challenged with Bacillus calmette-guerin, and subsequently 
injected with endotoxin, contained a compound which could cause haemorrhagic 
killing of a number of murine tumours in vivo including the s-180 sarcoma in CD-I
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Swiss mice, the BP8 leukaemia in C3H mice and the chemically induced Meth A 
sarcoma in B ALB/c mice. This same group showed that the effect of the serum was 
greatest if the tumours were allowed to develop for at least five days prior to the 
treatment with the serum, thus suggesting that a vascularised tumour was essential to 
the action for the endotoxin treated serum to be effective.
Administration of concentrations of TNF-a several-folds higher than the antitumour 
dose results in a severe weight loss in experimental animals. This weight loss, or 
cachexia, is accompanied by an inhibition of lipoprotein lipase (LPL; an essential 
protein which is involved in the clearence of triglyceride from the blood) secretion 
by adipose tissue (Cerami, A., et. al., 1985). Cessation of TNFa administration, 
however, results in a rapid recovery, and a gain in weight (Lee, et. al., 1987).
TNF is now known to have a large spectrum of effects on a large number of cell 
types. TNF causes the adhesion of neutrophils to endothelial cells (Gamble, J.R., et. 
al., 1985) and may be the primary cause of endotoxin induced neutropenia. TNF has 
also been shown to be growth inhibitory in that it causes vascular endothelial cell 
remodelling in which the cells flatten, become overlapping, rearrange their actin 
filaments and lose stainable fibronectin (Schweigerer, L., et. al., 1987). In addition 
to causing adhesion of neutrophils to endothelial cells, TNF also acts on neutrophils 
to enhance their production of superoxide (Shalaby, M.R., et. al., 1985), induce the 
release of lysozymes and hydrogen peroxide and also induces neutrophil 
degranulation (Kiobanoff, S.J., et. a l, 1986).
TNF-a is now known to be synthesised by a number of cell types, including cells of 
the haematopoietic and non-haematopoietic lineages (Beutler, B., 1990; Spriggs, 
D.R., et. al. 1988; Jevnikar,A.M., et. al. 1991) although it is now recognised that 
macrophages are one of the major sources of TNFa (Mannel, D.N., et. al, 1981). 
Although macrophages do express receptors for TNFa, little is known about the
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function of TNFa on the macrophage although it has been shown to be chemotactic 
to these cells (Ming, W.J., et. al., 1987). TNFa is known to induce the production 
of GM-CSF by a number of cell lines and may cause the activation of macrophages 
indirectly via this pathway (Munker, R., et. al., 1986).
TNFa also exerts an effect on lymphocytes. TNFa acts to induce the upregulation 
of TNFR on primary cultured T-cells (Scheurich, P., et. al., 1987) and has also been 
shown to induce the expression of the HLA-DR antigen and the high affinity IL-2 
receptor thus resulting in an enhanced proliferative response of T-cells, particularily 
to IL-2. Conversely TNF has been shown to inhibit poke weed mitogen induced 
proliferation and differentiation of B-cells (Kashiwa, H., et. al., 1987).
Although this is by no means a comprehensive description of the intricate 
interactions that TNF and LT are involved in, it can be clearly seen that TNFa, as 
well as having direct cytotoxic effects, also acts as an important immune modulator 
and is one of the primary initiators and modulators of the immune response.
TNFa exists in solution as a homotrimer of 17 kD subunits each synthesised from a 
26kd transmembrane propeptide that itself appears to exhibit biological activity 
when membrane bound (Kreigler,M., et. al. 1988), whilst LT-a (originally TNF-P) 
is a 25 kD soluble protein, synthesised primarily by lymphocytic cells (Paul,N.L., 
and Ruddle, N.H., 1988). Although antigenically distinct, it displays approximately 
30% sequence homology with TNF-a and also close homology with the newly 
cloned LT-p (Browning, J.L., et. al. 1993). The function of both lymphotoxins still 
remains unclear.
Within the last year a new member of the TNF gene family has been identified and 
with its discovery a change in the nomenclature of the three TNF proteins has arisen. 
This new molecule, termed Lymphotoxin-P (LT-p; Browning, J.L., et. al. 1993), has
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recently been cloned. LT-p is a 33 kD glycosylated transmembrane protein. LT-a 
(originally TNF-p) is present on the surface of activated T-cells, B-Cells and 
lymphokine activated killer cells (LAK cells) heterodimerised to the LT-p protein. 
No function has yet been ascribed to this new molecule although human peripheral 
blood mononuclear cells (PBLs) stimulated with either anti-CD3 antibody or 
interleukin-2 (IL-2) express mRNA for both lymphotoxins (Browning, J.L., et. al.
1993). It is interesting that this heterodimeric molecule is incapable of binding to 
either of the two known TNFa receptors (p55 and p75; see below). Crowe et. al. 
(1994) have recently identified a receptor specific for LTp, however little is know 
about its function. Browning et. al. (1993) hypothesise that the surface-bound LT-a 
P dimer may be important in cell-cell contact-dependent programmed cell death, but 
this still remains unproven, whilst Crowe et. al. (1994) suggest that, since LTa 
knock-out mice display a disfuction in lymphoid organ development, yet TNFR5 5  or 
TNFR7 5  knock-out mice develop a normal lymphoid organ system, the LTa-LTp 
complex and the LTpR may play an important role in immune development.
Two separate receptors have been identified for TNF-a, which also show a high 
degree of specificity for LT-a but a low degree of specificity for LT-p. These 
receptors, termed p55 and p75 (or sometimes p60 and p80) differ in both their 
molecular weight and also in the mechanism by which they mediate the biological 
effects of TNF-a (Brockhaus, M., et. al., 1990). The p55 receptor is expressed on a 
wide range of cell types and expression of p55 seems to be sufficient to result in the 
cytotoxic action of TNF-a on tumour cells in vitro (Balkwill, F.R., et. al., 1993), 
independent of the expression of the p75 receptor (Higuchi, M., & Aggarwal, B.B.,
1994). The p75 receptor shows a more specific pattern of expression and is found 
primarily on lymphoid and myeloid cells (Balkwill, F.R., et. al., 1993). Whether or 
not the p75 receptor plays a function in the cytotoxicity of TNF-a is debatable, with 
a number of studies suggesting that in some cases this receptor is capable of
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inducing cytotoxicity upon crosslinking with specific antisera (Medvedev, A.E., et. 
a l, 1994).
1.3.2 TNF and human malignant disease
A number of studies have examined the role of TNFa in human solid tumours with 
the majority of these studies having looked at breast and ovarian cancer, although a 
number of studies have examined other tumour types including colorectal cancer.
Both immunohistochemical and in situ hybridisation techniques have demonstrated 
the presence of TNF-a protein and TNF-a mRNA within colorectal tumour biopsy 
samples (Beissert, S., et. al., 1989). The source of this material tends to be 
associated with tumour associated macrophages (TAM). Semiquantitative data from 
Beissert et. al. (1989) suggest that, whilst levels of TNF-a mRNA were detectable in 
all of the samples examined, less than 1% of the TAMs were synthesising 
immunoreactive TNF-a. By using a Northern blot technique Naylor et. al. (1992) 
were able to support the idea that TNF-a is produced within colorectal tumours.
This study, however, failed to positively identify the nature of the TNF-a secretory 
cells. The authors suggested that these cells could either be macrophage derived or a 
subset of T-cells.
Studies of TNFa mRNA expression in breast cancer have demonstrated that over 
90% of breast tumours have detectable mRNA localised to sporadic cells within the 
stroma (Vitolo, D., et. al., 1992). A variety of breast epithelial tumour cell lines 
have been shown to secrete TNF-a in vitro (Spriggs, D.R., et. al., 1988). These cells 
often show resistance to the cytotoxic activity of TNF-a, and it has been suggested 
that low levels of TNF-a secretion can result in the desensitisation of tumour cells to 
TNF (Spriggs et. al., 1987). Indeed it has been demonstrated that TNF-a induces the 
internalisation of the p55 receptor and the extracellular release of the p75 receptor
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(Higuchi, M., & Aggarwal, B.B., 1994). It is entirely possible that this 
internalisation results in the loss of the sensitivity to TNFa-mediated cytotoxicity, 
whilst the p75 receptor acts to bind and neutralise free TNFa.
There are a number of ongoing clinical trials involving the use of TNFa. These 
trials, like those of other cytokines, have been severely restricted due to the level of 
toxicity of high dose TNFa. The response of patients to recombinant TNF-a (rTNF 
a) as a single therapeutic agent have been mixed. Studies in metastatic breast cancer 
involving the administration of rTNFa as a single therapeutic agent have had no 
success (Budd, G.T., et. al. 1991), however the regional administration of rTNFa to 
metastatic lessions in the liver of patients has shown a partial response in 14% of 
patients with primary colorectal cancer (Mavligit, G.M., et. al., 1992).
A number of studies have attempted to assess the feasibility of administering rTNFa 
in conjunction with a number of other therapeutic agents. A phase IB trial involving 
the administration of rTNFa in conjunction with 7 -IFN has shown no significant 
increase in the biological response of patients with widely disseminated cancer 
(Schiller, J.H., et. al., 1992). Recent studies involving isolated limb perfussion to 
treat advanced melanoma have given some hope to the use of TNFa in the therapy of 
malignant disease. Studies involving the infusion of rTNFa and Melphalan into 
melanoma patients presensitised with y-IFN results in an increase in complete 
response from 50% to almost 90% (Lienard, D., et. al., 1994), whilst studies 
involving patients with irresectable soft tissue sarcomas demonstrates a limb salvage 
rate of almost 90% (Eggermont,A.M.M., et. al., 1994).
Although these studies have not been performed on large numbers of patients, the 
results are promising. Perhaps the use of mutated forms of TNF-a such as those 
which only bind to the p55 receptor (Vaan Ostade, X., et. al., 1993) may facilitate
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reduction of the toxicity associated with TNF therapy and may allow more 
widespread use of rTNF in the therapy of malignant disease.
1.3.3 The TNF genes
The tumour necrosis factor genes (TNF-a, LT-a and LT-P) are located within the 
region p21.1 to p21.3, of human chromosome 6 . By using the technique of Southern 
blotting Spies et. al. (1986) proposed that the two original TNF (TNFa and LTa) 
genes map to two possible regions either between HLA-DR and HLA-A or slightly 
centromeric to HLA-DP. These results were confirmed by chromosome in situ 
hybridisation. In 1987 Dunham et. al., using pulsed-field gel electophoresis, mapped 
the human TNF-a and LT-a genes to their now accepted position approximately 250 
kb centromeric to HLA-B (Figure 1.5). The most recent member of the TNF gene 
family (LTp) has also been located to within the class III region of the MHC, 
approximately 2 kb centromeric to TNF-a (Figure 1.5; Browning, J.F., et. a l,  1993).
1.3.3.1 The TNF-a gene
TNF-a is coded for by a 3634 bp gene consisting of 4 exons which results in a 157 
amino acid mature protein with a 76 amino acid signaling sequence (Nedwin, G.E., 
et. al. 1985). The 5' untranslated region of TNF-a is 180 bp long and begins at 
nucleotide 615 of the published sequence. Intron one is 607 bp in length and disect 
the genomic sequence at codon 62. The second intron is 187 bp in length and disects 
the sequence within the second codon of the mature protein sequence. The third 
intron is of 301 bp in length and occurs within codon 18 of the mature protein 
sequence. There is a TATA box located at position 590, an AGC putative site of 
anitiation of transcription located at position 615, an AATAAA site located at 
position 3368 and a putative site of polyadenylation (poly(A)) at position 3382
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(Nedwin, G.E., et. al. 1985). There is also an AU-rich region which is involved in 
determining mRNA stability is located at position 3050 (Shaw, G., et. a l, 1986).
1.3.3.2 The LT-a gene
The sequence of both the TNF-a and LT-a mature proteins show approximately 
28% homology (Pennica, D., et. al. 1984) with a maximal homology of 56% at the 
nucleotide level in the coding region of exon 4 of both genes. The introns also 
show a very low degree of homology at only 35% (Nedwin, G.E., et. al. 1985).
Like TNF-a, the LT-a gene is constructed of 4 exons and 3 introns and is coded for 
by a 3037 bp stretch of DNA. The first intron of LT-a is 287 bp in length and 
disects the 5' untranslated region 9 bp before the beginning of the coding region.
The second intron is 8 6  bp in length and disects the signal sequence one amino acid 
residue before the begining of the coding sequence of the mature protein. The third 
intron is 247 bp long and disects the coding sequence at amino acid 35 of the mature 
protein. The site of initiation of transcription is located at position 818 and the 
poly(A) site is at position 2854. The TATA box is located at position 790 and the 
AATAAA region located at position 2735. Again, like TNF-a, there is also an AU- 
rich region at the 3' end of the gene (at position 2587) which is involved in 
determining mRNA stability (Shaw, G., et. al., 1986).
1.3.3.3 The LT-B gene
Like the other members of the TNF gene family LT-p has four exons and three 
introns and is coded for by a 2200 bp fragment of DNA (Browning, J.F., 1994). The 
promotor region of this gene contains a putative TATA box at position 109 and a 
CAAT element at position 266. The 5' untranslated region of LT-p is only 10 bp 
long and begins at nulcleotide 293. Intron one is 96 bp in length and disects the
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Figure 1.5. Diagramatic representation of the TNF locus showing the 
position of the TNFa, LTa and LTP genes and there intron/exon 
arrangement and the relative position of the TNF polymorphisms.
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genomic sequence between codon 54 and 55. The second intron is 83 bp in length 
and disects the sequence within codon 70. The third intron is of 395 bp in length 
and occurs within codon 94 of the protein sequence. The AU-rich motif that is 
common to the 3'-untranslated regions of both the TNF and LT-a genes is not 
present in the LT-p suggesting that the LT-p mRNA displays a differing degree of 
stability than TNF or LT-a. The site of initiation of transcription is located at 
position and the poly(A) site is at position 2127.
1.3.4 Polymorphisms within the TNF locus
The number of polymorphic regions identified to date within the human genome has 
not been formally calculated but there are at least 10 within the TNF locus. These 
polymorphic regions are divided into two distinct types comprising of restriction 
fragement length polymorphisms (LT-a EcoRl RFLP, LT-a Ncol RFLP, -308 TNF- 
a  RFLP, -238 TNFa RFLP and AspHl LTa RFLP; Partanen, J. and Koskimies, S., 
1988; Messer, G., et. al., 1991; Wilson, A.G., et. al. 1992; D' Alfonso, S. & 
Richiardi, P.M., 1994; Ferencik, S., et. al., 1992) and five microsatellite 
polymorphism (TNFa, TNFb, TNFc, TNFd and TNFe; Jongeneel, C.V., et. al., 1991 
and Udalova, I.A., et. al. 1993). These regions exhibit various degrees of 
polymorphism and span the entire length of the TNF gene cluster (Figure 1.5).
1.3.4.1 LT-oc EcoM  RFLP
With the strong association between TNFa and autoimmune disease there has 
always been a search for polymorphisms within the region of the TNF genes which 
could be associated with the secretion pattern of TNFa seen in various autoimmune 
diseases. The EcoKl RFLP described by Partanen and Koskimies (1988) is a biallelic 
polymorphism with the polymorphic restriction enzyme site locate in the 3' 
untranslated region of exon 4 of the LT-a gene. This RFLP produces two alleles
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defined by Southern hybridisation of a common 2.4kb and a rare 2.5kb which was 
present in 4 of the 67 (6 %) unrelated individuals in the original study. This RFLP 
shows no association with the common autoimmune-associated HLA antigens B8 , 
DR3 or B27 but does show a strong association with B40 (Partanen, J. and 
Koskimies, S., 1988). Since the 2.5kb allele of the EcoRl RFLP is so rare little work 
has been performed regarding the function or associations of this polymorphism in 
disease.
1.3.4.2 LT-a Ncol RFLP
The LT-a Ncol RFLP was initially defined by Southern hybridisation with a TNF-a 
probe to give two alleles of 5.5kb (termed the B*1 allele) and 10.5kb (termed the 
B*2 allele) and for a number of years it was thought that the polymorphic Ncol site 
was within the TNF-a gene (Fugger, L., et. a l , 1989a). Messer et. al. (1991), 
however, mapped a 56.8kb region of a number of overlapping genomic DNA clones 
and by direct sequencing located the polymorphic restriction site to within the first 
intron of the LT-a gene, at position 252. This polymorphism results in a guanine to 
adenine substitution to create the Ncol recognition site. Messer et. al. (1991) also 
showed an associated amino acid substitution at position 26 of the LT-a gene with 
an asparagine associated with B*1 allele and threonine with the B*2 allele.
A number of studies have examined the role of this RFLP in various autoimmune 
and non-autoimmune diseases, and like the EcoKl RFLP this polymorphism seems 
to show a high degree of association with an extended MHC. The B*2 allele shows 
strong association with HLA-DR4 and -B15, whilst the B*1 allele shows an 
association with HLA-A1, -B8 , -DR3, in normal control individuals (for review see 
Verjans, G.M.G.M., et. al., 1992).
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Unlike the EcoKL RFLP, functional analysis of the various LT-a RFLP genotypes 
have demonstrated an association with specific genotypes and the production of TNF 
a  in vitro. The most recent study by Pociot et. al. (1993a) shows a distinct pattern 
of TNF-a secretion, but interestingly not LT-a secretion, associated with various 
LT-a RFLP genotypes. The authors report a significantly higher production of TNF- 
a  by lipopolysaccharide (LPS)-stimulated monocytes from individuals homozygous 
for the B*2 allele than those levels seen in B*1 homozygous individuals, whilst 
individuals heterozygous at this locus showed an intermediate level of TNF-a under 
the same stimulatory conditions. Although the LT-a RFLP is located within the 
gene for LT-a and is also associated with a variant amino acid within the LT-a 
protein, Pociot et. al. (1993a) report no difference in the level of LT-a secretion by 
phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells 
(PBMCs). These results are in contrast to those reported by Messer et. al. (1991), 
who reported an increased level of LT-a secretion associated with the TNFB*1 
allele, in PHA stimulated T-cells. In the study by Messer et. al. (1991a) the authors 
report no association between TNF-a secretion in PHA-stimulated PBMCs from 
individuals homozygous for either of the two LT-a alleles, whilst individuals 
homozygous for the B*1 allele showed a significant increase in LT-a production 
over those individuals homozygous for the B*2 allele.
The reason for the differences seen between these two studies is unclear. It is now 
accepted that these alleles form part of an extended MHC haplotype which includes 
alleles of the other TNF associated polymorphisms. Although neither of the other 
RFLPs have been associated with distinct patterns of TNF-a or LT-a secretion, 
alleles of the microsatellite polymorphisms, particularity the TNFa microsatellite, 
have been reported to show association with TNF-a secretion. It is probable that 
alterations in the control of TNF-a and LT-a secretion cannot be associated with one 
polymorphism alone. The genetic control of production seems to be affected by 
numerous factors such as MHC and TNF microsatellite genotypes as well as the
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TNF RFLP genotypes. Classical mechanisms known to alter the levels of TNF-a or 
LT-a in vitro and in vivo will also play an important role in the degree of response 
seen upon stimulation of various cell types and will contribute to the differences 
reported in the two studies described above.
1.3.4.3 -308 TNF-a RFLP
The -308 TNF-a RFLP is one of two RFLPs that have been identified, to date, 
within the gene for TNF-a. Like all RFLPs the -308 RFLP is a biallelic 
polymorphism describing two alleles, a common allele termed TNF1 and a rare 
allele termed TNF2 (Wilson, A.G., et. al., 1992). This polymorphism results in the 
substitution of a guanine by an adenosine in the promotor region at position -308, 
relative to the site of initiation, in the rare TNF2 allele.
Like the LT-a RFLP this polymorphism shows a strong association with alleles of 
the MHC. Wilson et. al. (1993) have shown a strong association with the 
uncommon, TNF2 allele, and the extended HLA haplotype HLA-A1, -B8 , -DR3. 
This extended haplotype has now been expanded to include the alleles of the LT-a 
RFLP as well as alleles of the TNFa, TNFb and TNFc microsatellites (see bellow). 
This haplotype now extends to DQB 1*0201, DQA 1*0501, DRB 1*0301, TNF2, LT- 
a  B*l, B8 , Al/2, C4A null and has been observed in control individuals, in patients 
with insulin-dependent diabetes mellitus (IDDM; Pociot, F., et. al., 1993b) and in 
patients with systemic lupus eryuthematosis (SLE; Wilson, A.G., et. a l, 1994a).
Constructs involving the two TNF-a allelic promotors upstream of a CAT reporter 
system result in a six to seven fold increase in transcription in both PHA stimulated 
and unstimulated Raji B-cell line transfected with the TNF2 bearing promotor 
(Wilson, A.G., et. al., 1994b). Studies by a group in The Netherlands on similar 
CAT constructs have failed to show a similar effect. In this study a CAT construct
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containing the region -619 to +108 of the two allelic promotor regions of TNF-a, 
failed to show any difference upon transfection into the Jurkat T-cell line (Brinkman, 
et. al., 1994). The differences between the results of the two groups 
remains unexplained. It is unclear in the paper by Wilson et. al. what region of the 
TNF-a promotor was used in the study. Its is possible that these regions differ 
between the two studies and that differences in the number of transcriptional factor 
binding sites such as NFk-B binding sites, have been missed. However this 
hypothesis remains unproven.
Studies of CAT constructs of the two polymorphisms cannot be directly related to 
differences in production of TNF-a in vivo and the study of the in vivo effects has 
yet to be performed.
1.3.4.4 The A sdH I  RFLP
A further RFLP has been reported within the same intron of the LTa gene as the LT 
a  Ncol RFLP (Ferencik, S., et. al., 1992). Like all of the RFLPs this polymorphism 
results due to the substitution of a single base resulting in the formation or 
destruction of a restriction endonuclease recognition sequence. Like the EcoKL 
RFLP there is very little further data available regarding this polymorphism. It has 
been reported that there is no linkage between the two RFLP loci in this intron or 
with alleles of the MHC (Ferencik, S., et. al., 1992).
1.3.4.5 -238 TNFa RFLP
A recent report by D' Alfonso and Richiardi (1994) identifies a further RFLP within 
the promotor region of the TNFa gene. It has been shown that changes in nucleotide 
sequence can result in changes in the superhelical structure of genomic DNA and 
that these changes can influence the electrophoretic mobility (Calladine, C.R., et. al.,
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1988). Using this knowledge D' Alfonso and collegues were able to detect a 
polymorphism distinct from the -308 TNFa RFLP at position -238 of the TNFa 
gene. This region of the promotor forms part of the highly conserved Y box which 
has been shown to be essential for MHC class II promotor function (Benoist, C. & 
Mathis, D., 1990).
Again this polymorphism seems to form part of an extended MHC haplotype and the 
authors report a number of associations including the rare TNFA-A allele with HLA- 
DR3. To date no further studies have examined the relationship between this 
polymorphism and disease although it seems likely that these studies will be 
forthcoming since this polymorphism seems to occur in a very important part of the 
TNFa promotor.
1.3.4.6 TNF microsatellite polymorphisms
Although the two RFLPs within the TNF locus can provide invaluable evidence to 
the function of TNF in various diseases, their usefulness is limited due to their small 
degree of polymorphism. Recently five regions of dinucleotide repeat microsatellite 
polymorphism have been found distributed within the TNF locus (Nedospasov, S.A., 
et. al., 1991; Jongeneel, C.V., et. a l, 1991, Udalova, I.A., et. a l, 1993). These loci 
show varying degrees of polymorphism.
The TNFa and TNFb polymorphisms consist of AC/GT and TC/GA repeat units 
respectively. These two loci are found within a 200 bp region located 3.5 kb 
upstream of the LT-a promotor and show 13 and 7 alleles respectively (Nedospasov,
S.A., et. a l,  1991; Jongeneel, C.V., et. a l, 1991). The TNFc polymorphism is 
biallelic and consists of TC/GA repeat units and is found within the first intron of 
the LT-a gene (Nedospasov, S.A., et. a l, 1991). The two most recently described 
misrosatellite polymorphisms have been termed TNFd and TNFe and are located 8 -
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10 kb downstream of the TNF-a gene. These polymorphisms both consist of 
TC/GA repeat units and have 7 and 3 alleles respectively (Udalova, I.A., et. a l,
1993).
A recent study by Pociot et. al. (1993a) has shown an association between the 
TNFa2 allele and high secretion of TNF-a by LPS stimulated monocytes (-3.4 
ng/ml) whilst TNFa6  was associated with a significantly lower level of secretion of 
TNF-a (-2.4 ng/ml), compared to a base line taken as 3 ng/ml. TNFc2 positive 
monocytes also displayed a significantly high level of TNF-a secretion, although the 
exact value for this was not presented. Like the LT-a RFLP this study failed to 
show any association with TNFa or TNFc alleles and the secretion of LT-a by PH A 
stimulated PBMCs (Pociot, F., et. al., 1993a). The only report of an association with 
alleles of the other microsatellite loci describes an association with the TNFd3 allele 
and an elevated level of TNF-a secretion in endotoxin stimulated monocytes from 
patients homozygous for the TNFd3 allele as compaired to patients heterozygous for 
the TNFd3 allele (Turner, D.M., et. al., 1994).
Like the three RFLPs within the TNF locus, the alleles of the five microsatellites 
seem to form part of an extended MHC haplotype. Four such haplotypes have been 
identified which correlate with TNF-a secretory capacity of LPS stimulatyed 
monocytes (Pociot, F., et. al., 1993a). These haplotypes are, in order of increasing 
TNF-a secretion, as follows
DRw6 , TNFB*1, TNFa4, B40, A2 
DQw8 , DR4, TNFB*1, TNFa6 , B44, A2 
DQw2, DR3, TNFB*1, TNFa2, B8 , Al 
DQw8 , DR4, TNFB*2, TNFa2, B115, A2.
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Although the authors report a difference in the mean level of TNF-a secretion 
between these four groups the differences are not significant.
Analysis of 101 cell lines from the Human Leukocyte Antigen Workshop reference 
panel for alleles of the five microsatellite polymorphisms and the LT-a ,Nco-I RFLP 
have identified a number of common extended MHC haplotypes (for a complete 
description of these haplotypes please see the ref. Udalova, I.A., et. al., 1993). The 
authors report a number of unusual differences between the cell lines. Whilst a 
number of the cell lines were shown to be identical for their extended haplotype, a 
number of lines extended haplotypes were created by recombination, which in one 
case occured between the TNFb microsatellite locus and the HLA-B locus. Other 
cases were identified where cell lines shared the same HLA-serological haplotype 
but showed differing TNF alleles. These cell lines have been used as control for 
HLA typing due to the fact that the majority of them are homozygous for the 
serologically-defined HLA alleles. On analysis of the TNF alleles of several of these 
cell lines Udalova et. al. (1993) report that some of these lines show heterozygosity 
for alleles of the TNF locus. Those cell lines which showed heterozygosity for one 
of the TNF alleles, also showed heterozygosity for one of the HLA alleles. It is now 
clear that alleles within the TNF locus show a high degree of association with alleles 
of the HLA system. The ability to subdivide extended HLA haplotypes by 
incorporating haplotypes of the TNF polymorphisms may allow a more detailed 
analysis of the association of the MHC and in particular TNF with human diseases.
1.3,5 TNF polymorphisms and human disease
TNFa is now widely accepted to be one of the major mediators of autoimmune 
disease, with alterations in the level of TNFa being implicated in the pathogenisis of 
diseases such as RA, SLE and IDDM. Within the last few years a number of groups
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have attempted to determine whether this alteration in TNFa secretion is genetically 
controlled, and in particular whether this loss of normal control can be associated to 
one or more polymorphism within the TNF locus.
In 1989, Fugger et. al., (1989a) performed a screen of the TNF locus in an attempt to 
ascertain the degree of polymorphism within the TNF locus. Of 20 restriction 
enzymes the authors examined only Nco-I displayed a polymorphic pattern when 
hybridised in a Southern blot with a TNF-a cDNA probe. In this original study the 
authors wrongly assumed that the Nco-I polymorphism that they had detected was 
within the TNF-a gene, however they were the first group to document an 
association with the decrease in the presence of a particular allele of this RFLP, in 
this case the TNFB*2 allele, and and the presence of the autoimmune disease 
primary biliary cirrhosis (pBS). Studies by the same group showed a further 
association with alleles of the Nco-I RFLP and three of four other autoimmune 
disease (Fugger, L., et. al., 1989b). A high degree of association was seen between 
the TNFB*1 allele and pauciarticular juvenile rheumatoid arthritis (P-JRA), primary 
Sjogren's syndrome (pSS) and SLE, whilst a decrease in the frequency of the 
TNFB*2 allele was observed in patients with P-JRA, pSS, SLE and RA, however 
the decrease was only significant in the SLE group. The authors also note a strong 
association between HLA-A8  and the TNFB*1 allele and suggest that any decrease 
in the observed frequency of the TNFB*2 allele could be a secondary effect of this 
strong linkage disequilibrium.
A number of groups have also examined the role of the LT-a Nco-I polymorphism 
in insulin-dependent diabetes mellitus (IDDM). IDDM is characterised by a 
mononuclear cell infiltration of the pancreatic islets resulting in the autoimmune 
destruction of the pancreatic |3-cells (Kolb-Bachofen, V and Klob, H., 1989). TNF- 
a  has been widely implicated in the pathogenesis of this disease, and the disease is 
known to be associated with the HLA antigens DR3 and DR4, with individuals
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displaying both of these antigens having the highest relative risk (Svejgaard, A., et. 
al., 1986). Initial studies by Pociot et. a l (1989) demonstrated that the TNFB*2 
allele is found more commonly associated with the HLA-DR3 haplotype in IDDM 
patients than in normal control individuals, however this study fails to show an 
independent association with the TNFB*2 allele and this disease. Further studies in 
normal individuals have demonstrated that the IL-lp and TNF-a response of 
monocytes from these individuals can be associated with the LT-a RFLP. LPS 
and/or gamma interferon and/or TNF-a stimulated monocytes from individuals 
homozygous for the TNFB*2 allele demonstrated a higher level of TNF-a and IL-ip 
than heterozygous individuals, however this pattern of response was also 
demonstrated in patients with recent-onset and long-standing IDDM (Molvig, L., et. 
al., 1990). Two further studies involving groups headed by J Nerup of the Steno 
Memorial Hospital in Gentofte, Denmark, and involving both Pociot and Molvig, 
have continued to examine the role of the LT-a Nco-I RFLP in IDDM (Pociot, F., et. 
al., 1991; Honen, J., et. al., 1992). The first of these studies reinforced the idea of an 
involvement of the TNFB*2 allele in IDDM, however the second study, which 
examined IDDM in a Finnish population, failed to show any association between the 
TNFB*2 allele and DR4/DQ8-associated IDDM. There are now a number of other 
studies demonstrating linkage between this RFLP and disease. Messer et. al. (1994) 
have recently demonstrated an association between both the LTa Ncol RFLP and the 
-308 TNFa RFLP in dermatitis herpetiformis, whilst Tomita et. al. (1993) have 
demonstrates an association with the TNFB*1 allele and SLE, however Goldstein 
and Sengar (1993) report no independent correlation in this disease. Interestingly, 
and possibly some what surprisingly, an association has been described between this 
locus and the C4 'null' allele and recurrent spontaneous abortion in Finnish couples 
(Laitinen, T., et. al., 1992), however the reason for this association remains unclear.
Attempts to show linkage of disease to polymorphic markers at the TNF locus had, 
until 1991, been restricted to the use of the RFLP technique. In 1991 Nedospasov et.
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al. reported the first recorded series of microsatellite polymorphisms within the 
region of the TNF genes (see section 1.3.4.4). Pociot et. al. (1993a) were the first 
group to use these microsatellites, in conjunction with HLA haplotypes, and the L i ­
ce Nco-I RFLP, to examine, in detail, the the role of the MHC, and in particular the 
TNF locus, in IDDM. In a group of 26 DR3/DR4 heterozygous patients with IDDM, 
the authors found a significantly higher frequency of the TNFa2 and a lower 
frequency of the TNFa6  allele than healthy HLA-DR matched controls. Twelve of 
this same group of patients also demonstrated an extended haplotype , DSQw8 , DR4 
(Dw4), C4A3, TNFB*2, TNFa2 and B 15, identical to the DR4 haplotype which the 
authors report correlates with an elevated TNF-a response in LPS stimulated 
monocytes.
Until recently all of the polymorphic loci within the TNF genes have been found 
either distant from the coding sequence of the TNF proteins or within the gene for 
LT-a, however a polymorphic site within the promotor region of the TNF-a gene 
has recently been identified (Wilson, A.G., et. al., 1992; see section 1.3.4.3). The 
rare allele of this polymorphism does show an association with the common 
autoimmune disease HLA haplotype A l, B8 , DR3 (Wilson, A.G., et. a l, 1993).
This HLA haplotype is known to be common in diseases such as EDDM, SLE, 
Graves' disease and celiac disease however, unlike the LT-a RFLP, this 
polymorphism shows no association with IDDM (Pociot, F., et. al., 1993b). An 
abstract submitted to the British Society for Rheumatology in 1994, by Wilson et. al. 
examines the relationship between this polymorphism and systemic scleroderma 
(SSc). In this study of 19 patients no association between the alleles of this 
polymorphism and the presence of the disease was noted, however some association 
was observed between the rare allele and the presence of anti-PM-Scl antibodies. 
Two further studies of the -308 TNF-a RFLP have examined the relationship 
between alleles of this polymorphism and autoimmune disease, and in both cases no 
independent association between alleles of this locus and either SLE (Wilson, A.G.,
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et. al., 1994) or ankylosing spondylitis could be demonstrated (Verjans, G.M, et. al.,
1994).
Although there is considerable evidence to suggest that TNFa plays an important 
role in tumourigenesis only one study to date has examined the role of 
polymorphisms within the TNF locus and human malignancy. A number of 
associations between various HLA alleles and lung cancer have been reported 
including Aw 19, B5 and DR7 conferring resistance to this disease and A29 
conferring susceptibility (Rogentine, G.N., et. al., 1977; Terasaki, P.I., et. al., 1977; 
Romano,P.J., et. al. 1991). A recent study of the LT-a polymorphism in a group of 
135 lung cancer patients has identified an association between TNFB*2 
homozygosity and resistance to lung cancer and also with an improved prognosis of 
patients with the disease (Shimura, T., et. al., 1994).
It is clear from these studies that polymorphisms at the TNF locus could be of great 
importance in the attempt to understand the role of TNFa and the MHC in human 
disease. However, the mechanism behind the effects seen of these polymorphisms is 
still not understood and will require further study. Studies performed in the mouse 
perhaps give the best possible chance to allow a better understanding of the function 
of the TNF polymorphisms. There are a number of studies that have demonstrated a 
relationship between murine TNF locus polymorphisms and disease. The New 
Zealand White (NZW) mouse strain probably represents the best murine model for 
studying the association between TNF polymorphisms and disease. This mouse 
when crossed with the New Zealand Black (NZB) mouse results in an FI generation 
which are susceptible to a lupus nephritis. An RFLP in the mouse TNFa gene has 
been related to the H-2 susceptibility of this disease and studies have shown that this 
polymorphism correlates with reduced TNFa production by NZW mice peritoneal 
macrophages and it has also been shown that treatment with rTNFa can delay
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disease onset (Jacob, C.O. and McDevitt, H.O., 1988). The contribution of the 
NZW parent to the disease has been mapped to a single dominant allele within or 
very close to the mouse MHC (Kotzin, B.L. and Palmer, E. 1987). Although the 
RFLP described by Jacob and McDevitt does not define a unique allele 
corresponding to susceptibility to this disease a recent study by Jacob and Hwang 
(1992) identifies a unique TNFa microsatellite allele in the NZW mouse and an 
associated unique HSP70 allele and the authors suggest that these polymorphisms 
could be important in defining inter-individual differences which result in 
susceptibility to disease, whilst in an earlier paper Jongeneel et. al. (1990) also 
describe a particular TNFa microsatellite allele unique to the NZW mouse strain.
An association has also been described between a two TNFa polymorphisms in the 
mouse and resistance to toxoplasmic encephalitis (Freund, Y.R., et. al., 1992), whilst 
Vincek et. al. (1993) also show a correlation with a TNFa polymorphisms and the 
reduction of cutaneous immunity on exposure of mice to UV-B.
It is far easier in the mouse to determine whether the relationships identified between 
TNF polymorphisms and disease are truly linked to the function of the TNF genes or 
whether they are just markers of a disease association with the MHC, or other close 
by genes, in that it is easy to treat mice with either recombinant TNFa or with 
antibodies against TNFa. It will be by extrapolating from the mouse studies that we 
will be able to gain the most insight into the function of TNF polymorphisms. For 
example in Jacob and McDevitt's (1988) lupus nephritis model it is clear that 
treatment with TNFa can significantly delay the onset of the disease and that 
therefore the TNF polymorphism must be at least a marker of impaired TNFa 
production.
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1.4 Aims of this project
The role of TNF in the tumourigenesis of colorectal cancer is still unclear, however 
it has been shown that TNF is produced in very small quantities within colorectal 
tumours. A number of studies have shown that polymorphisms within the TNF 
locus can alter the secretion of TNFa by stimulated monocytes and a number of 
further studies have shown significant correlations between these polymorphisms 
and a number of disease in which TNF has been implicated as a major factor in the 
disease. It was therefore of interest to examine the role of these polymorphisms in 
colorectal carcinogenesis. Outlined below is a list of the six major aims of this 
work.
1. To develop a protocol for examining the association between polymorphisms 
within the TNF locus and malignant disease.
2. To correlate genotypes and alleles of the TNF polymorphisms with the presence 
of colorectal adenocarcinoma.
3. To establish if there is any correlation with genotypes and alleles of the TNF 
polymorphisms and the commonly used Dukes' system for the pathological grading 
of colorectal tumours.
4. To establish if any correlations could be detected between the genotypes and 
alleles of these polymorphisms and the progression of colorectal cancer patients to 
either local recurrence or metastatic disease subsequent to a curative resection of the 
primary tumour.
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5. To determine if extended genotypes exist between the alleles of the 
polymorphisms at the TNF locus and to examine the role of such extended 
genotypes in colorectal cancer.
6 . To examine briefly, in a small pilot study, if similar correlations could be made 
between these polymorphisms in gastric adenocarcinoma.
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2.1 Colorectal adenocarcinoma patients
The follow-up clinic of Professor C. S. McArdle was used as a source for all of the 
patients represented in this thesis. Patients attending this clinic had previously either 
received surgery for the resection of a primary colorectal tumour within Glasgow 
Royal Infirmary under the care of C. S. M. or had been referred to the Unit for 
treatment of hepatic metastases from primary colorectal tumours. Patients 
undergoing surgery for colorectal cancer under the care of C. S. M. are requested to 
attend a follow-up clinic every 3 months for the first year, followed subsequently by 
yearly appointments, or until further intervention is required. All patients undergo 
colonoscopy and computed tomographic scanning (CT scanning) at routine intervals. 
In total 100 consecutive patients were entered into this study. Figure 2.1 shows a 
complete list of the clinical data obtained for all of the patients in this study.
2.1.1 Epidemiology
The most recent statistics for Scotland shows that colon and rectum cancer 
accounted for 2,957 cases of cancer in 1991 representing 13% of all cancers 
(Directorate of information services, Scottish health statistics, 1993). The male-to- 
female ratio reported in this same study for colon was 1:1.18 and for rectum was 
1.24:1 giving an overall ratio for colorectal cancer of 1:1.06. The male-to-female 
ratio in the study group presented here is 1.13:1 with 53 males and 47 females. Chi 
squared analysis of the male to female ratio from our population and the 1991 data 
for Scotland shows no significant deviation from the expected frequency (%2= 0.58, 
p<0.45).
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Figure 2.1. Complete list of the clinical data obtained for all of the 
patients in this study
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It is widely accepted that cancer is a disease of the elderly and colorectal cancer is no 
exception. The mean age of patients in this study group was 6 6  with a maximum 
age of 8 8  and a minimum age of 34.
Family history was obtained, where possible, from all of the patients entering into 
this study. No patient reported any form of family history of colorectal 
adenocarcinoma that they could recall and no further examination of the families of 
these patients was undertaken due to the restraints of time on both the clinical and 
scientific staff within the department. These results are unusual given the frequency 
of hereditary colorectal cancer. From a population of 100 individuals statistically 
you would expect at least five individuals to have HNPCC and at least one 
individual to have FAP, however with out further analysis these data remain 
unavailable.
2.1.2 Pathology
Pathology reports were obtained for all of the patients which had undergone surgery 
within Glasgow Royal Infirmary. Full pathological data was obtained for 81 of the 
100 (81 %) patients entered into this study and is detailed in Figure 2.1. Of 81 
primary tumours where pathological reports were available, these were graded as 
follows:
8  well-differentiated adenocarcinomas,
1 invasive well-differentiated adenocarcinoma,
25 moderately well-differentiated adenocarcinomas,
1 moderately well -differentiated mucin-secreting adenocarcinoma,
1 ulcerating moderately well-differentiated adenocarcinoma,
31 moderately-differentiated adenocarcinomas,
2  moderately-differentiated invasive adenocarcinomas,
1 moderately-differentiated mucoid adenocarcinoma,
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8  poorly-differentiated adenocarcinomas,
1 transmural invasive adenocarcinoma,
1 invasive adenocarcinoma,
1 adenocarcinoma.
Although these descriptions are clinically useful, scientifically they are meaningless 
since they give no indication of the true invasiveness of the tumours. The original 
and most widely-used system for the grading of rectal tumours is that described by 
Dukes (Dukes, C.E., 1932). This staging system proposed a method of describing 
the level of penetration of the tumour mass into the bowel wall with stage A 
indicating penetration into, but not through, the bowel wall, stage B indicating 
penetration through the bowel wall and stage C indicating involvement of lymph 
nodes regardless of the degree of bowel wall penetration. A number of refinements 
have been made to this classification system to take into account the finer levels of 
penetration of the bowel wall and the degree of nodal metastases. The Dukes' staging 
system is now commonly used in the classification of all colorectal 
adenocarcinomas.
The original Dukes' staging system did not contain any classification for 
haematologically disseminated metastatic disease. In 1949, Dukes characterised a 
fourth stage in which he described the disease as being beyond the limits of surgical 
resection. In 1967 Turnbull et. al. formally defined this fourth stage as stage D, in 
which distant metastasis had occurred independent of the degree of penetration of 
the tumour through the bowel wall or lymph node involvement.
Figure 2.2 shows a comparison of the more descriptive American Joint Committee 
on Cancer and the Union Internationale Contre le Cancer staging classification 
system for colorectal cancer, with Dukes' staging. This system takes into account a
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Primary Tumour (T)
TX Not Assessable
TO No tumour in resected sample
Tis Carcinoma in situ
T1 Invades submucosa
T2 Invades muscularis propria
T3-T4 Serosa present:
T3 Invades through muscularis propria into subserosa
T4 Invades through serosa into peritoneal cavity or into
contiguous organs 
Serosa absent:
T3 Invades through muscularis propria
T4 Invades other organs (vagina, prostate, ureter, kidney)
Regional Lvmph Nodes IN)
NX No assessable nodes
NO No regional node metastases 
N1 1-3 nodes positive
N2 4 or more nodes positive
N3 central nodes positive
Distant Metastases OVO
MX Not assessable
MO No distant metastases
M l Metastases present
Corrrelation with TNM and Dukes* Staging
Dukes' A T1N0M0 
T2N0M0 
Dukes’B T3N0M0 
T4N0M0 
Dukes'C T(any)NlMO 
T(any)N2M0 
T(any)N3M0 
Dukes'D T(any)N(any)Ml
Table 2.2. Comparison of the original Dukes' staging system for 
colorectal malignancy with the AJC/UICC classification system.
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number of important clinical factors such as degree of invasion, degree of lymph 
node metastases and degree of distant metastases.
Dukes' staging was available for 92 of the 100 patients represented in this study. 
These included 7 (8 %) stage A tumours, 50 (54%) stage B tumours, 28 (30%) stage 
C tumours and 7 (8 %) stage D tumours. In a study of 70 patients from the west of 
Scotland by Finlay and McArdle (1986) the authors reported a distribution of 10% 
stage A tumours, 43% stage B and 47 % stage C. If we remove the stage D patients 
from this study and perform a Chi square analysis on the relative distribution of the 
three stages between the two studies we find that there is no significant difference 
between the Dukes' stage distribution between the two studies (%2=3.99, p=0.0678).
2.1.3 Survival analysis
The date of initial operation, date of "last seen" within the Department of surgery 
and date of death were recorded where possible for all patients within this study. 
Figure 2.3 shows a Kaplan-Mier survival analysis for 6 8  patients for whom date of 
initial operation and date of last appointment in clinic or date of death was available. 
The three-year survival rate for these patients is over 75%. The high survival rate 
seen within this population precludes a formal analysis of the difference in survival 
between subgroups of these patients determined by sex, Dukes' staging, site of 
disease and pathology of primary tumour. However it is widely accepted that there 
is some difference in mortality rate between males and females with women having 
a more favourable prognosis than men (Chapuis, P.H., et. al., 1985).
The degree of invasiveness as defined by Dukes' staging is known to have a 
significant effect on the survival of colorectal cancer patients. There is an expected 
five-year survival in the west of Scotland of 100% for stage A, 67% for stage B,
39% for stage C and 6 % for individuals with overt liver metastases (Finlay, I.G, and
90
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Figure 2.1. Kaplan-Meir survival curve for 68 patients for whom 
complete follow up data was available.
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McArdle, C.S., 1986). Eisenberg et. al. (1982) report five-year survival figures of 
82% for stage A, 73% for stage B and 40% for stage C whilst Willet et. al. (1984) 
report 97% for T1N0M0 tumours (-Stage A), 90% for T2N0M0 tumours (-Stage 
A), 78% for T3N0M0 tumours (-Stage B), 63% for T4N0M0 tumours (-Stage B), 
74% for T2N1M0 tumours (-Stage C), 48% for T3N1M0 tumours (-Stage C) and 
38% for T4N1M0 tumours (-Stage C).
Although these figures are interesting in terms of survival for these patients they 
have no bearing on the results of this study and are therefore reported only for 
completeness.
2.1.4 Metastatic disease
It was important to ascertain whether any association between polymorphisms at the 
TNF locus and the presence of colorectal cancer also showed an association with the 
development of metastatic disease within this study population. Development of 
metastatic disease was determined following standard clinical procedures including 
the use of CT scanning. 24 of the 100 patients within this study either had metastatic 
disease at the time of initial surgery or subsequently developed metastatic disease 
with or without local recurrent disease, whilst 4 patients developed local recurrent 
disease (Figure 2.1).
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2.2 Control individuals
115 samples of peripheral blood genomic DNA from control individuals were 
obtained as a generous gift from the department of Tissue Typing within Glasgow 
Royal Infirmary.
This DNA represents a random sample obtained from individuals entering a number 
of studies within the Tissue Typing department and including a number of 
volunteers for bone marrow donation. Very little data is available regarding these 
individuals, however no individuals at the time of donation of blood were reported to 
have any form of malignant disease. Data regarding the sex of the donors were 
available for 69 of the 115 controls. 36 of the 69 control individuals are male and 33 
are female, giving a male to female ratio of 1.09:1 compared to a ratio of 1.13:1 for 
the colorectal cancer patients. Chi square analysis of the sex distribution of the two 
populations shows no difference between the two groups (%2 =0 .0 1 , p=0.92).
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Materials and Methods.
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All reagents used within this study were obtained from Sigma unless otherwise 
stated.
3.1 Isolation of genomic DNA.
Since a good source of full-length genomic DNA was central to the success of this 
study it was decided from the outset that the traditional 'salting out' method for the 
isolation of genomic DNA would be used, rather than turning to (and having to rely 
upon) commercially available kits which at the time seemed only to be able to offer a 
low success rate at a high cost.
In theory the Polymerase Chain Reaction (PCR) is capable of amplifying one 
fragment of intact genomic DNA. In practice, however, it is clear that a number of 
factors do influence the ability of Taq DNA polymerase to amplify genomic DNA. 
The key factor in the reaction is of course the target DNA, and although many other 
factors can influence the reliability of the reaction, none of these will enable 
successful amplification with a poor preparation of the target DNA.
3.1.1 Collection of peripheral venous blood
7 ml of whole peripheral venous blood from consenting patients was collected into 
either pre-chilled blood tubes or into a "Vacutainer" containing 54|il of 0.34M tri­
potassium ethylene diamino tetra-acetic acid (K3  EDTA) and placed on ice prior to 
processing. Whole blood samples were stored for no longer than 3 hours prior to the 
isolation of peripheral blood mononuclear cells (PBMCs).
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3.1.2 Isolation of PBLs from peripheral venous blood
K3  EDTA-treated peripheral venous blood was removed from the collection tubes 
and placed into 50ml centrifuge tubes (Greiner). Three volumes of a red blood cell 
(RBC) lysis solution (8.3% w/v ammonium chloride, 0.037% w/v EDTA, 1% w/v 
potassium hydrogen carbonate) was placed into each of the 50ml tubes and the 
contents mixed gently. Tubes were then incubated at room temperature for 15 
minutes. Whole cells remaining were collected by centrifugation at 1,400 rpm for 
10 mins at room temperature. The supernatant was discarded and the process 
repeated a further two times. At this stage if whole RBCs were still present in the 
white cell pellet then the process of incubation in the RBC lysis solution was 
repeated one further time. However, if the white cell pellet was seen to be free from 
RBC contamination then the resultant cells were resuspended in a 500 pi volume of 
sterile phosphate buffered saline (PBS: 0.8% w/v sodium chloride, 0.02% w/v 
potassium chloride, 0.144% w/v disodium hydrogen phosphate, 0.02% w/v 
potassium dihydrogen phosphate pH 7.4) and transferred to 1.5 ml microcentrifuge 
tubes. The resultant purified PBL suspension was then stored at a temperature of -20 
°C until required for DNA purification.
3.1.3 Isolation of full-length genomic DNA from whole cells.
Human PBLs were isolated as above and allowed to thaw on ice if frozen. The 
PBLs were lysed as follows.
To each 500pl sample of PBL suspension, 500pl of a 0.6M solution of sodium 
acetate was added (final concentration of 0.2M) and the solutions mixed gently. 150 
pi of a 10% w/v aqueous solution of sodium dodecyl sulphate (SDS; final 
concentration of 1% w/v), 150pl of a 1 mg/ml solution of Proteinase K (final 
concentration of 0.1 mg/ml; Stratagene) and 200pl of sterile water were subsequently
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added to the PBL sodium acetate mixture and the solutions were again mixed gently. 
Digestion was performed at 37°C for a period of 48 hours.
The resultant viscous solution was split between two 1.5 ml microcentrifuge tubes 
and the cellular protein removed by a phenolxhloroform extraction. An equal 
volume of Tris EDTA (lOmM Tris-Cl, 0.5mM EDTA, pH 8.0) saturated 
phenol:chloroform (1:1 v/v) was added and the solutions mixed. The aqueous and 
solvent layers were separated by centrifugation in a microcentrifuge at 13,500 rpm 
for 10 mins at room temperature. The upper aqueous layer (containing the genomic 
DNA) was then aspirated by pipetting and placed into a new microcentrifuge tube 
and a fresh equal volume of Tris EDTA saturated phenolxhloroform was added.
The solutions were again mixed and the aqueous and solvent layers again separated 
by centrifugation and the upper aqueous layer was aspirated and placed into a further 
new microcentrifuge tube and this time an equal volume of chloroform was added. 
The solutions were mixed and the aqueous and solvent layers were separated again 
by centrifugation and the aqueous layer aspirated and placed into a further new 
microcentrifuge tube. Genomic DNA was precipitated by adding a 10th volume of 
5M ammonium acetate and 1 ml of ice cold 100% pure ethanol. The precipitated 
genomic DNA was removed from the mixture by spooling onto a sealed glass 
pasture pipette. The DNA, still attached to the pipette, was washed in 70% pure 
ethanol, then sterile water and left to resuspend in a 500jil volume of sterile, UV 
treated, water overnight at 37°C.
Once the DNA had resuspended a lOjil sample was removed, diluted in 990jil of 
sterile water, and used to calculate the concentration of the stock DNA by measuring 
absorbance at 260nm. One O.D.260 uni t was taken to represent 50p,g per ml of 
undiluted genomic DNA. The genomic DNA was aliquoted, coded and then stored 
at 4°C.
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3.2 Confirmation of integrity of genomic DNA
In order that the integrity of the isolated genomic DNA be controlled I have adopted 
a scheme by which all DNA samples were analysed by horizontal submarine gel 
electrophoresis on a 1% w/v LE SeaKem agarose gel (FlowGen).
3.3 Genotype determination at the -308 TNFa RFLP Locus
3.3.1 PCR primers
Oligonucleotide PCR primers were synthesised according to published sequences 
(Wilson, A.G., et. al., 1992) on an Applied Biosystems automated synthesiser.
-308TNFa 5' 5'- AGGCAATAGGTTTTGAGGGCCAT -3'
-308TNFa 3' 3'- TCCTCCCTGCTCCGATTCCG -3'
Primers were obtained as an ammonia elution and were subsequently deprotected by 
incubation at 56°C over night. The primers were purified by precipitation, by adding 
a lOth of a volume of 5M ammonium acetate (ammonium acetate was used due to its 
ability to volatilize at 37°C during the subsequent rotary evaporation) and 2 volumes 
of ice-cold 100% pure ethanol and incubating at -70°C for 1 hour. The precipitated 
oligonucleotide was pelleted by centrifugation at 14,000 rpm and 4°C for 30 mins 
straight from the -70°C freezer. The resultant oligonucleotide pellet was washed in 
70% pure ethanol, centrifuged for a further 15 mins and the ethanol evaporated off 
by centrifugation in a rotary evaporator. The lyophilised oligonucleotide pellet was 
resuspended in a 500jxl volume of sterile, UV treated water and the concentration 
calculated by measuring the optical density at 260nm (one O.D.260 unit 1S taken to 
represent 33pg per ml of single stranded oligonucleotide DNA) and the molarity of
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each of the primer solutions calculated and noted for future reference. (Note- no 
further dilution of the stock solutions were made at this point). The resultant stock 
primer solutions were stored at -20°C until required. Before use primers were 
diluted to give a lOpM working solution to be used at a 1:10 dilution to give a final 
concentration of lpM  per reaction.
3.3.2 PCR amplification
250ng of genomic DNA was added to 45pl of a PCR master mix containing IjiM of 
each primer, 1 unit of Taq DNA polymerase (Applied Biotechnology), 2mM dATP, 
dTTP, dCTP, dGTP (GibcoBRL), 1,5mM magnesium chloride (Applied 
Biotechnology) and a lx final concentration of reaction buffer (Applied 
Biotechnology). The samples were overlayed with 50 pi of light mineral oil to 
eliminate evaporation during cycling and centrifuged briefly to separate the two 
layers.
The samples were subjected to temperature cycling on a Biometra Uno Block 
thermocycler as follows
Step 1 Melting temp 94°C for 180 seconds
Annealing temp 60°C for 60 seconds 
Extension temp 72°C for 60 seconds
Step 2 Melting temp 94°C for 60 seconds
Annealing temp. 60°C for 60 seconds } x35 
Extension temp. 72°C for 60 seconds
Step 3 Final extension 72°C for 300 seconds
99
After amplification the PCR products were stored at 4°C until required for analysis.
3.3.3 Nco-I restriction endonuclease digestion of PCR products.
The basis of the -308TNFa RFLP is that the PCR amplification produces a 117bp 
fragment which incorporates a polymorphic Nco-I restriction endonuclease site 
within the 3' end of the PCR product. In order to assign genotypes, the resultant 
PCR products were therefore subjected to Nco-I restriction endonucleases digestion.
To a 1 Ojul aliquot of PCR product 1.5 fil of appropriate 10 x buffer (GibcoBRL), 5 
units of Nco-I restriction endonuclease (GibcoBRL) and sterile deionised water to a 
final volume of 20p,l was added on ice. All reagents were mixed by vortexing and 
centrifuged briefly and then incubated at 37°C for 1 hour. The resultant products 
were analysed on a 9% polyacrylamide gel as described below.
3.3.4 Polyacrylamide gel electrophoresis (PAGE) of PCR products
10|il of restriction endonuclease digested PCR products and lOpl of the undigested 
PCR products were electrophoresed in parallel on 9% non-denaturing 
polyacrylamide gel on a 20cm x 20cm Protean II gel electrophoresis system,
(Biorad) in TAE buffer, with ())X174 digested with Hae ID (GibcoBRL) as a 
molecular weight marker. Electrophoresis was performed at a constant current of 30 
mA per gel until the bromophenol blue in the gel loading buffer was 2cm above the 
bottom of the gels. The gel assembly was dismantled and the gels submerged in lx 
TAE containing 0.4 pg/ml w/v ethidium bromide and incubated for 30 minutes 
before being rinsed in lx TAE. The resultant banding pattern was visualised and 
photographed under translumination with an ultraviolet (UV) light source.
Genotypes were assigned as follows;
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1) homozygosity for the T1 allele as a band of 97bp in size, plus a band of 20bp;
2) heterozygosity for T1 and T2 alleles as a band of 107bp size, plus bands of 97bp 
and 20bp in size;
3) homozygosity for T2 allele as band of 107bp in size only, (Figure 3.1).
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Figure 3.1. Polyacrylamide gel showing the three possible -308 TN Fa 
RFLP genotypes. Sequence specific polymerase chain rection products 
are digested with Ncol restriction endonuclease give give two possible 
products per individual. Lanes 1 and 3 -homozygous TNF2 allele, Lane 2, 
4 and 6 - hetezozygous for TNF1 and TNF2 alleles, Lane 5 homozygous 
for TNF1 allele. Note- although not shown on this photograph (J)X174 
digested with Haelll was routinely used as a size marker.
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3.4 Genotype determination at the LTa Nco-I RFLP Locus
3.4.1 PCR primers
Oligonucleotide PCR primers were synthesised according to the published sequence 
(Messer,G., et. al., 1991) on an Applied Biosystems automated synthesiser.
LT-oc Nco-I 5' 5'- CCGTGCTTCGTGCTTTGG ACT A -3’
LT-a Nco-I 3’ 3’- AGAGCTGGTGGGGACATGTCTG -3'
The primers were deprotected and the resultant stock primer solution stored at -20°C 
until required as previously described (see section 3.3.1).
3.4.2 PCR Amplification
250ng of genomic DNA was added to 45pl of a PCR master mix containing l|uM of 
each primer, 1 unit of Taq DNA polymerase (Applied Biotechnology), 2mM dATP, 
dTTP, dCTP, dGTP (GibcoBRL), 1.5mM magnesium chloride (Applied 
Biotechnology) and a lx final concentration of PCR reaction buffer (Applied 
Biotechnology). The samples are overlayed with 50 pi of light mineral oil to 
eliminate evaporation during cycling and centrifuged briefly to separate the two 
layers.
The samples were subjected to 40 cycles on a Biometra Uno Block thermocycler as 
follows
Step 1 Initial Melt 95°C for 6  mins
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Step 2 Melting temp 95°C for 60 seconds
Annealing temp. 64°C for 60 seconds } x40 
Extension temp. 72°C for 60 seconds
Step 3 Final extension 72°C for 5 mins
After amplification the PCR products were stored at 4°C until required for analysis.
3.4.3. Nco-I restriction endonuclease digestion of PCR products.
The basis of the LTa Nco-I RFLP is that the PCR amplification produces a 750bp 
fragment which straddles a polymorphic Nco-I restriction endonuclease site. In 
order to assign genotypes the resultant PCR products were therefore subjected to 
Nco-I restriction endonucleases digest.
To a 10|Ltl aliquot of PCR product 1.5 p i of appropriate 10 x buffer (GibcoBRL), 5 
units of Nco-I restriction endonuclease (GibcoBRL) and sterile deionised water to a 
final volume of 2 0 p l were added on ice. All reagents were mixed by vortexing and 
centrifuged briefly and then incubated at 37°C for 1 hour. The resultant products 
were analysed on a 2% LE SeaKem agarose gel (Flowgen) as described below.
3.4.4 Agarose gel electrophoresis of PCR products
lOpl of restriction endonuclease digest PCR products were electrophoresed in 
parallel on a 2% agarose gel in a TAE buffer containing 0.4 pg/ml of Ethidium 
Bromide, with <j)X174 digested with Hae III (GibcoBRL) as a molecular weight 
marker. Gels were electrophoresed at a constant current of 50 mA until all bands 
were clearly resolved.
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Genotypes were assigned as follows;
1) homozygosity for TNFB*1 allele as bands of 500bp and 250bp in size only;
2) heterozygosity for TNFB*1 and TNFB*2 alleles as a band of 750bp size, plus 
bands of 500bp and 250bp in size;
3) homozygosity for the TNFB*2 allele as a single band of 750bp in size (Figure
3.2).
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Figure 3.2. Agarose gel showing the three possible L T a Ncol 
RFLP genotypes. Sequence specific polymerase chain rection products 
are digested with Ncol restriction endonuclease give give two possible 
products per individual. Lane 1 - <}>X174 HaeIII digested ladder, Lane 2 - 
undigested PCR product from TNFB*2 homozygous individual, Lane 3 - 
Ncol digested PCR product from Lane 2, Lane 4 - undigested PCR product 
from heterozygous individual, Lane 5 - Ncol digested PCR product from 
Lane 4, Lane 6 - undigested PCR product from TNFB* 1 homozygous 
individual, Lane 7 - Ncol digested PCR product from Lane 6.
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3.5 Genotype determination at the four TNF microsatellite
polymorphism loci 
3.5.1 PCR primers
Oligonucleotide PCR primers were synthesised according to published sequences 
(Udalova, I.A., et. al., 1993) on an Applied Biosystems automated synthesiser.
TNFa 5' 5'- GCCTCT AG ATTTC ATCC AGCC AC AG-3'
TNFa 3' 5’- CCTCTCTCCCCTGCAACACACA-3'
TNFc 5’ 5'- GGGAGGTCTGTCTTCCGCCG-3'
TNFc 3’ 5'- CGTTCAGGTGGTGTCATGGG-3'
TNFd 5' 5 - AGATCCTTCCCTGTGAGTTCTGCT-3'
TNFd 3' 5'- CATAGTGGGACTCTGTCTCCAAAG-31 
TNFe 5' 5’- GTGCCTGGTTCTGGAGCCTCTC-3'
TNFe 3’ 5’- TGAGACAGAGGATAGAGACAG-3'
The primers were deprotected and the resultant stock primer solution were stored at 
-20°C, as previously described (see section 3.3.1), until required.
3.5.2 PCR amplification
lOOng of genomic DNA were added to 18jll1 of a PCR master mix containing IjliM of 
each primer, 1 unit of Taq DNA polymerase (Applied Biotechnology), 2mM dATP, 
dTTP, dCTP, dGTP (GibcoBRL), 1.5mM magnesium chloride (Applied 
Biotechnology), 0.4pCi of a^ 2P dCTP (Amersham) and a lx final concentration of 
PCR reaction buffer (Applied Biotechnology). The samples are overlayed with 50 |il
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of light mineral oil to eliminate evaporation during cycling and centrifuged briefly to 
separate the two layers.
The samples were subjected to 40 cycles on a 96 well Biometra Uno Block 
thermocycler as follows
Step 1 Initial Melt 94°C for 5 mins
Step 2 Melting temp. 94°C for 25 seconds
Annealing temp. 60°C for 60 seconds } x40 
Extension temp. 74°C for 60 seconds
Step 3 Final extension 74°C for 10 mins.
After amplification the PCR products were stored, under appropriate conditions for 
the storage of radioactive material 4°C, until required for analysis.
3.5.3 Polyacrylamide gel electrophoresis of microsatellite PCR 
products.
3.5.3.1 Production of y32p labelled 10bp ladder
l|il of lObp ladder (GibcoBRL) was end-labelled with y32p ATP (Amersham) by 
incubating with 2pl of lOx T4 polynucleotide kinase buffer (0.5M Tris.Cl pH 7.6, 
0.1M MgCl2,50mM dithiothreitol, ImM spermidine HC1, ImM EDTA pH 8.0), 5pl 
of ^ 32p ATP (~50pCi; Amersham), 1 lpl sterile deionised H2 O and lp.1 T4 
polynucleotide kinase (1 Unit/|il). The reaction mixture was centrifuge briefly before 
being incubated at 37°C for 30 mins.
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3.5>3.2 Non-denaturing PAGE
3jlx1 aliquots of the radiolabelled PCR products were analysed on a 15% non­
denaturing polyacrylamide gel in TAE buffer on a Base Ace vertical sequencing gel 
rig (Stratagene) with 2 lanes of the y ATP labelled lObp ladder as size references 
(plus M31A (American Tissue Culture Collection) in the case of TNFa,b and c).
Gels were run overnight at 22 mA until the bromophenol blue had run off the bottom 
and the xylene cyanol was within 5 cm of the bottom of the gel. The resultant gels 
were removed from the glass plates and dried onto Whatman 3MM filter paper on a 
vacuum gel dryer (Biorad).
The dry gels were incubated with X-ray sensitive photographic film overnight to 
produce an autoradiographic image of the gel and the electrophoretic mobility for 
each of the samples was measured in reference to the lObp ladder and compared 
with that of the cosmid M31A which has a known TNF genotype of a8 , b2 and cl or 
with reference to each other in the case of TNFd and TNFe (Figures 3.3, 3.4, 3.5, 
3.6). Although it is common to see shadow bands running at lower molecular 
weights than the actual alleles the TNFa microsatellites produced shadow bands of a 
higher molecular weight. This phenominon was consistant throughout the whole of 
this study and alleles were taken to be the most dense bands on the gels (see figure
3.3)
In order to eliminate operator bias a number of gels were analysed by two seperate 
individuals, the author of this thesis and Dr Grant Gallagher. In some cases 
duplicate samples were also run on separate gels and amplified on seperate occasions 
in order to confirm allele calls.
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3.5.3.3 TNF allele sizes
TNFa Size bp
1 93
2 95
3 97
4 99
5 101
6  103
7 105
8  107
9 109
10 111
11 113
12 115
13 117
TNFc Size bp
1 96
2 98
TNFd Size bp
1 105
2 107
3 109
4 111
5 113
6  115
7 117
110
TNFe Size bp
1 108
2 110
3 112
I l l
4 5 6 7
♦
Figure 3.3. Section from a representative polyacrylamide gel showing 
a range of the possible TNFa microsatellite alleles. Sequence specific a  
32p dCTP labelled polymerase chain reaction products are separated on a 
15% non-denaturing polyacrylamide gel. Lane 1 - 10103 with genotype 
TNFa7,al 1, Lane 2 - 10104 with genotype TNFa3,a8, Lane 3 - 10105 
with genotype TNFa5,a8, Lane 4 - 10106 with genotype TNFa3,a3, Lane 
5 - 10069 with genotype TNFa6,al 1, Lane 6 - 10070 with genotype 
TNFa3,al0, Lane 7 - lObp 32p^ATP labelled lObp ladder (GibcoBRL). 
Bands representing the alleles are marked with arrowheads.
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Figure 3.4. Section from a representative polyacrylamide gel showing 
the two possible TNFc microsatellite alleles. Sequence specific a ^ p  
dCTP labelled polymerase chain reaction products are separated on a 15% 
non-denaturing polyacrylamide gel. Lane 1 - 10089 with genotype 
TNFcl,c2, Lane 2 - 10090 with genotype TNFcl,c2, Lane 3 - 10091 with 
genotype TNFc 1 ,c2, Lane 4 - 10092 with genotype TNFc 1 ,c 1, Lane 5 - 
10093 with genotype TNFc2,c2, Lane 6 - 10094 with genotype 
TNFc 1 ,c 1, Lane 7 - 10095 with genotype TNFc 1 ,c 1, Lane 8 - 10096 with 
genotype TNFc 1,cl. Bands representing the alleles are marked with 
arrowheads.
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Figure 3.5. Section from a representative polyacrylamide gel showing 
a range of the possible TNFd microsatellite alleles. Sequence specific a  
32p dCTP labelled polymerase chain reaction products are separated on a 
15% non-denaturing polyacrylamide gel. Lane 1 - 20068 with genotype 
TNFd 1 ,d 1, Lane 2 - 20069 with genotype TNFd 1 ,d5, Lane 3 - 20070 with 
genotype TNFd2,d6, Lane 4 - 20071 with genotype TNFd4,d7, Lane 5 - 
20072 with genotype TNFd4,d7, Lane 6 - 20073 with genotype 
TNFd4,d7, Lane 7 - 20075 with genotype TNFd2,d6, Lane 8 - lObp yATP 
labelled lObp ladder (GibcoBRL). Bands representing the alleles are 
marked with arrowheads.
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Figure 3.6. Section from a representative polyacrylamide gel 
showing a range of the possible TNFe microsatellite alleles.
Sequence specific dCTP labelled polymerase chain reaction products 
are separated on a 15% non-denaturing polyacrylamide gel. Lane 1 - 2001 1 
with genotype TNFel,e2, Lane 2 - 20012 with genotype TNFe2,e2, Lane 
3 - 20013 with genotype TNFel,e2, Lane 4 - 20014 with genotype 
TNFe2,e2, Lane 5 - 20015 with genotype TNFel,e3, Lane 6 - 20016 
with genotype TNFe2,2, Lane 7 - with genotype TNFe2,e2. Bands 
representing the alleles are marked with arrowheads.
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3.6 Statistical Analysis
All data were compiled in tabulated form on Excel 4 for Windows on a Packard Bell 
PC. Statistical analysis was performed in all cases by Chi-square test on the Minitab 
for Windows (Minitab version 10.1) computer program running on a standard PC. 
Reference was made to the book Practical Statistics for Medical Research by 
Douglas G. Altman. Further reference was made to a number of statisticians 
including the group of Dr. Gordon Murray in the University of Glasgow.
Alleleic frequencies were calculated following the protocol of Nedospasov et. al. 
(1991) using the following equation
Allelic frequency of allele X = No of occurences of X in the given population
(No.of individuals in Population) X 2
It is assumed that there are no "null" alleles at any of these loci and therefore where 
only one band was observed on the gel this was taken to indicate homozygosity for 
that particular allele. This was taken into consideration during the calculations by 
counting this as two occurences of the particular allele.
Statistical significance was taken at the 95% level with p<0.05 being taken as 
significant. Comparisons of the frequency of individual allelels of the various 
polymorphisms are reported in various sections of this thesis. For each of these 
instances two p values are stated. The first p is derived directly from the Chi-square 
analysis, whilst the second (pc) takes into account the Bonferroni correction required 
for multiple analysis. Although considerable emphasis is placed on the uncorrected 
p values in the discussion of the results of this thesis it must be remembered that it is 
the corrected (pc) values that indicate true statistical significance in this study.
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Results
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4.1 Associations between alleles of polymorphisms at the TNF locus
and the presence of colorectal cancer
There is compelling evidence to suggest that TNF may have a role in the 
development and progression of colorectal cancer (see section 1.3.2 of this thesis). 
Since a number of alleles of the polymorphisms located within the TNF locus have 
been associated with either over- or under-production of TNF (see section 1.3.4 of 
this thesis) it was of interest to determine if there is any association between alleles 
of these polymorphisms and the presence of colorectal cancer. 100 individuals with 
histologically proven colorectal cancer were obtained following the criteria as 
described in section 2.1 of this thesis and were compared to a panel of 115 control 
individuals who had no form of malignant disease at the time of collection of blood. 
Table 4.1 shows a complete list of the genotypes at all of the six polymorphisms 
examined in both the colorectal cancer population and the normal control group.
4.1.1 -308 TNFa RFLP analysis
The -308 TNF-a RFLP is the only polymorphism examined in this thesis which is 
located within the gene encoding TNF-a. It is characterised by a single base 
substitution at position -308 within the promotor region of TNF-a. It is identified in 
genomic DNA by performing a sequence specific polymerase chain type reaction to 
amplify a 107bp stretch of DNA which incorporates a polymorphic Nco-I restriction 
endonuclease site. Restriction digestion results in the identification of a bi-allelic 
polymorphism resulting in the ability to assign one of three possible genotypes to 
any individual. These genotypes are termed homozygous for the TNF1 allele 
(Tl/Tl), homozygous for the TNF2 allele (T2/T2) or heterozygous for both alleles 
(T1/T2).
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Code No. TNFa TNFc TNFd TNFe LT-alpha Nco-I 308 TNF-alpha
10001 3,3 1,2 6,7 2,3 B*l/B*2 Tl/Tl
10002 10,11 1 7,7 3,3 B*l/B*2 Tl/Tl
10003 2,2 1,2 7,7 B*2/B*2 T1/T2
10004 2,2 1,2 4,6 2,3 B*2/B*2 T1/T2
10005 2,2 1,2 6,6 2,3 B*2/B*2 T1/T2
10006 2,2 1 6,6 3,3 B*2/B*2 T2/T2
10007 4,10 1 B*l/B*2 T1/T2
10008 6,10 1,2 3,3 B*l/B*2 T1/T2
10009 3,10 1,2 3,4 3,3 B*2/B*2 T1/T2
10010 1,6 1,2 5,5 B*2/B*2 T1/T2
10011 3,5 1 1,2 3,3 B*l/B*2 T2/T2
10012 2 3,4 T1/T2
10013 1 2,3 Tl/Tl
10014 5,5
10015 1,2 3,3 3,3 Tl/Tl
10016 1,3
10017 1,2 3,3 1,3 Tl/Tl
10018 1 2,2 Tl/Tl
10019 7,12 1
10020 1,2 1,2 2,2 B*2/B*2 Tl/Tl
10022 7,11 1 B*l/B*2 Tl/Tl
10023 3,3 1,2 3,3 B*2/B*2 Tl/Tl
10025 9,10 1 3,3 B*2/B*2 Tl/Tl
10026 7,7 1,2 4,4 1,3 B*l/B*2 Tl/Tl
10027 2,4 2 B*2/B*2 Tl/Tl
10028 2,4 1,2 5,5 B*2/B*2
10029 10,12 1 5,5 B*2/B*2
1(0030 7,10 1 4,5
1(0031 7,7 1 5,5 B*l/B*l Tl/Tl
1(0032 3,11 1,2 1,3 B*l/B*2 Tl/Tl
10033 3,11 1 4,4 B*l/B*2
10034 2,9 2 B*2/B*2
10035 3,7 1,2 2,3 B*l/B*2 T1/T2
10036 6,11 1 2,2 B*l/B*2
10037 3,9 2 2,2 B*2/B*2
10038 1,2 1,2 B*2/B*2 Tl/Tl
10039 3,4 1 B*2/B*2 T2/T2
10040 7,11 1 2,2 Tl/Tl
10041 8,11 1 2,2 B*l/B*2 Tl/Tl
10042 3,3 2 3,3 B*2/B*2 Tl/Tl
10043 7,11 1 4,4 B*2/B*2 Tl/Tl
10044 7,7 1,2 Tl/Tl
10045 4,4 2,4
10046 8,11 1 3,3 B*2/B*2 Tl/Tl
10047 3,11 1,2 3,6 3,3 Tl/Tl
10048 11,12 1 B*2/B*2
10049 10,10 1 3,4 B*2/B*2 Tl/Tl
10050 3,11 1,2 3,4 1,2 B*2/B*2 Tl/Tl
10051 1 3,4 T1/T2
10052 1,2 1,4 1,2 B*l/B*2 T1/T2
10053 1 2,4 T1/T2
10054 3,3 1,2 2,4 T1/T2
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Code No. TNFa TNFc TNFd TNFe LT-alpha Nco-I 308 TNF-alpha
10055 3,3 1 2,2 T1/T2
10056 1.2 3,3 3,3 B*2/B*2 Tl/Tl
10057 3,3 1 2,4 T1/T2
10058 1 4,4 T1/T2
10059 1,2 5,5 3,3 B*2/B*2 Tl/Tl
10060 3,6 1,2 B*l/B*2 Tl/Tl
10061 3,9 1,2 4,4
10066 3,3 2 B*2/B*2 Tl/Tl
10068 3,10 1,2 5,6 B*2/B*2 Tl/Tl
10069 6,11 1 5,5 1,3 B*l/B*2 Tl/Tl
10070 3,10 1,2 6,7 3,3 B*2/B*2 T1/T2
10071 6,10 1,2 1,3 B*l/B*2
10072 7,10 1 1,3 B*2/B*2
10073 7,10 1 3,3 B*l/B*2
10074 2,7 1,2 5,5 3,3 B*l/B*2
10075 7,11 1 3,3 B*l/B*2
10076 2,10 2 5,6 3,3 B*2/B*2 Tl/Tl
10077 3,10 2 2,3 B*l/B*2 Tl/Tl
10078 5,11 1,2 4,5 2,3 B*l/B*2 Tl/Tl
10079 3,7 1 4,5 3,3 B*l/B*l T1/T2
10080 3,11 1 3,3 . B*l/B*2 T1/T2
10081 5,5 1 1,2 3,3 B*l/B*l T1/T2
10082 3,11 2 3,3 3,3 B*2/B*2 Tl/Tl
10083 4,7 1,2 1,5 3,3 B*l/B*2 Tl/Tl
10084 4,8 1 3,4 2,3 B*l/B*2 T1/T2
10085 8,11 1 3,3 B*l/B*2 Tl/Tl
10086 8,11 1,2 4,4 3,3 B*l/B*2 Tl/Tl
10087 7,12 1 3,5 2,2 B*l/B*2 Tl/Tl
10088 7,12 1 3,5 3,3 B*l/B*2 Tl/Tl
10089 3,11 1,2 1,3 3,3 B*l/B*2 T1/T2
10090 3,11 1,2 1,3 B*l/B*2 T1/T2
10091 3,7 1,2 3,3 1,3 B*l/B*2 Tl/Tl
10092 10,10 1 4,4 3,3 B*2JB*2 Tl/Tl
10093 5,10 2 2,4 2,2 B*2JB*2 Tl/Tl
10094 6,6 1 1,2 3,3 B*l/B*l Tl/Tl
10095 10,10 1 2,4 2,3 B*2JB*2 Tl/Tl
10096 6,10 1 3,3 2,3 Tl/Tl
10097 6,11 3,4 1,3
10098 6,10 1,2 3,4 2,2
10099 3,11 1,2 3,3 Tl/Tl
10100 3,3 1,2 4,4 3,3 Tl/Tl
10101 4,8 1 1,3 3,3
10102 6,8 1,2 3,5 1,3 Tl/Tl
10103 7,11 1 3,3 3,3 Tl/Tl
10104 3,8 1,2 2,4 2,3 Tl/Tl
10105 5,8 1,2 2,3 Tl/Tl
10106 3,3 1,2 1,4 1,3 T1/T2
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Code No. TNFa TNFc TNFd TNFe LT-alpha Nco-I 308 TNF-alpha
20001 5,10 4,5 3,3 B*l/B*2
20002 6,9 1,1 3,5 B*l/B*2 Tl/Tl
20003 2,10 2,2 4,6 B*2/B*2 Tl/Tl
20004 7,12 1,1 4,4 3,3 B*2/B*2 Tl/Tl
20005 5,10 1,2 5,5 2,2 B*2/B*2 Tl/Tl
20006 7,11 1,1 B*2/B*2 Tl/Tl
20007 2,4 1,2 3,5 3,3 B*l/B*2 T1/T2
20008 4,10 1,1 3,3 B*l/B*2 T1/T2
20009 7,10 1,2 3,3 2,2 B*2/B*2 Tl/Tl
20010 9,10 1,1 3,3 B*2/B*2 Tl/Tl
20011 2,6 1,1 5,5 1,2 B*l/B*2 Tl/Tl
20012 4,9 1,2 4,5 2,2 B*l/B*2 T1/T2
20013 2,6 4,4 1,2 B*l/B*2 Tl/Tl
20014 2,6 1,1 4,4 2,2 B*l/B*l T1/T2
20015 2,7 1,2 2,2 1,3 B*2/B*2 Tl/Tl
20016 7,7 1,1 1,3 2,2 B*2/B*2 Tl/Tl
20017 6,6 2,3 2,2 B*l/B*l Tl/Tl
20018 6,10 1,1 4,4 B*l/B*2 Tl/Tl
20019 2,11 1,2 B*2/B*2 Tl/Tl
20020 2,11 1,1 3,3 2,2 B*l/B*2 T1/T2
20021 B*l/B*2 T1/T2
20022 7,7 B*l/B*2 T1/T2
20023 6,6 B*2/B*2 Tl/Tl
20024 B*2/B*2 Tl/Tl
20025 2,2 B*2/B*2
20026
20027 8,8 1,1 B*l/B*2
20028 4,9 1,2 B*2/B*2
20029 5,10 1,2 B*2/B*2
20030 9,10 B*2/B*2
20031 5,10 1,2 B*l/B*2
20032 5,10 1,2 B*l/B*2
20033 2,6 1,1 B*l/B*2
20034 2,5 1,1 B*2/B*2
20035 2,2 2,2 B*2/B*2
20036 2,8 1,3 B*2/B*2
20037 1,1 1,1 B*l/B*2
20038 1,5 1,2 B*l/B*2
20039 1,4 1,1 B*l/B*2
20040 4,10 B*2/B*2
20041 1,8 1,2 B*2/B*2
20042 6,6 1,1 B*l/B*2
20043 5,5 1,1 B*l/B*2
20044 4,4 1,1 1,3 B*l/B*2
20045 2,9 B*l/B*2
20046 2,7 1,1
20047 6,12 1,1 4,6 2,2 B*2/B*2
20048 8,8 1,1 5,5 1,2 B*l/B*2 Tl/Tl
20049 6,9 1,2 5,5 3,3 B*2/B*2 Tl/Tl
20050 7,9 1,1 4,6 B*l/B*l T1/T2
20051 6,7 1,1 3,4 B*l/B*l T2/T2
20052 4,10 1,2 4,5 2,2 B*2/B*2 Tl/Tl
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Code No. TNFa TNFc TNFd TNFe LT-alpha Nco-I 308 TNF-alpha
20053 4.4 2,2 5,5 1,2 B*2/B*2 Tl/Tl
20054 1,1 4,4 2,2 B*2/B*2 Tl/Tl
20055 12,12 1,2 4,4 2,2 B*2/B*2 Tl/Tl
20056 12,12 1,1 2,4 2,2 B*2/B*2 Tl/Tl
20057 6,12 1,1 1,4 2,3 B*l/B*2 T1/T2
20058 4,6 1,2 3,5 1,3 B*l/B*2 T1/T2
20059 1,2 2,3 3,3 B*2/B*2 Tl/Tl
20060 2,2 2,3 B*l/B*2 Tl/Tl
20061 6,6 3,3 2,2 Tl/Tl
20062 4,4 1,2 1,3 B*l/B*l T1/T2
20063 1,1 4,4 B*2/B*2 Tl/Tl
20064 6,6 2,2 1,3 Tl/Tl
20065 4,4 1,1 Tl/Tl
20066 3,3 3,3 B*l/B*2 Tl/Tl
20067 13,13 1,1 2,2 2,3 B*2/B*2 Tl/Tl
20068 6,11 1,2 1,1 2,3 T1/T2
20069 1,2 1,5 3,3 B*l/B*2 T2/T2
20070 6,13 1,2 2,6 B*l/B*2 T1/T2
20071 11,11 1,2 4,7 3,3 Tl/Tl
20072 12,13 2,2 4,7 B*l/B*l T1/T2
20073 8,10 1,1 4,7 1,1 B*2/B*2 Tl/Tl
20074 7,7 1,2 T1/T2
20075 4,11 2,7 3,3 B*l/B*2 T1/T2
20076 11,11 B*2/B*2 Tl/Tl
20077 11,13 4,4 3,3 B*l/B*l T1/T2
20078 10,10 B*2/B*2 Tl/Tl
20079 10,10 4,4 3,3 Tl/Tl
20080 5,5 4,4 2,3 B*l/B*2 Tl/Tl
20081 10,10 4,6 B*2/B*2 Tl/Tl
20082 8,8 B*l/B*2 T1/T2
20083 10,10 1,2 B*2/B*2 Tl/Tl
20084 9,10 2,4 2,2 B*2/B*2 Tl/Tl
20085 9,10 2,4 2,2 B*2/B*2 Tl/Tl
20086 9,9 1,4 T1/T2
20087 3,5 B*2/B*2 Tl/Tl
20088 1,1 2,2 B*l/B*2 T1/T2
20089 8,9 1,4 B*l/B*l T2/T2
20090 3,8 2,4 3,3 T1/T2
20091 2,6 2,4 T1/T2
20092 5,5 3,6 3,3 B*l/B*2 Tl/Tl
20093 5,5 4,6 3,3 B*l/B*2 Tl/Tl
20094 1,8 4,4 3,3 B*l/B*2 Tl/Tl
20095 3,3 4,6 3,3 B*l/B*l T1/T2
20096 2,4 6,6 3,3 B*l/B*l Tl/Tl
20097 5,5 T1/T2
20098 8,9 4,4 3,3 Tl/Tl
20099 8,8 5,5 B*2/B*2 Tl/Tl
20100 2,3 1,2 3,3 1,2 B*l/B*l T1/T2
20101 1,9 2,2 4,5 2,2 Tl/Tl
20102 7,7 1,1 2,4 B*2/B*2 Tl/Tl
20103 7,7 1,1 2,2 B*2/B*2 Tl/Tl
20104 3,8 1,2 2,2 B*l/B*2 Tl/Tl
122
Code No. TNFa TNFc TNFd TNFe LT-alpha Nco-I 308 TNF-alpha
20105 3,3 1,2 5,5 B*l/B*2 Tl/Tl
20106 6,6 1,2 2,7 B*2/B*2 Tl/Tl
20107 1,2 1,5 B*l/B*l T2/T2
20108 1,5 1,2 2,2 Tl/Tl
20109 1,1 1,2 1,5 B*l/B*2 T1/T2
20110 1,9 1,1 1,2 B*l/B*2 T1/T2
20111 3,3 1,1 2,2 T1/T2
20112 3,5 1,1 6,6 B*l/B*l Tl/Tl
20113 4,4 1,2 3,7 B*l/B*2 Tl/Tl
20114 1,1 B*l/B*2 T1/T2
20115 2,2 2,2 5,5 B*2/B*2 Tl/Tl
Table 4.1 Complete genotypes at the six TNF polymorphisms in a) 
the colorectal cancer patients, and b) the normal control individuals.
Colorectal cancer patients are coded 10001 to 10106 whilst the normal 
individuals are coded 20001 to 20115.
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The -308 TNF a  RFLP genotype for each individual was determined by the method 
described in section 3.3 of this thesis. Genotypes were determined for 86 (75%) of 
the normal control individuals and 79 (79%) of the colorectal cancer patients.
Genotype and allelic frequencies were calculated for the two populations and plotted 
as separate histograms. Figure 4.1 shows a histogram of the frequencies of the three 
possible genotypes of the -308 TNF-a RFLP of the normal and colorectal cancer 
populations. Examination of the relative frequencies between the two groups, by 
chi-square analysis, demonstrates that there is no significant difference between the 
genotype frequencies of the two groups (%^=0.630, p=0.3649, df=2). Figure 4.2 
shows a histogram of the frequency of the TNF1 and TNF2 alleles in the two 
populations. As expected from the results of the genotype analysis, chi-square 
analysis shows that there is also no statistically significant difference between the 
alleleic frequencies of the two populations, (%2=0.607, p=0.3780, df=l).
4.1.2 LT-q Nco-I RFLP analysis
The LT-a Nco-I RFLP (also known as the TNF-|3 Nco-I RFLP) is the most widely 
studied of the polymorphisms associated with TNF. Like the -308 TNF-a RFLP it is 
associated with a polymorphic Nco-I site which is located within the first intron of 
the gene for LT-a. Identification of genotypes of individuals was performed in a 
similar manner to that used for the analysis of the -308 TNF-a RFLP, and involves 
the sequence specific amplification of a 750bp stretch of genomic DNA which again 
incorporates a polymorphic Nco-I site. The restriction digestion of the resultant 
PCR product allows the identification of a bi-allelic polymorphism which results in 
the ability to assign one of three possible genotype as either homozygous for the 
TNFB*1 allele (B*l/B*l), homozygous for the TNFB*2 allele (B*2/B*2) or 
heterozygous for both alleles (B*l/B*2).
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Genotypes were determined according to the method described in section 3.4 of this 
thesis. LT-a Nco-I RFLP genotypes were determined for 98 (85%) of the normal 
individuals and 80 (80%) of the colorectal cancer patients.
As for the -308 TNF-a RFLP, both genotype and allelotype frequencies were 
calculated for the two populations and were plotted as seperate histograms. Figure
4.3 shows a histogram of the genotype frequency of the LT-a RFLP between the two 
populations. Chi-square analysis of the frequencies of the two populations shows no 
significant difference between the genotypes of the two groups
(%2=2.506, p=0.1428, df=2). Figure 4.4 shows a histogram of the allelic frequencies 
found in the normal and colorectal cancer populations. As expected from the 
analysis of the genotype distribution, no significant difference could be demonstrated 
between the frequency of the individual alleles of the two populations (%^= 1.754, p 
=0.1253, df=l).
4.1.3 TNF microsatellite polymorphism analysis
RFLPs, by nature, are bi-allelic, thus any attempt to identify linkage analysis with 
these loci is restricted due to the small number of alleles possible at each locus.
With the recent advent of microsatellite technology, which identifies regions of high 
degree of polymorphism, the problems associated with the RFLPs can potentially be 
resolved. There are in total five sites of microsatellite polymorphism within the TNF 
locus which exhibit varying degrees of polymorphism. Of these five microsatellites 
alleles of TNFa, TNFc and TNFd loci have been associated with alterations in the 
secretion of TNF-a by stimulated monocytes (see section 1.3 of this thesis). To 
determine the genotypes at each of the microsatellite loci for any individual genomic 
DNA is subjected to a polymerase chain reaction, sequence specific for each of the 
microsatellite loci. The resultant PCR products are variable in length and vary by 
2bp between alleles.
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4.1.3.1 TNFa microsatellite
The TNFa microsatellite is the most polymorphic of the microsatellites found within 
the TNF locus. It is located 3.5kb upstream of the LT-a gene and has 13 possible 
alleles. TNFa microsatellite genotypes were obtained for 98 (85%) of the control 
population and 81 (81%) of the colorectal cancer population. Figure 4.5 shows the 
alleleic frequencies in the control and colorectal cancer populations. A 2 x 13 chi- 
square analysis of the allelic frequencies between the two groups demonstrates that 
there is a significant association between alleles of the TNFa microsatellite and the 
presence of colorectal cancer (%2 =3 7 .9 6 2 , p=0.0001, df=12).
On closer analysis it can be seen that a number of the alleles show either over- or 
under-representation in the colorectal cancer population. Table 4.2 contains a 
complete analysis of the relative frequencies of each of the 13 TNFa alleles in both 
the normal and colorectal cancer populations. It can be seen from this table that the 
alleles TNFa3 and TNFal 1 show a higher frequency in the colorectal cancer 
population (TNFa3 - X2=4.44, p=0.035, df=l, pc=0.455); TNFal 1 - x 2=8.03, 
p=0.005, df=l, pc=0,065) than compared to the control group. Whilst these two 
alleles show an over expression in the cancer population the TNFal, TNFa5, TNFa9 
and TNFa 13 alleles all show under expression in the cancer population (TNFal - 
X2=6.83, p=0.009, df=l, pc=0.117; TNFa5 - x2=4.63, p= 0.031, df=l, pc=0.403; 
TNFa9 - X2=5.34, p=0.02, df=l, pc=0.26; TNFa 13 - X2=419, p=0.04, df=l, 
pc=0.52) when compared to the control population.
Of the 91 theoretically possible genotypes at the TNFa locus 49 were identified in 
the normal population whilst only 35 were seen in the colorectal cancer population. 
Eight (10%) of the colorectal cancer patients were homozygous for the TNFa3 allele 
whilst a further seven were TNFa3/al 1 (8%). Of the normal individuals, only three 
(3%) were homozygous for the TNFa3 allele whilst there were no individuals in the
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normal population with the genotype TNFa3/al 1. Of the remaining colorectal 
cancer patients who were positive for allele TNFa3, three were positive for TNFa 10, 
one was positive for TNFa8 , one was positive for TNFa5 , one was positive for 
TNFa6 and one was positive for TNFa9. Of the remaining TNFal 1 positive 
colorectal cancer patients three were also TNFa8 positive, three were TNFa7 
positive, two were TNFa6 positive, one was TNFa5 positive, one was TNFa 10 
positive and one was TNFal2 positive.
Of the four TNFa alleles which are under-represented in the colorectal cancer the 
most common genotypes associated with these alleles were TNFa5/a5 and 
TNFa5/al0. Four (4%) normal individuals were genotype TNFa5/a5 and five (5%) 
were TNFa5/al0, whilst only one colorectal individual was TNFa5/a5 (1%) and of 
the 81 colorectal cancer patients typed for TNFa none was found to be TNFa5/al0. 
The other three alleles represented within the colorectal cancer population were 
found in association with a number of other alleles.
Two alleles of the TNF locus have been shown to be associated with altered 
secretion of TNF-a. TNFa2 has been shown to correlate with increased secretion of 
TNF-a in LPS stimulated monocytes, whilst TNFa6 has been shown to correlate 
with reduced secretion. It is interesting to note that four (5%) of the colorectal 
cancer patients are homozygous for TNFa2, whilst this genotype is found in only two 
(2%) of the normal individuals. Five ( 5%) of the normal individuals are 
homozygous for TNFa6, whilst only one (1%) colorectal cancer patient is 
homozygous for TNFa6.
4.1.3.2 TNFc Microsatellite
The TNFc polymorphism is located within the first intron of the LT-a gene, and is 
the least polymorphic of the microsatellites within the TNF locus, with only two
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identifiable alleles. The TNFc genotype was determined using a sequence specific 
polymerase chain type reaction, as described in section 1.3.4.4, for 71 (62%) of the 
normal individuals and 96 (96%) of the colorectal cancer population.
Figure 4.6 shows a graph of the allelic frequencies of the two TNFc alleles within 
the colorectal cancer and normal populations. The allele TNFc2 has been reported to 
correlate with overexpression of TNF-a in stimulated monocytes, however, it can be 
seen that there is no difference in allelic frequencies between the two groups 
(%2=o.057, p=1.624, df=l). Analysis of the genotype at the TNFc locus also fails to 
show any difference between the two groups (data not shown; %2=0.774, p= 0.3395, 
df=2).
4.1.3.3 TNFd microsatellite
The TNFd microsatellite polymorphism is co-localized with the TNFe 
polymorphism, 8-10 kb down stream of the TNF-a gene, and has seven possible 
alleles. Again the specific genotypes of the TNFd polymorphism were determined 
using a sequence specific polymerase chain reaction, and were obtained for 83 (72%) 
of the normal control individuals and 78 (78%) of the colorectal cancer individuals.
Figure 4.7 shows the allelic frequency of each of the seven TNFd alleles in the two 
populations. 2 x 7  chi-square analysis of the allelic usage between the two groups 
shows that there is no overall difference between the two populations p
=0.1171, df=6). Table 4.3 shows the actual frequencies of each of the TNFd alleles 
in the two populations. The TNFd3 allele has been shown to correlate with 
overexpression of TNF-a in stimulated monocytes. Analysis of the frequency of this 
allele in the two populations demonstrates a significant over representation of this 
allele in the colorectal cancer population (%2=4.583, p=0.019, df=l, pc=0.133).
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Of the 28 possible genotypes at the TNFd locus seen within the normal individuals 
22 were observed in the normal population and 19 were seen in the colorectal cancer 
patients. The majority of genotypes found in both populations are homozygous 
genotypes. The genotype TNFd2/d2 is found in 5 (6%) normal individuals and 6 
(8%) colorectal individuals, the genotype TNFd4/d4 is found in 12 (14%) normal 
individuals and 8 (10%) colorectal individuals, the genotype TNFd5/d5 is found in 9 
(11%) normal individuals and 8 (10%) colorectal individuals. Although these 
homozygous alleles are common in the two populations there is no significant 
difference between the two groups. A difference can be observed in the number of 
individuals homozygous for the TNFd3 allele between the two populations with 6 
(7%) of the normal individuals having the genotype TNFd3/d3, whilst 12 (15%) of 
the colorectal individuals display this genotype. Chi-square analysis, however, fails 
to prove this difference is statistically significant (%2=2.693, p=0.063, df=l, p 
c= 1.764).
4.1.3.4 TNFe microsatellite
As described above the TNFe microsatellite locus is co-localized with the TNFd 
microsatellite 8-10 kb down stream of the TNF-a gene, and has three possible 
alleles. As for the other microsatellite polymorphisms, the specific genotypes at the 
TNFd locus were obtained for 51 (44%) of the normal individuals and 55 (55%) of 
the colorectal cancer patients, by sequence specific PCR.
The allelic frequency for each of the three alleles of both the normal individuals and 
the colorectal cancer patients can be seen in figure 4.8. 2x3 Chi-square analysis 
shows an extremely high difference between the alleles observed in the normal 
individuals and the colorectal cancer patients (%2=24.413, p<0.0000, df=2).
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Table 4.4 shows a list of the allelic frequencies at each of the three alleles of the 
TNFe locus in both the normal and colorectal cancer patients. Chi-square analysis 
confirms that TNFe2 is significantly under-represented in the colorectal cancer 
population (%2=23.485, p<0.0000, df=l, pc<0.0000), whilst the TNFe3 allele shows 
a significant over-representation in the cancer group (%^= 19.357, p<0.0000, df=l, 
pccO.OOOO).
All six possible genotypes at the TNFe locus have been identified within this study 
group, however the frequency of a number of the genotypes does differ significantly 
between the two groups. There is a significant difference between the frequency of 
the TNFel/e2 genotype (frequency- 0.14 and 0.04, normal and colorectal 
respectively; %^=3.467, p=0.038, df=l, pc=0.228), the TNFel/e3 genotype 
(frequency- 0.04 and 0.2, normal and colorectal respectively; %^=635S, p=0.007, 
df=l, 0.042) and also the TNFe2/e2 genotype (frequency- 0.37 and 0.07, normal and 
colorectal respectively; %^= 14.001, p=0.0001, df=l, pc=0.0006) in the normal and 
colorectal cancer populations.
4.1.3.5 Family analysis
It is common in this sort of study to include a number of families in order to confirm 
mendelian inheritance of the alleles and also to confirm integrity of allele calls.
Large extended families were not available at the initial time of starting this study 
however three small partial families were found to be included within the control 
individuals. Allele calling was performed on these individuals before family 
pedigrees were disclosed and although small errors can be seen in families one and 
two (underlined alleles) these pedigrees provide reassurance that allele calling was 
consistent. The pedigrees were as follows.
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Family One
Father -
20064 (a6,6,c2,2,d 1,3,e?,LToc?,-308T 1 ,T2)
Sons -
20057 (a6,12,cl,l,dl,4,e2,3,LTaB*l,B*2,-308Tl,T2)
20058 (a4.6.cl.2.d3.5.el.3.LTaB* 1 ,B*2,-308T1 ,T2) 
Family Two
Three siblings -
20068 (a6 ,l l,cl,2,dlJ.,e2,3,LTa?,-308Tl,T2)
20069 (a?.c 1.2.d 1.5.e3.3.LTaB* 1 .B*2.-308T 1 .T2)
20070 (a6,13.cL2.d2.6.e?.LTocB*l,B*2,-308T1,T2) 
Family Three
Three siblings -
20083 (al0,10,c?,d?,el,l,LTcxB*2,B*2,-308Tl,Tl)
20084 (a9,10,c?,d2,4,e2,2,LT(xB *2,B *2,-308T 1 ,T 1)
20085 (a9,10,c?,d2,4,e2,2,LTocB*2,B*2,-308Tl,T1)
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Figure 4.1. Histogram showing the distribution of the three possible 
-308 TNFa RFLP genotypes in the normal and colorectal cancer 
populations. Chi-square analysis shows no significant association 
between genotypes at this locus and the presence or absence of 
colorectal cancer.
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Figure 4.2. Histogram showing the distribution of the two possible 
-308 TNFa RFLP alleles in the normal and colorectal cancer 
populations. As for the -308 TNFa genotypes, Chi-square analysis 
shows no significant association between alleles at this locus and the 
presence or absence of colorectal cancer.
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Figure 4.3. Histogram showing the distribution of the three possible 
LTa Ncol RFLP genotypes in the normal and colorectal cancer 
populations. Chi-square analysis shows no significant association 
between genotypes at this locus and the presence or absence of 
colorectal cancer.
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Figure 4.4. Histogram showing the distribution of the two possible 
LTa Ncol RFLP alleles in the normal and colorectal cancer 
populations. Again Chi-square analysis shows no significant association 
between alleles at this locus and the presence or absence of colorectal 
cancer.
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Figure 4.5. Histogram showing the distribution of the 13 TNFa 
microsatellite alleles in the normal and colorectal cancer 
populations. Chi-square analysis shows a significant difference between 
the distribution of the TNFa alleles at this locus and the presence or 
absence of colorectal cancer.
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TNFa Normals Colorectals Chi-square P-value
1 0.06 0 .0 1 6.83 0.009
2 0 .1 0.08 0.5 ns
3 0.05 0.23 4.44 0.0006
4 0 .1 0.06 1 .8 8 ns
5 0.09 0.04 4.63 0.031
6 0 .1 2 0.09 1 .2 1 ns
7 0.08 0 .1 2 2.32 ns
8 0.08 0.04 2 .1 ns
9 0.08 0 .0 2 5.34 0 .0 2
1 0 0 .1 2 0.14 0.34 ns
11 0.05 0.14 8.03 0.005
1 2 0.04 0 .0 2 0 .6 8 ns
13 0.03 0 4.19 0.04
Table 4.2. Breakdown of the allelic frequencies and associated Chi- 
square values of the 13 TNFa alleles in the normal and colorectal 
cancer populations. A significant linkage, by Chi-square, can be seen 
with 6  of the 13 TNFa alleles and either the presence or absence of 
colorectal cancer. TNFa3 and TNFal 1 are over represented in the cancer 
population, whilst TNFal, TNFa5, TNFa9 and TNFal3 are all under 
represented in the cancer group.
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Figure 4.6. Histogram showing the distribution of the 2 TNFc 
microsatellite alleles in the normal and colorectal cancer 
populations. Chi-square analysis shows no significant difference 
between the distribution of the TNFc alleles and the presence or absence 
of colorectal cancer.
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Figure 4.7. Histogram showing the distribution of the 7 TNFd 
microsatellite alleles in the normal and colorectal cancer 
populations. Chi-square analysis shows no significant difference 
between the distribution of the TNFd alleles and the presence or absence 
of colorectal cancer.
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TNFd Normals Colorectals Chi-square P-value
1 0.1 0.07 1.05 ns
2 0.14 0.17 0.04 ns
3 0.17 0.27 4.58 0.019
4 0.28 0.24 0.94 ns
5 0.17 0.15 0.28 ns
6 0.08 0.06 0.5 ns
7 0.05 0.04 0.19 ns
Table 4.3. Breakdown of the allelic frequencies and associated Chi- 
square values of the 7 TNFd alleles in the normal and colorectal 
cancer populations. A significant linkage, by Chi-square, can be seen 
with TNFd3 and the presence colorectal cancer.
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Figure 4.8. Histogram showing the distribution of the 3 TNFe 
microsatellite alleles in the normal and colorectal cancer 
populations. Chi-square analysis shows no significant difference 
between the distribution of the TNFe alleles and the presence or absence 
of colorectal cancer.
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Normals Colorectals Chi-square P-value
0.11 0.12 0.08 ns
0.49 0.18 23.48 <0.000
0.4 0.7 19.36 <0.000
Table 4.4. Breakdown of the allelic frequencies and associated Chi< 
square values of the 3 TNFe alleles in the normal and colorectal 
cancer populations. A significant linkage, by Chi-square, can be seen 
with TNFe2 and the absence of colorectal cancer, whilst TNFe3 
correlates with the presence of colorectal cancer.
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4.2 Association between alleles at the TNF locus and Dukes1 staging
in colorectal adenocarcinoma
Dukes' staging was initially described in 1932 as a method of pathologically grading 
rectal tumours. By 1967 this system had been adapted to include colonic tumours. 
Dukes' staging generally correlates with the degree of aggresiveness of a colorectal 
tumour and has been shown to correlate well with prognosis, and to date this system 
still remains the most widely used system for the pathological grading and clinical 
assesment of colorectal cancer. Dukes' staging was available for 92 (92%) of the 
colorectal cancer patients in this study (see section 2.1.2). Having established that a 
number of alleles of the polymorphisms within the TNF locus correlate with the 
presence of colorectal cancer it was of interest to determine if either the same alleles 
or a group of other alleles could be correlated with the pathological grading of the 
colorectal tumours.
4.2.1 -308 TNFa RFLP and Dukes1 stage
Although no significant differences in the alelles of the -308 TNFa RFLP were 
identified between the normal and colorectal cancer individuals, it was still of 
interest to determine if any differences could be observed between the different 
Dukes' stages in the colorectal cancer patients.
Figure 4.9 shows a histogram of the frequency of the three possible genotypes at the 
-308 TNFa RFLP locus in colorectal cancer patients group. A 3x4 Chi-square 
analysis of the genotype frequencies within each of the four Dukes' stage groups 
shows that there is no overall difference between the four groups (%^=9.019, 
p=0.056, df=6). Closer analysis does however show that the genotype TNF2/2 is 
only found in those patients that are Dukes' C (%^=7.747, p=0.003, df=l, pc=0.009).
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Figure 4.10 shows the allelic frequencies of the two -308 TNFa alleles in the four 
Dukes' stage groups. Again, as for the genotype frequencies, there is no significant 
difference suggesting a linkage between -308 TNFa RFLP alleles and Dukes' stage 
(X2=5.153, p=0.069, df=3).
4.2.2 LTa Nco-I RFLP and Dukes' stage
The LTa RFLP genotype of 64 patients with histologically proven colorectal cancer 
and for whom Dukes' staging was available, were examined to determine if there is 
linkage between the LTa genotype and Dukes' stage.
Figure 4.11 shows the histogram of the genotype frequencies of each of the three 
possible genotypes at the LTa RFLP locus in the four Dukes' stage groups. A 3x4 
chi-square analysis of the genotype frequencies produces a borderline value for chi- 
square (x^=8.898, p=0.058, df=6), suggesting that, although no statistically 
significant at 95%, there may be some association between the LTa genotype and 
Dukes' staging. Closer analysis of the frequencies demonstrates that all of the 
individuals with Dukes' A tumours were the genotype TNFB*2/B*2 (x^=4.545, 
p=0.019, df=l, pc=0.057).
Figure 4.12 Shows a histogram of the allelic usage between the four Dukes' stage 
groups. A 2x4 chi-square analysis of this data fails to show any significant linkage 
between alleles of this locus and Dukes' staging (%2=4.551, p= 0.087, df=3), 
although as expected there is a significant association with the TNFB*2 alelle and 
Dukes' A (x2=3.392, p=0.039, df=l).
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4.2.3 TNF microsatellites and Dukes1 stage
Alleles of the TNF microsatellites are the only alleles that show any linkage with the 
presence of colorectal cancer and since Dukes' staging is the most widely used 
marker for disease severity and it was of interest to determine if alleles of the TNF 
microsatellites show any association with Dukes' stage.
4.2.3.1 TNFa microsatellite
The TNFa genotype of 78 colorectal cancer patients for whom Dukes' staging was 
available were examined to determine if linkage occurs between the TNFa locus and 
Dukes' staging.
Figure 4.13 shows the allelic frequency of the 13 possible alleles at the TNFa locus 
in the four Dukes' stage groups. A 13x4 chi-square analysis of the frequency of the 
13 alleles in the four Dukes' groups was not possible due to the small number of 
Dukes' A patients (computer analysis reports that the chi-square analysis is invalid 
due to a significant number of cells having expected values of less than 1.0). Closer 
analysis of the individual alleleic frequencies shows two major differences between 
the four groups. The allele TNFa3 shows a high degree of association with Dukes' 
stage A (%2= 12.650, p=0.0002, df=l, pc=0.0026). An association between TNFa8 
and Dukes' stage D is also noted (%2=12.128, p=0.0003, df=l, pc=0.0039).
4.2.3.2 TNFc microsatellite
The TNFc genotype of 90 colorectal cancer patients for whom Dukes' staging was 
available were examined to determine if any linkage could be seen between alleles at 
the TNFc locus and Dukes' staging.
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Figure 4.14 shows the allelic frequency of the two alleles of the TNFc locus in the 
four Dukes' stage groups. A 2x4 chi-square analysis of the allelic frequencies 
between the four groups fails to predict any linkage between alleles at this locus and 
Dukes' staging (%2= 1.090, p=0.24, df=3). Although there is a slight increase in the 
frequency of the TNFc2 allele in the Dukes' A group than compared to the other 
Dukes' stage groups this difference is not significant (%2=0.545, p=0.41, df=l).
4.2.3.3 TNFd microsatellite
The TNFd genotype of 76 colorectal cancer patients for whom details of Dukes' 
stage had been obtained were examined in order to ascertain whether there is any 
linkage between alleles at the TNFd locus and Dukes' stage.
Figure 4.15 shows the allelic frequency of the seven alleles of the TNFd locus in the 
four Dukes' stage groups. Analysis using a 4x7 chi-square test demonstrates a 
significant linkage between alleles at the TNFd locus and Dukes' staging 
0c2=24.981, p=0.027, df=18).
In terms of TNFa production, the most important TNFd allele is the TNFd3 allele. 
Analysis of the frequency of this allele in the four Dukes' stage groups shows a over­
representation of this allele in the Dukes' A patients when compared with Dukes' D 
patients individually (%^=4.338, p=0.022, df=l), however this is not significant 
when compared to the other Dukes' stage groups combined (%2=1.75, p=0.13, df=l). 
An under-representation of the TNFd3 allele is observed in the Dukes' D patients, 
however this is not significant by chi-square (%2=2.771, p=0.06, df=l, pc=0.42).
The TNFd5 allele is absent in the Dukes' A patients, and this difference is 
statistically significant when compared to the frequency of this allele in the other 
three Dukes' stage groups (%2=3A69, p=0.038, df=l). However since there are only
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a small number of Dukes' A patients in this study the exact meaning of this 
relationship is still unclear.
4.2.3.4 TNFe microsatellite
TNFe microsatellite genotypes were obtained for 55 colorectal cancer patients for 
whom Dukes' staging was available. Statistical analysis of these data was performed 
to determine if any linkage was present between alleles at the TNFe locus and 
Dukes' staging.
Figure 4.16 shows the allelic frequency of the three alleles of the TNFe locus in each 
of the three Dukes' stages. 3x4 chi-square analysis shows a borderline figure for 
suggesting that there may be some linkage between the TNFe locus and Dukes' 
staging (%2=9.412, p=0.05, df=6).
The TNFe3 allele is not represented in the Dukes' stage A patients, and 2x2 chi- 
square analysis confirms that this difference is significant {yj^=A.153, p=0.017, df=l, 
pc=0.051) however since there is only one individual represented within the Dukes' 
A patients this result is probably invalid.
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Figure 4.9. Histogram showing the distribution of the three possible 
-308 TNFa RFLP genotypes in the four Dukes' stage groups. Chi- 
square analysis shows a significant association between the TNF2/2 
genotype and Dukes' stage C, however no further differences are noted.
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Figure 4.10. Histogram showing the distribution of the two possible 
-308 TN Fa RFLP alleles in the four Dukes’ stage groups. Chi-square 
analysis shows no significant association between alleles at this locus 
and Dukes' staging.
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Figure 4.11. Histogram showing the distribution of the three possible 
L T a  Ncol RFLP genotypes in the four Dukes' stage groups. Chi- 
square analysis shows a borderline association between the LTa Ncol 
genotype and Dukes' stage. Closer analysis demonstrates a significant 
association between the TNFB*2/B*2 genotype and Dukes' stage A, 
howver since the number of individuals with stage A is so small the true 
relevence of this result is unclear.
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Figure 4.12. Histogram showing the distribution of the two possible 
LTa Afcol RFLP alleles in the four Dukes’ stage groups. Chi-square 
analysis shows an association between the TNFB*2 allele and Dukes’ 
stage A, however no further differences are noted.
151
712043
Fr
eq
ue
nc
y
I
1 2 3 4 5 6 7 8 9 10 111213
Alleles
□ TNFa Dukes' A n=5
^ TNFa Dukes' B n=44
■ TNFa Dukes' C n=21
■ TNFa Dukes' D n^S
Figure 4.13. Histogram showing the distribution of the 13 TNFa 
microsatellite alleles in the four Dukes1 stage groups. Chi-square 
analysis shows a significant association between the TNFa3 allele and 
Dukes' stage A and also a significant association between TNFa8 and 
Dukes' stage D.
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Figure 4.14. Histogram showing the distribution of the 2 TNFc 
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analysis fails to shows any association between the TNFc alleles and 
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Figure 4.15. Histogram showing the distribution of the 7 TNFd 
microsatellite alleles in the four Dukes' stage groups. Chi-square 
analysis shows any association between the TNFd3 allele and Dukes' 
stage A when compared to Dukes' stage d, but not with stage B or C. 
The TNFa5 allele shows a significant association with Dukes' stage A 
when compared to the other three stages, however since the numbers of 
Stage A tumours was small the exact meaning of this result is unclear.
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Figure 4.16. Histogram showing the distribution of the 3 TNFe 
microsatellite alleles in the four Dukes’ stage groups. Chi-square 
analysis shows any association between the TNFe3 allele and Dukes' 
stage B, C and D when compared to Stage A, however since the numbers 
of Stage A tumours is small the exact meaning of this result is unclear.
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4.3 Association between alleles at the TNF locus and disease
progression in colorectal adenocarcinoma
Figures from a 1984 study suggest that out of 100 patients 51 will be cured by 
surgical intervention. Of the other 49, 44 will die due to the presence of metastatic 
disease or local recurrence and 5 will die with unresectable primary disease (August 
et. al., 1984).
Follow up data was available for almost all of the patients represented within this 
study and on the 1st of July 1994 the number of individuals that had survived for 
greater than two years from the date of their initial operation and the number of 
individuals that had developed recurrent disease, in the form of either metastatic 
disease or local recurrence, were calculated. These sub groups of patients were 
analysed for their TNF polymorphism genotypes in an attempt to determine whether 
alleles of any of the polymorphisms could be correlated with the progression of 
colorectal cancer.
4.3.1 -308 TNFa RFLP and disease progression
Thirty colorectal cancer patients for whom -308 TNFa RFLP genotype was available 
were found to have survived disease free for greater than two years from the time of 
their initial operation. The genotypes of these disease free patients were compared 
with the genotypes of twenty three patients who had developed either metastatic 
disease or local recurrence within two years from the date of their initial operation.
Figure 4.17 shows the genotype frequencies of each of the two groups. Chi-square 
analysis shows that there is no linkage between alleles at this locus and the 
progression of colorectal cancer (%2=4.162, p=0.06, df=2). Figure 4.18 shows the 
allelic frequence of the same group of patients and chi-square analysis of this data
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confirms that there is no link between the -308 TNFa RFLP locus and the 
progression of colorectal cancer to either local recurrence or the development of 
metastatic disease (%2=2.06, p=0.1, df=l).
4.3.2 LTa Nco-I RFLP and disease progression
The LTa Nco-I RFLP genotype was available for 23 colorectal cancer patients who 
had survived for greater than two years disease free and 19 patients with either 
metastatic or recurrent disease. The genotypes of these two groups were compared 
in an attempt to determine whether the LTa Nco-I RFLP locus is linked with disease 
progression.
Figure 4.19 shows a histogram of the genotype frequencies of the two colorectal 
cancer groups. Chi-square analysis of the genotype frequencies of the two groups 
shows a significant association between the genotype of the LTa Nco-I RFLP and 
the progression of colorectal cancer (x2=5.324, p=0.035, df=2). The TNFB*1/B*2 
genotype is over represented in the metastatic/recurrent population than in the 
normal population (%2=3.359, p=0.04, df=l, pc=0.12). Whilst the TNFB*2/B*2 
genotype is under represented in the metastatic/recurrent population (x^=4.709, 
p=0.018, df=l, pc=0.054).
Figure 4.20 shows a histogram of the allelic frequencies of the LTa RFLP alelles 
between the two populations. Again chi-square analysis demonstrates a significant 
association between alleles of this RFLP and the progression of colorectal cancer 
(%^=4-073, p=0.026, df=l). As expected the TNFB*1 allele is over represented in 
the metastatic/recurrent population, whilst the TNFB*2 allele is under represented in 
this same group.
157
4.3.3 TNF microsatellite polymorphisms and disease progression
Again, due to the fact that the two RFLPs within the TNF locus show a low degree 
of polymorphism, it was of interest to examine if the more polymorphic 
microsatellite loci showed any association with the progression of colorectal cancer.
4.3.3.1 TNFa microsatellite
The TNFa microsatellite genotype was obtained for 28 colorectal cancer patients 
with no evidence of recurrent disease 2 years after their initial surgery and for 23 
patients with either local recurrent disease or distant metastases. The allelic 
frequency of the 13 TNFa alleles was compared between the two poulations to 
determine if alleles of this polymorphism could be correlated with disease 
progression.
Figure 4.21 shows the allelic frequency of the 13 alleles at the TNFa locus in both 
populations. Due to the small numbers involved in this particular grouping a 2x13 
chi-square analysis is not possible. Analysis of individual alleles does, however 
show a number of differences. Allele TNFa3 shows an over representation in the 
recurrent/metastases patients as does TNFa4, TNFa9 and TNFalO however neither 
of these differences reaches statistical significance (TNFa3 - %2=1.642, p=0.13, 
df=l, pc=1.69; TNFa4 - x2=0.44, p=0.48, df=l, pc=6.42; TNFa9 - x2=2.539, 
p=0.07, df=l, pc=.91; TNFalO - %2= 1.577, p=0.14, df=l, pc=1.82).
Analysis of the allelic frequency of the TNFa2 and TNFal 1 alleles shows that both 
are under represented in the recurrent/metastases patients. However, on chi-square 
analysis, only the difference of the TNFal 1 alleleic frequency is statistically 
significant before correction(TNFa2 - %^=2.821, p=0.058, df=l, pc=0.754; TNFal 1 
- %2=3 672, p=0.033, df=l, pc=0.429). Other minor differences can be seen
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between these two poulations however statistical analysis was thought not to be 
warranted due to the low frequency of the alleles concerned.
4.3.3.2 TNFc microsatellite
The TNFc microsatellite genotype was obtained for 34 of the patients that had 
survived 2 years disease free from the time of initial operation and 25 of the 
recurrent/metastases patients. As for the TNFa microsatellite the allelic frequency of 
the two TNFc alleles was compared between the two populations.
Figure 4.22 shows the allelic frequency of the two TNFc alleles between the two 
populations. Chi-square analysis of this data shows that there is no significant 
difference between the allelic frequencies in the two populations (%^=0.193, 
p=0.825, df=l).
4.3.3.3 TNFd microsatellite
The TNFd genotype of 28 colorectal cancer patients with no sign of recurrent or 
metastatic disease two years post initial surgical intervention and 19 patients with 
recurrent/metastatic disease were obtained. Again the allelic frequencies of the 
populations were compared.
Figure 4.23 shows the allelic frequencies of the seven TNFd alleles in the two 
colorectal cancer populations. A 2x7 chi-square analysis of the allelic frequencies 
between the two poulations shows no significant difference between the two 
populations (%2=7.89, p=0.075, df=6).
Closer analysis of the allelic frequencies between the two populations shows two 
major differences. The TNFdl allele shows a significant over representation in the
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recurrent/metastases population (% 2=5.21, p = 0 .0 1 3 , df=l, p c = 0 .0 9 1 )  and the TNFd3 
allele shows a significant under representation in this same population {y^=AAl\, 
p = 0 .0 2 , df=l, p c = 0 .1 4 ).
4.3.3.4 TNFe microsatellite
The TNFe genotype of 13 colorectal cancer patients clear from any recurrent disease 
2 years post operative and 20 patients with recurrent/metastatic disease disease were 
obtained. As for the other TNF polymorphisms, the allelic frequencies at this locus 
were compared between the two populations.
Figure 4.24 shows the allelic frequency of the three TNFe alleles between the two 
populations. A 2x3 chi-square analysis shows no association between the TNFe 
alleles and the progression of colorectal cancer. No other association can be seen at 
this locus.
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Figure 4.17. Histogram showing the distribution of the three possible 
-308 TNFa RFLP genotypes in the 2 years clear and 
metastatic/local recurrence individuals. Chi-square analysis shows that 
there is no association between the -308 TNFa genotype and disease 
progression.
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Figure 4.18. Histogram showing the distribution of the two possible 
-308 TNFa RFLP alleles in the 2 years clear and metastatic/local 
recurrence individuals. Chi-square analysis shows that there is no 
association between the distribution of the -308 TNFa alleles and disease 
progression.
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Figure 4.19. Histogram showing the distribution of the three possible 
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recurrence individuals. Chi-square analysis shows a significant 
association with the TNFB*l/*2 genotype and the presence of 
metastatic disease, and a reciprocal association with the TNFB*2/B*2 
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Figure 4.20. Histogram showing the distribution of the two possible 
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recurrence individuals. Chi-square analysis shows a significant 
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Figure 4.22. Histogram showing the distribution of the 2 possible 
TNFc microsatellite alleles in the 2 years clear and metastatic/local 
recurrence individuals. Chi-square analysis shows no significant 
association with the TNFc alleles and either two years disease free 
survival or metastatic/local recurrence.
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Figure 4.24. Histogram showing the distribution of the 3 possible 
TNFe microsatellite alleles in the 2 years clear and metastatic/local 
recurrence individuals. Chi-square analysis shows no significant 
association with the TNFe alleles and either metastatic/local recurrence 
or two years disease free survival.
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4.4 Extended genotypes of the five TNF polymorphisms
It is now clear that the region of the MHC is highly polymorphic. However, it is 
widely accepted that alleles of the HLA show some degree of linkage in that they 
form extended haplotypes spanning from the HLA-A locus, across the class III 
region to the DP locus. A number of studies have now suggested that these extended 
haplotypes can also include alleles from the polymorphisms, including the TNF 
polymorphisms, found within the class III region of the MHC.
4.4.1 Extended genotypes involving the two RFLPs
As described in section 1.3.4.3 an extended genotype has been suggested between 
the LTa Nco-I RFLP locus and the -308 TNFa RFLP locus. This association 
involves linkage between the TNFB*1 allele and the TNF2 allele. It was of interest 
to determine if this association can be seen within the control population described 
within this study, and to see if there was any difference in this linkage between the 
normal and colorectal groups.
For all of the control individuals who were typed at both the LTa RFLP and the -308 
TNFa RFLP the possible genotypes over these two loci were calculated. 76 such 
individuals can be identified, resulting in a total of 304 possible genotypes since it is 
impossible to determine the individual pairing of alleles. Of these 304 possible 
genotype the TNFB*2/TNF1 genotype accounts for 58% of the genotypes, the 
TNFB*1/TNF1 accounts for 23%, the TNFB*1/TNF2 genotype accounts for 14 % 
and the TNFB*2/TNF2 accounts for the final 5%.
Figure 4.25 shows a comparison of these extended genotype frequencies between the 
normal control individuals and the whole colorectal cancer population. Both the 
TNFB*1/TNF1 and the B*2/T1 extended genotypes are observed with equal
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frequency between the two populations. However, the TNFB*1/TNF2 extended 
genotype shows a significant under representation in the colorectal cancer population 
(%^=8.347, p=0.002, df=l, pc=0.008), and the TNFB*2/TNF2 extended genotype 
shows a significant over representation in the colorectal cancer population (% 
2=9.678, p=0.001, df=l, pc=0.004).
The relationship between this extended genotype and the pathological staging of the 
colorectal cancer patients was also examined. Figure 4.26 shows a graph of the 
genotype frequences in each of the four Dukes' stages. A 4x4 chi-square analysis of 
the frequencies demonstrates a significant difference between the four groups 
(%2=51.848, p<0.0000, df=9). Closer analysis shows that the TNFB*1/TNF1 
genotype is more frequent in the Dukes' B group than in the Dukes' C group 
(%^=4.022, p=0.003, df=l, pc=0.012), whilst the TNFB*2/TNF2 genotype is more 
common in the Dukes' C genotype than in the Dukes' B genotype (%2= 13.527, 
p=0.0001, df=l, pc=0.0004).
Analysis of this extended genotype in the 2 years clear verses the 
metastatic/recurrent patients also shows an association between this extended 
genotype and disease progression (Figure 4.27; %2=14.56, p=0.001, df=3).
Significant differences in the genotype frequencies can be seen at three of the four 
genotypes, with an under representation of the TNFB*2/TNF1 genotype in the 
metastatic/recurrent patients (%2=13.52, p=0.0001, df=l, pc=0.0004) and an over 
representation of both the TNFB*1/TNF2 (%2=3.91, p=0.03, df=l, pc=0.12) and the 
TNFB*2/TNF2 genotypes (%^=4.072, p=0.03, df=l, pc=0.12).
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Figure 4.25. Histogram showing the distribution of the 4 possible 
extended RFLP genotypes in the normal and colorectal cancer 
populations. Chi-square analysis shows a significant under 
representation of the TNFB*1/TNF2 genotype in the colorectal cancer 
individuals and an over representation of the TNFB*2/TNF2 genotype 
in this same group.
171
oa
o
0
c r
o
<D
Oh
Oa
o
O
T3
O
T3
do
4- *
X
w
*
CQ
<N
*
ffl
(S
H
t-H
*
ffl
CS
H
c ?
*
PQ
Extended Genotypes
□ Dukes' A n=4 
^ Dukes' B n=31 
M Dukes' C n=13 
■ Dukes' d n=4
Figure 4.26. Histogram showing the distribution of the 4 possible 
extended RFLP genotypes in the four Dukes' stage groups. Chi- 
square analysis shows that the TNFB*1/TNF1 genotype is more 
common in the Dukes' stage B group than in the stage C group whilst the 
TNFB*2/TNF2 genotype is more common in the stage C group than in 
the stage B group.
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Figure 4.27. Histogram showing the distribution of the 4 possible 
extended RFLP genotypes in the two years disease free clear and 
the metastatic/local recurrence individuals. Chi-square analysis shows 
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disease free individuals and that the TNFB * 1 *2/TNF2 and the 
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Gastric Cancer
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The following chapter has been included to demonstrate the similarities seen at both 
the TNFa microsatellite polymorphism and the LTa Nco-I RFLP in an other human 
adenocarcinoma. The work was performed primarily by an undergraduate student 
working within the department of surgery, at Glasgow Royal Infirmary, as part of her 
final year course in biochemistry at the University of Glasgow. Although the work 
was performed on a very limited sample of patients, it helps to extend the 
investigation into the role of these polymorphisms in human cancer.
5.1 Gastric cancer
If gastric cancer is defined as cancer of either the stomach or oesophagus, then this 
disease accounted for 1697 cases of cancer in Scotland in 1991 (Directorate of 
Information Services, Scottish Health Statistics, 1993), with over 97% of gastric 
cancers being adenocarcinomas of the stomach. Gastric cancer is the fifth most 
common malignancy in the western world and has a male to female ratio of 2:1.
Like colorectal cancer, gastric cancer has seen a steady decline in its frequency of the 
past 50 years (Sandler, R.S. and Holland, K.L., 1987), however there has been little 
change in the 5-year survival rate which has remained between 7% and 11%. Diet is 
still thought to be the major risk factor for this malignant disease, however other 
studies have implicated exposure to compounds such as coal dust or asbestos 
(Mewhouse, M., 1981).
Since the study group involved is so small, readers are refered to the chapter in 
Surgical Oncology (Ed. C.S. McArdle) by D. Cunningham entitled "The 
management of gastric cancer", for a more detailed review of this disease.
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5.2 Gastric cancer and TNF
There is very little evidence in the literature to indicate a role for TNFa in the 
development of Gastric adenocarcinoma. Monocytes from gastric cancer patients 
recieving BCG therapy in combination with 5-flurouracil, adriamycin and mitomycin 
C, have been shown to secrete elevated levels of TNFa (Zembala, M., et. al., 1993). 
Apart from this study there seems to be no further evidence to suggest a role for TNF 
a  in vivo. However, since there is little data to support the hypothesis for a role of 
TNFa in gastric cancer it therefore seemed likely that this tumour typre would be a 
good control for the analysis of the TNF polymorphisms in colorectal cancer.
5.3 TNFa polymorphisms
The TNFa genotypes of 23 patients with primary gastric adenocarcinoma were 
determined using the methods as outlined in chapter 2 of this thesis. Table 5.1 
shows the individual genotypes for each of the 25 patients. Figure 5.1 shows a graph 
of the TNFa allelic frequencies in the normal control individuals and the 23 gastric 
adenocarcinoma patients. Chi-square analysis of the frequencies of the two groups 
is not possible due to the small number of gastric patients however a number of 
differences in the frequency of the individual alleles can be seen. Table 5.2 shows 
the individual alleleic frequencies of the normal and gastric patients. Chi-square 
analysis shows that the only significant difference is that of the frequency of the 
TNFa3 allele ( x 2 = 1 0 .7 7 2 , p = 0 .0 0 0 6 , df=l, p c = 0 .0 0 7 8 ) .
It was of interest to determine if the allelic frequencies at the TNFa microsatellite 
polymorphism were equivalent between the colorectal and gastric populations.
Figure 5.2 shows a graph of the allelic frequency of the TNFa polymorphism in these 
two populations. Again chi-square analysis of the two populations is not possible 
due to the small number of gastric patients, however the two populations look
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similar. Table 5.3 shows the individual frequencies at of the 13 alleles in both 
groups. The only difference between the two populations is in the frequency of the 
TNFa5 allele which is over represented in the gastric cancer patients (%^=4.565, 
p=0.019, df=l, pc=0.247).
5.4 LTa Ncol RFLP
The LTa Nco-I RFLP genotype of 23 individuals with histologically proven gastric 
adenocarcinoma were obtained by using the method as described in section 3.4 of 
this thesis. Figure 5.3 shows a graph of the frequencies of the three possible 
genotypes at the LTa Nco-I RFLP locus in 98 normal control individuals and 23 
gastric adenocarcinoma patients. Chi-square analysis demonstrates a significant link 
between genotypes at the LTa Nco-I RFLP and the presence of gastric cancer 
(%2=8.192, p=0.008, df=2). Closer analysis shows that there is a decrease in the 
frequency of the B*l/B*l genotype (x^=3.418, p=0.039, df=l, pc=0.117) and a 
significant increase in the frequency of the B*l/B*2 genotype (%^=7.191, p=0.004, 
df=l, pc=0.012) in the gastric cancer patients. The observed difference the B*2/B*2 
genotype frequencies fails to reach significance (%^=2.447, p=0.075, df=l, 
pc=0.225).
Figure 5.4 shows a graph of the individual allelic frequencies of the two LTa Nco-I 
RFLP alleles in the normal and gastric individuals. Chi-square fails to show any 
difference between the alleleic frequencies of the two populations (%^=0.084, p=l, 
df=l).
Having identified a difference in the frequency of the LTa Nco-I RFLP genotypes in 
the gastric patients it was of interest to compare the genotype and allelic frequencies 
at this loci with those for the colorectal cancer patients since no association with the
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presence of colorectal cancer can be asscribed to either genotypes or alleles at this 
locus.
Figure 5.5 shows the graph of the genotype frequencies of the 23 gastric patients in 
comparison with those of the colorectal cancer patients. Chi-square analysis 
demonstrates a significant difference in genotype frequencies between the two 
groups (%2=6.944, p=0.016, df=2). Closer analysis of the frequencies of the 
individual genotypes demonstrates an over representation of the B*l/B*2 genotype 
in the gastric cancer patients (%2=6.502, p=0.006, df=l, pc=0.018) and an under 
representation of the B*2/B*2 genotype in the gastric patients (%2=4.133, 
p=0.025, df=l, pc=0.075).
Figure 5.6 shows a graph of the individual allelic frequencies between the gastric 
and colorectal cancer populations. Chi-square analysis of this data fails to show any 
significant difference between the two populations (%^= 1.325, p=0.179, df=l).
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Patient Code TNFa LT Ncol
40001 5,7 B*2,B*2
40002 7,3 B*1,B*2
40003 3,10 B*2,B*2
40004 6,8 B*1,B*2
40005 3,10 B*2,B*2
40006 3,10 B*2/B*2
40007 3,6 B*1,B*2
40008 6,7 B*1,B*2
40009 2,4 B*1,B*2
40010 5,10 B*1,B*2
40011 5,11 B*1,B*2
40012 3,10 B*1,B*2
40013 5,10 B*1,B*2
40014 3,11 B*l,B*2
40015 3,7 B*1,B*2
40016 5,8 B*1,B*2
40017 3,7 B*1,B*2
40018 2,4 B*1,B*2
40019 11,12 B*2,B*2
40020 7,12 B*1,B*2
40021 6,9 B*2,B*2
40022 5,6 B*1,B*2
40023 6,11 B*1,B*2
Table 5.1 Complete genotypes at the TNFa microsatellite 
polymorphisms and the L T a Ncol RFLP in the 25 gastric 
adenocarcinoma cancer patients.
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Figure 5.1. Histogram showing the distribution of the 13 TNFa 
microsatellite alleles in the normal and gastric cancer populations. Due
to the small number of gastric cancer patients formal statistical analysis was 
not possible to compare these two groups
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TNFa Normals Gastrics Chi-square P-value
1 0.06 0 2.705 ns
2 0.1 0.04 1.546 ns
3 0.05 0.2 10.77 0.0006
4 0.1 0.04 1.546 ns
5 0.09 0.13 0.827 ns
6 0.12 0.13 0.022 ns
7 0.08 0.13 1.366 ns
8 0.08 0.04 0.788 ns
9 0.08 0.02 2.046 ns
10 0.12 0.13 0.022 ns
11 0.05 0.09 0.883 ns
12 0.04 0.04 0.007 ns
13 0.03 0 U 9 8 ns
Table 5.2. Breakdown of the allelic frequencies and associated Chi- 
square values of the 13 TNFa alleles in the normal and gastric cancer 
populations. A significant linkage, by Chi-square, can be seen with the 
TNFa3 alleles and either the presence of gastric cancer. No other significant 
associations are observed.
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Figure 5.2. Histogram showing the distribution of the 13 TNFa 
microsatellite alleles in the colorectal and gastric cancer populations.
Due to the small number of gastric cancer patients formal statistical analysis 
was not possible.
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TNFa Gastrics Colorectals Chi-square P-value
1 0 0.01 0.285 ns
2 0.04 0.08 0.724 ns
3 0.2 0.23 2.267 ns
4 0.04 0.06 0.219 ns
5 0.13 0.04 4.565 0.019
6 0.13 0.09 0.799 ns
7 0.13 0.12 0.016 ns
8 0.04 0.04 0.016 ns
9 0.02 0.02 0.013 ns
10 0.13 0.14 0.04 ns
11 0.09 0.14 0.782 ns
12 0.04 0.02 0.451 ns
13 0 0 0 ns
Table 5.3. Breakdown of the allelic frequencies and associated Chi- 
square values of the 13 TNFa alleles in the colorectal and gastric 
cancer populations. The only significant difference between the two groups 
is the increased frequency of the TNFa5 allele in the gastric cancer 
individuals.
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Figure 5.3. Histogram showing the distribution of the three possible 
LTa Ncol RFLP genotypes in the normal and gastric cancer 
populations. Chi-square analysis shows a significant association between the 
presence of gastric cancer and the B*l/B*2 genotype and a association with 
the absence of gastric cancer and the B*l/B*l genotype.
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Figure 5.4. Histogram showing the distribution of the two possible 
L T a  Ncol RFLP alleles in the normal and gastric cancer 
populations. Chi-square analysis shows no significant association between 
alleles at this locus and the presence or absence of gastric cancer.
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Figure 5.5. Histogram showing the distribution of the three possible 
L T a Ncol RFLP genotypes in the colorectal and gastric cancer 
populations. Chi-square analysis shows a significant difference between 
gastric and colorectal cancer with the frequency of the B*l/B*2 genotype 
being increase in the gastric cancer patients and frequency of the B*2/B*2 
genotype being increased in the colorectal cancer patients.
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Figure 5.6. Histogram showing the distribution of the two possible 
L T a  Ncol RFLP alleles in the colorectal and gastric cancer 
populations. Chi-square analysis shows no significant difference between 
alleles at this locus and gastric or colorectal cancer.
187
Discussion
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Over the last few decades, the results of a number of major studies have provided an 
important insight into the mechanisms involved in the development and progression 
of colorectal adenocarcinomas. Despite such major improvements in the 
understanding of this common disease, the mechanism of treatment and the 
subsequent outcome has changed little in this same period.
The exact nature that genetic factors play in the tumourigenesis of colorectal 
neoplasms is still unclear. However, a common system of genetic changes, 
involving a number of recently identified oncogenes and tumour suppresser genes, 
has been suggested (Fearon, E.R. & Vogelstein, B., 1990). These genetic events, at 
least in part, support the idea of an adenoma-carcinoma sequence in which normal 
colonic mucosa progresses through a non-malignant adenoma stage before 
developing into a malignant adenocarcinoma (see section 1.1.7 and Figure 1.3 of this 
thesis).
Although the picture is becoming clearer, techniques which could facilitate the 
identification of individuals at an elevated risk of developing colorectal 
adenocarcinoma are still few and far between and those which do exist tend only to 
be used experimentally. Section 1 of this thesis describes a number of the biological 
and molecular markers that have been used in the past few years in an attempt to 
identify individuals in the general population who may be at risk of developing this 
malignant disease. Common to all of these markers is the problem associated with 
the stage at which they can detect the presence of abnormalities within the colorectal 
mucosa.
Markers such as the aberrant mucosal crypt cell production rate (Rooney, P.S., et. 
al., 1993) require the detection of areas of change within the colon or rectum that 
can be detected and biopsied by colonoscopy. Other biochemical markers such as 
CEA (Thompson, D.P.M., et. al., 1969) and the mucin-type glycoproteins, such as
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CA19-9 (Koprowski, H., et. al., 1981) can be found at elevated levels in individuals 
with malignant disease, but tend to lack sufficient sensitivity to be clinically useful 
and can often result in false positive and false negative results. Even the standard 
clinical forms of screening rely on the presence of noticeable changes within the 
colon or rectum and thus patients often tend to be presented for surgery too late to 
allow a sufficient cure rate.
The ability to identify individuals who may be at risk of developing colorectal cancer 
due to a genetic predisposition is therefore attractive. It is widely accepted that the 
host immune system is aware of the presence of a malignant lesion and that under 
the correct conditions is capable of mounting an immune response against the 
tumour (for example the work of Rosenberg and colleagues (1988)on the 
augmentation of T-cell cytotoxicity upon pre-treatment with IL-2 for the treatment of 
metastatic melanoma). Why the immune system therefore allows tumours to 
develop still remains a mystery.
Central to the modulation of the immune system is the family of compounds 
commonly termed tumour necrosis factors (TNFs). This family consists of three 
compounds termed TNFa, lymphotoxin-a (LTa) and LTp. The most widely studied 
of these molecules is TNFa and many studies have shown TNFa to be involved in 
the pathogenesis of a number of autoimmune and non-autoimmune diseases; TNF is 
now regarded to play a pivotal role in the inflammatory response.
Levels of TNFa at both the mRNA and the protein level have been examined in a 
number of human solid tumours. Although a substantial amount of data is available 
on the presence of this molecule particularly in breast cancer (Spriggs, D.R., et. al.,
1988), there is very little data with regards to colorectal cancer. Those studies which 
have examined levels of TNFa mRNA and protein report a very low level of TNFa 
within the tumour with the majority of the material being associated with tumour
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associated macrophages (Beissert, S., et al, 1983; Naylor, M.S., et al, 1992). It has 
been suggested that this low level of TNF may be responsible for the 
"desensitisation" of tumour cells to the cytotoxic activity of the tumour associated 
macrophage derived TNFa, however the reason why such a low level of secretion 
should occur is unclear.
Recently a number of polymorphisms have been described within the TNF locus and 
subsequent publications have reported alterations in the ability of cells to produce 
members of the TNF family associated with specific alleles of these polymorphisms 
(Pociot, F., et. a l , 1993a; Wilson, A.G., et. al., 1994a; Turner, D.M., et. al., 1994). 
The data reported in this thesis now suggest a role for these polymorphic markers in 
understanding the development and progression of colorectal adenocarcinoma, 
whilst a small preliminary study also suggests a similar role in gastric 
adenocarcinoma. Although the true function of these markers in the pathology 
which underlies these two malignant diseases still remains unclear, it is possible to 
make a number of comparisons with both other human disease which show 
associations with these markers and also with a number of studies which have 
examined the function of equivalent murine polymorphisms.
There are at least ten TNF associated polymorphisms located within a 12kb region of 
the human MHC class III region on chromosome 6. These polymorphisms can be 
split into two groups. The first group comprises five restriction fragment length 
polymorphisms, designated as the LT-a EcoKl RFLP, the LT-a Nco-I RFLP, the 
-308 TNF-a RFLP, the -238 TNFa RFLP and the AspHl LTa RFLP (Partanen, J. 
and Koskimies, S., 1988; Messer, G., et. al., 1991; Wilson, A.G., et. al. 1992; D' 
Alfonso, S. & Richiardi, P.M., 1994; Ferencik, S., et. al., 1992), and the second 
comprises five di-nucleotide repeat microsatellite polymorphisms designated as the 
TNFa, TNFb, TNFc, TNFd and TNFe polymorphisms (Jongeneel, C.V., et. al., 1991 
and Udalova, I.A., et. al. 1993).
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The data in this thesis shows a comparison of the allelic frequencies of the alleles of 
six of these TNF associated polymorphisms in a group of normal control individuals, 
a group of pathologically proven colorectal cancer patients and a small group of 
gastric cancer patients. Although the methodology used in this study has been 
adapted from a number of publications (see elsewhere in this thesis) it is standard 
practice in adapting and transferring such protocols to include a series of families to 
allow for a validation of the allele calling protocol. No large families were available 
at the beginning of this study however, three partial families have been subsequently 
identified within the control individuals. Although there are small anomalies at the 
TNFc locus for family one and at the TNFd locus for family two and although the 
genotypes are incomplete for a number of the individuals this data provides 
reassurance that the allele calling strategy used in this study produced consistently 
reproducible results in terms of accuracy of allele calling at all of the TNF 
polymorphism loci examined (see section 4.2.3.5).
Further reassurance of accuracy of allele calling is obtained from the examination of 
data from other groups. Four separate studies have reported population frequencies 
for the TNF microsatellite alleles (Nedospasov, S.A., et. al., 1991; Jongeneel, C.V., 
et. al., 1991; Udalova, I.A., et. al., 1993, Crouau-Roy et. al., 1993). Taken together 
these four studies demonstrate the wide variation in allelic frequencies at the TNFa 
and TNFc loci in a total of six different populations. Table 6.1 shows a direct 
comparison with the allelic frequencies of the normal individuals in this study and 
the six published populations. There are a number of other differences between the 
control population in this study and the six reported populations however without the 
raw data from these studies it is impossible to statistically compare the distribution 
of the alleles between the different studies. Crouau-Roy et. al. have, however, 
performed a statistic analysis of the distribution of the TNFa alleles in their four 
populations and report significant differences when these are compared. Although 
the allele frequencies from the normal population in this study do not directly match
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TNFa Normals
Crou
Basque
au-Roy
French
:i993)
Greek Danish
Jongeneel (1991) 
French
Nedospasov (1991) 
Russian
1 0.06 0.116 0.031 0 0.007 0.02 0
2 0.1 0.25 0.208 0.219 0.32 0.215 0.11
3 0.05 0.035 0.031 0.012 0.033 0.034 0
4 0.1 0.045 0.042 0.037 0.1 0.04 0.9
5 0.09 0.036 0.031 0.11 0.067 0.04 0.4
6 0.12 0.071 0.094 0.134 0.14 0.101 0.22
7 0.08 0.17 0.125 0.073 0.04 0.134 0.15
8 0.08 0 0.052 0 0 0.04 0
9 0.08 0.027 0 0.085 0.033 0 0.07
10 0.12 0.107 0.104 0.134 0.093 0.154 0.15
11 0.05 0.089 0.187 0.098 0.147 0.128 0.13
12 0.04 0 0.073 0.012 0.033 0.074 0.02
13 0.03 0.054 0.021 0.085 0.007 0.013 0.02
TNFc
1 0.69 0.596 0.771 0.697 0.706 0.772 0.87
2 0.31 0.404 0.23 0.303 0.294 0.228 0.13
Table 6.1. Comparison of the allelic frequencies at the TNFa and TNFc 
loci of the normol control individuals with 6 published populations. A
number of differences can be seen between the six populations and the 
allelic frequencies of the TNFa and TNFc alleles from this studyand also 
within the six published populations. ‘Crouau-Roy et. al., 1993; 2Jongeneel, 
C.V., et. al., 1991; 3Nedospasov, S.A., et. al., 1991.
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any of the allelic frequencies from either of the other studies there are sufficient 
similarities to provide sufficient reassurance that the allelic frequencies reported in 
this study are correct.
Having identified these differences it is tempting to speculate why these differences 
should occur. It is unfortunate that Crouau-Roy et. al. have not included MHC data 
in their study. The study by Jongeneel et. al. (1991) clearly demonstrates the 
existence of linkage between the TNF polymorphisms and both the MHC class I and 
class II regions. It is therefore almost certain that the differences reported between 
the six different populations, and indeed the normal population used in this study, is 
associated with the MHC background of the populations. Indeed the two 
independent studies of the French population (Jongeneel, C. V., et. a l, 1991 and 
Crouau-Roy, B., et. al., 1993) show very similar frequencies of both the TNFa and 
TNFc alleles, with a few differences at the TNFb locus. Having established that the 
allele calling strategy from this study provides reproducible and comparable results it 
is now possible to further speculate on the exact meaning of the data presented 
within this thesis.
Of the ten TNF associated polymorphism loci, two restriction fragment length 
polymorphisms have gained much attention over the past few years. The LTa Ncol 
RFLP is located within the first intron of the LTa gene and results is a biallelic 
polymorphism resulting in three possible genotypes per individual. Associated with 
this polymorphism is an amino acid substitution at codon 26 of the mature LTa 
protein resulting in a asparagine to a threonine conversion (Messer, G., et. al., 1991). 
Data from a number of groups has now suggested that the genotype at this locus 
correlates with a distinct pattern of TNFa, but not LTa, secretion by stimulated 
monocytes in vitro. In the most recent study (Pociot et. al., 1993a), monocytes from 
individuals homozygous for the common B*2 allele were shown to produce a 
significantly higher amount of TNFa upon LPS-stimulation whilst individuals
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homozygous for the rare B*1 allele showing low levels of secretion and 
heterozygous individuals secreting an intermediate level of TNFa. These results are 
in contrast with earlier results of Messer et. al. (1991) which show no association 
with TNFa secretion in PHA-stimulated PBMCs, but do show a distinct pattern of 
LTa secretion associated with the LTa Ncol RFLP genotype, whilst a study by 
Abraham et. al. (1993) also reports an association with the B*1 allele and high TNF 
a  and LTa production. There are a number of reason why these discrepancies 
should occur and it is probable that the results obtained are dependent on a number 
of factors. These factors would include cell type, stimulus used, type of assay used 
to measure the cytokine and probably more importantly the MHC background of the 
cells.
More recently a polymorphism has been detected within the promotor region of the 
TNFa gene. This polymorphism is located at position -308 relative to the start 
codon of the TNFa gene. Like the LTa Ncol RFLP an number of studies have 
attempted to correlate alleles of this polymorphism with ability to produce TNFa. 
Studies involving a CAT construct reporter system have demonstrated that the rare 
TNF2 allele bearing promotor produces a 6-7 fold increase in reporter activity in the 
Raji B-cell line (Wilson, A.G., et. al., 1994b) although in another study a similar 
CAT construct, but this time in the Jurkat T-cell line, failed to show any difference 
in reporter activity (Brinkman, B.M.N., et. al., 1994).
Given the possible influence of these two polymorphisms on the ability of a cell to 
produce TNFa it was of great interest to examine whether the genetic component of 
colorectal carcinogenesis could include alleles of these two polymorphisms.
However an examination of both the genotype and allelotype frequencies of these 
two polymorphisms in the panel of colorectal cancer and normal individuals failed to 
show any significant association with either specific individual alleles or with 
specific genotypes and the presence of histologically proven colorectal cancer.
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The majority of publications which have described associations with alleles of these 
two RFLPs and either disease or the production of TNFa also showed that these two 
loci form part of a large extended haplotype which covers the MHC class I, class II 
and a number of the class III genes. Since there is no association between the 
presence of colorectal cancer and either alleles or genotypes of the -308 TNFa RFLP 
and the LTa Ncol RFLP individually this would suggest that the low level of TNFa 
seen within colorectal tumour biopsies (Beissert, S., et. a l, 1989) is not genetically 
predisposed by alleles of either of these two genotypes. However, when both of the 
polymorphisms are examined in the form of an extended genotype, there is an under 
representation of the TNFB*1/TNF2 genotype, which should predispose to the 
secretion of low levels of TNFa corresponding to the presence of the rare TNFB*1 
allele but high levels of TNFa corresponding to the presence of the TNF2 allele and 
an over representation of the TNFB*2/TNF2, or high TNFa secretion, genotype. 
These results would therefore suggest that perhaps individuals with colorectal cancer 
are predisposed to secretion of high levels of TNFa and that therefore either TNFa 
is not involved in the initial process of tumourigenesis or that aberrant high 
expression of TNFa may be important in the initial process.
Pei et. al. (1991) have demonstrated the existence of extended MHC haplotypes 
involving polymorphisms of loci of the Class III region including the LTa Ncol 
RFLP. In this study, the authors clearly demonstrate an association between alleles 
of the LTa polymorphism, the HLA-B-associated transcript-3 gene (BAT3) and two 
RFLPs (termed R5A and M20A) located between the HLA-B locus and the TNF 
locus. The authors demonstrate that the extended haplotypes A l, B8, DR3 and A3, 
B7, DR2 both showed a characteristic haplotype profile at the four polymorphisms. 
However when the authors attempted to examine the association between these 
polymorphisms and individual HLA-B or -DR antigens they found that this was 
highly variable in that the alleles associated with B7 or DR2 and B8 or DR3 were 
not the same as those associated with the respective extended haplotypes. This
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would suggest that these RFLPs were defined during the evolution of this part of the 
genome, prior to the selection of the common extended haplotypes. The authors 
suggest that since all of these polymorphisms are closer to HLA-B than they are to 
HLA-DR it is therefore no surprise that certain HLA-B antigens such as B14, B35, 
B44, Bw62, Bw57 and B27 demonstrate significant linkage disequilibrium with one 
or more of the class III polymorphisms. In general these associations were 
independent of HLA-DR. In fact most HLA-DR antigens in this study showed no 
association with any of the class III polymorphisms except for HLA-DR2 which 
showed a strong association with the BAT3 and the R5A polymorphisms and HLA- 
DR3 which shows a strong association with the BAT3, LTa, R5A and M20A 
polymorphisms. The ancestral MHC haplotype 8.1 (Al, B8, BfS, C4AQ0, C4B1, 
DR3) has been shown to include the TNFB*1 allele of the LTa Ncol RFLP 
(Dawkins, R.L., 1989; Abraham, L.J., 1991). A more recent study by Abraham et. a l 
(1993) demonstrated that the TNFa activity of supernatants from lymphoblastoid 
cell lines carrying the 8.1 haplotype was greater than in cell lines homozygous for a 
number of other ancestral haplotypes. The authors also show an association with the 
TNFB*1 allele and the increase in TNFa production which is in conflict with the 
view of Pociot et. al. (1993) who suggest that it is the TNFB*2 allele which is 
associated with high TNFa production. The authors do suggest, however, that since 
the LTa Ncol RFLP is within a non-coding region of the LTa gene that it is perhaps 
either another polymorphism within the TNF locus that is associated with the 
alterations in TNFa secretion or that it is the MHC ancestral haplotype which is 
directly responsible.
It has been demonstrated in RA patients that the HLA-DR antigens play an important 
role in the pathogenesis of this autoimmune disease. A study by Weyand et. al. 
(1992) demonstrated that individuals either homozygous or heterozygous for specific 
HLA-DR alleles display different extra-articular manifestations of the disease. They 
report that homozygosity for the common HLA-DRB 1*0401 was common among
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patients with major organ involvement, whilst combinations of either DRB 1*0401 
with B 1 *0404 or B 1 *0101 was typical in patients with nodular disease. A system 
similar to this may also involve the alleles of the TNF RFLPs. It may not just be the 
presence of the TNFB*2/TNF2 genotype that confers the susceptibility to the 
development of colorectal cancer but rather it may be the way in which the alleles of 
these two loci have come together due to inheritance with themselves and/or with 
other alleles of the TNF polymorphisms and the MHC, that may result in the 
development of the predisposition to the disease.
There are no data in the literature to suggest that the initial development of 
colorectal cancer is associated with a particular MHC haplotype although there are a 
number of studies that report altered expression of both class I and class II antigens 
(see section 1.2.3 of this thesis). A recent study by Shimura and co-workers 
described an association between TNFB*2 homozygosity and the protection from 
the development of lung cancer (Shimura, T., et. al., 1994) and a number of MHC 
haplotypes have been associated with this disease. Of particular interest, Aw 19 and 
B5 are associated with resistance to the progression of bronchogenic carcinoma 
(Rogentine, G.N., et. al., 1977), whilst more recently HLA-DR7 has also been 
suggested to confer resistance to lung cancer (Romano, P.J., et. al., 1991). It is 
probable that the effect on protection from the development of lung cancer is 
conferred by the MHC haplotype of the unaffected individuals rather than being 
independently associated with the LTa Ncol haplotype. Why there is an association 
between extended haplotype and the presence of colorectal cancer is unclear and 
perhaps a similar system exists in colorectal cancer as has been demonstrated in lung 
cancer by Shiumara et. al.(1994). It is possible that there is an as yet undetected 
association between the MHC and the susceptibility of colorectal cancer, and that 
rather than it being an independent association with the classical MHC antigens it is 
with an extended MHC haplotype encompassing the TNF polymorphisms. In order 
to fully establish whether there is an association between the genotypes of the two
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RFLPs and the presence of colorectal cancer a study of the individuals extended 
MHC haplotype and that of their parents would be required. This would enable the 
determination of the inheritance pattern of the alleles of these genotypes and may 
provide a key to the genetic predisposition of non-familial colorectal cancer.
Although there is no data available regarding the MHC genotypes of the colorectal 
cancer individuals limited data is available for the control individuals. The small 
numbers involved do not allow for a formal analysis of association with TNF alleles 
and MHC however this data does at least provide reassurance that the control 
individuals represent a reasonable spread of the expected MHC genotypes in a South 
West of Scotland population.
Until recently polymorphic analysis of the TNF locus has been restricted to the use 
of RFLPs, however recently a panel of five microsatellites has been described within 
this locus ( Jongeneel, C.V., et. al., 1991; Nedospasov, S.A., et. al., 1991; Udalova,
I. A., 1993). Analysis of these more polymorphic microsatellite loci also identifies a 
number of associations with specific alleles and colorectal adenocarcinoma. The 
most polymorphic of the four microsatellites examined is the TNFa microsatellite 
which displays 13 possible alleles. An association with increased allelic frequency 
of the TNFa3 and TNFal 1 alleles is observed in the colorectal cancer patients. 
Conversely TNFal, TNFa5, TNFa9 and TNFal3 all show an association with the 
absence of, or protection from the development of, colorectal cancer. Like the 
RFLPs alleles of a number of the microsatellite polymorphisms have been associated 
with increased or decreased levels of secretion of TNFa. Of the two TNFa 
microsatellite alleles which have been associated with the increase or decrease in 
TNFa production (Pociot et. a l, 1993), namely TNFa2 (high production) and 
TNFa6 (low production), neither of these alleles shows any association with either 
the presence or absence of colorectal cancer in this population suggesting that the 
linkage between these markers and the presence of colorectal cancer may not
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indicate a genetic predisposition to either over or under production of TNFa by 
colorectal cancer individuals.
The TNFc microsatellite has also been implicated in the control of the production of 
TNFa with TNFc2 positive monocytes displaying increased production upon 
stimulation (Pociot et. al., 1993). However no difference is observed between the 
colorectal cancer individuals and the normal controls in terms of the allelotypes of 
the TNFc microsatellite again suggesting a lack of genetic susceptibility to aberrant 
TNFa production.
More recently the TNFd3 allele has been demonstrated to be important in the control 
of TNFa secretion in heart transplant biopsies (Turner et. al., 1994). Analysis of the 
TNFd allelotypes of the normal individuals and the colorectal cancer patients 
demonstrates a difference between the frequency of the TNFd3 allele with the 
highest frequency being observed in the colorectal cancer patients. However like the 
association with LTa RFLP haplotye there is some question regarding the 
association with TNFd3 and high levels of TNFa. This finding has only been 
reported by one group in a small number of individuals who had undergone cardiac 
transplantation and it is possible that, since the individuals were receiving large 
amounts of immunosupressant therapy and were under significant immunological 
stress due to the organ transplant, the data could be influenced by the procedures 
which the patients were undergoing.
To date no associations has been demonstrated between alleles of the TNFe 
polymorphism and the production of TNFa, however analysis of the TNFe 
genotypes of the normal and colorectal cancer individuals demonstrates a significant 
difference between the allelotypes of the two populations. In particular TNFe3 is 
significantly over represented within the colorectal cancer population, whilst TNFe2 
is significantly under represented within this same group. Like the TNFa3 allele,
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these TNFd and TNFe associations could be markers of a linkage with a gene or a 
number of genes within this region that are associated with malignancy.
Why there should be this association with microsatellite alleles is even more unclear 
than for the RFLPs. The vast majority of studies that examine microsatellites use 
them as markers to detect linkage between regions of the genome and specific 
diseases. By performing linkage analysis of this sort it has been possible to identify 
numerous candidate genes important in a large number of human malignant and non- 
malignant diseases. It is therefore perhaps just luck that an association has been 
identified between alleles of the various TNF associated microsatellites and the 
presence of malignant disease. If these data do demonstrate a linkage between this 
region of the genome and colorectal cancer it would be easy to speculate which gene 
or genes within this region may be important in colorectal carcinogenesis since this 
region contains a number of important immunoregulatory genes. This region 
contains amongst other genes the TAP genes which are a family of genes involved in 
the transport of antigens derived from the cytoplasmic protein pool to a pre-golgi 
region where they are incorporated into the MHC class I molecule. Recently a down 
regulation of TAPI has been demonstrated in colorectal carcinomas (Kaklamanis,
L., et. al., 1994). In order to identify which gene or genes are important would 
require a more detailed and larger study and would require more detailed statistical 
analysis. It must also be remembered that the TNFa microsatellite locus is 3.5kb 
away from the LTa gene and that to date there has been no search for a gene 
reported within this region. The sequence between the TNFa and b microsatellite 
loci and the LTa gene has recently been published and it is therefore now open for a 
formal analysis to be performed on this region to determine whether it contains an 
further gene (Iris, F.J.M., et. a l, 1993). Indeed loss of heterozygosity of 
chromosome 6 has been demonstrated in ovarian tumours (Foulkes, W.D., et. al., 
1993) suggesting that there may be a tumour suppressor gene on human 
chromosome 6. Data from the mouse also suggests that there could be a gene
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involved in determining tumour susceptibility within the region of the MHC. A 
recent paper by Fijneman et. al. (1995) suggests that a susceptibility gene for 
alveolar lung tumours in the mouse is located between the HSP70.3 and the G7 
genes within the H2 complex of the mouse although the exact gene has not yet been 
identified.
From this initial study it seems unlikely that the genetic polymorphisms which have 
been demonstrated to affect the control of TNFa production play any part in the 
initial development of colorectal adenocarcinoma. The specific association seen 
with various alleles does however suggest that there is some form of association with 
this region and a susceptibility to colorectal cancer.
It is also interesting to note the similar results observed when the TNFa genotypes 
are examined in a group of gastric adenocarcinoma patients. If the effect of specific 
alleles of the TNF polymorphisms are to be seen as markers for the development of 
adenocarcinomas in general then it would be expected that similar associations to 
those observed in colorectal adenocarcinoma would be observed in gastric 
adenocarcinomas. And indeed this is the case. In particular, again the TNFa3 allele 
shows a strong association with the presence of cancer. This would suggest that the 
TNFa3 microsatellite is a marker for a common event in the development of 
adenocarcinomas. Unlike the colorectal cancer group, however, the gastric cancer 
group also shows an independent association with genotypes of the LTa Ncol RFLP. 
The LTa Ncol RFLP association is with the heterozygous genotype and when the 
frequency of the individual alleles is examine the association is lost. This would 
suggest that the association between the LTa Ncol RFLP locus and gastric cancer is 
related to the combination of the two alleles and therefore possibly due to some form 
of inheritance pattern possibly associated with the MHC, rather than a function of 
these alleles on TNFa production.
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In contrast to the idea that these microsatellites are just markers for genes associated 
with disease susceptibility there are a number of studies that have identified 
associations between specific alleles of microsatellites and gene function. If these 
polymorphisms are functional in a manner which results in an alteration of the 
secretion of TNFa, LTa and/or LT(3, then it is easy to see a number of ways in 
which they could be involved in tumourigenesis. In the mouse a polymorphism 
immediately upstream of the TATA box within in the 5' regulatory region of TNFa 
has been shown to correlate with resistance to the deleterious effects of UVB light 
on cutaneous immunity (Vincek, V., et. al., 1993). In another study, Jongeneel and 
co-workers (1990) report the identification of an allele from a microsatellite within 
the TNFa promotor region of mice which is unique to the NZW strain of mice. 
These mice are defective in their ability to secrete TNF in response to LPS and when 
crossed with NZB mice are seen to develop a lupus-like glomerulonephritis which is 
curable on treatment with TNFa. This same microsatellite also shows an allele 
specific association with murine resistance to toxoplasmic encephalitis and has been 
shown to correlate with levels of TNFa mRNA in the brain of infected animals 
(Freund, Y.R., et. al., 1992). If the effects of the TNF microsatellite polymorphisms 
observed in the mouse can be extrapolated to the human system then it is entirely 
proper to suggest that there is a relationship between the microsatellite 
polymorphisms and production of TNFs and the susceptibility to colorectal cancer.
In humans an allele-specific association has been demonstrated between a 
microsatellite located approximately 100 bp down stream of the H-ras-1 gene, and 
the presence of four common human cancers (breast, urinary bladder, acute 
leukaemia and colorectal; Krontiris, T.G. et. al., 1993). The authors of this paper 
propose two possible reason for this association. The first proposal is that the rare 
alleles of this microsatellite are in linkage with a gene, possibly H-ras itself, which 
is involved in carcinogenesis. The second explanation they suggest is that the length 
of this microsatellite may alter the transcriptional control of genes within the vicinity
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of this locus. In two previous papers it has been demonstrated that this region binds 
at least four members of the re//NF-kB-family of transcriptional regulatory factors 
(Trepicchio, W.L., et. al., 1992) and that an allele specific alteration in the 
transcriptional activity of this region is also present. A microsatellite within the 
intron which separates the diversity and joining segment of the human 
immunoglobulin heavy-chain has also been shown to bind a transcription regulation 
factor which, this time, seems to be a member of the mycHLH family of proteins 
(Trepicchio, W.L., et. al., 1993).
TNFa is intimately involved in a wide number of immune functions and TNFa is 
now thought to be one of the central immunoregulators in autoimmune diseases such 
as RA where it can be found in excessive amounts in both the synovial fluid and 
membrane (Chu, C.Q., et. al., 1991). (Section 1.3 of this thesis provides an 
introduction of the role of TNF in human malignancy.) As previously stated, a 
number of studies have suggested that although TNFa can be detected in colorectal 
tumour biopsies, this is at an insufficient level to induce an immune response 
(Beissert, S., et. al., 1989; Naylor, M.S., et. al., 1992) and that low levels of TNFa 
production may result in a desensitisation of the tumour cells to TNFa (Spriggs,
D.R., et. al., 1987). Given that the true level of TNFa production in the tumours of 
the colorectal cancer patients in this study has not yet been defined it is impossible to 
determine whether these polymorphisms are associated with either over or under 
production of TNFa and whether there is any pathological function of these 
genotypes. In order to determine if this hypothesis is correct, some form of 
quantitative estimation of the TNFa protein content of colorectal tumours would 
have to be performed and an analysis of the correlation between this and RFLP and 
microsatellite genotypes would need to be performed. A study such as this would 
require relatively small numbers in order to determine the correlation between the 
TNF RFLPs and the level of TNFa, however this would require significantly higher
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numbers to fully determine whether the TNF microsatellites correlate with TNFa 
production.
Even if the TNF polymorphisms do not produce any change in the production of 
TNFa, LTa or LTp then it is still possible that they may have some influence on the 
function of the MHC. Although, to date, there has been no description of 
susceptibility to colorectal adenocarcinoma being associated with specific MHC 
haplotypes, it may be possible that the inclusion of the TNF polymorphisms within 
such a study would enable a link to be identified.
Given the role of the MHC in antigen presentation it is possible to suggest that the 
presence of extended haplotype spanning the entire length of the MHC could play an 
important role in antigen presentation. It is clear that specific HLA haplotypes can 
function differently in different individuals. For example, not all individuals who are 
HLA-DR4 antigen positive will develop rheumatoid arthritis although 70-80% of 
RA patients express this antigen (Stastny, P., 1978).
The work of a number of groups on the role of TNF polymorphisms within 
autoimmune diseases points to a number of important MHC-dependent and MHC- 
independent associations with alleles of these polymorphisms and the presence of 
autoimmune disease (See section 1.3.5). Autoimmune diseases are characterised by 
the presence of a specific immunological reaction. The site of the autoimmune 
reaction is normally characterised by an over expression of MHC antigens, 
particularly class II antigens. The expression of these antigens on cells which would 
generally not express them at such high levels has led to the hypothesis that the 
aberrant expression of auto-antigens on the surface of cells due to the up regulation 
of Class II antigen expression significantly contributes to the initial and continual 
activation of auto-antigen-reactive T cells (Feldmann, M., 1989). These T-cells, in 
turn, can induce the production of inflammatory cytokines such as TNFa and IL-4
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which are thought to be responsible for the pathogenesis of the autoimmune disease 
and also IFNy, which can induce the expression of class II antigens on the surface of 
a number of cell types. It is widely accepted that IFNy can synergise with TNFa to 
cause upregulation of MHC antigens on a number of other cell types.
The pathogenesis of an autoimmune reaction can be seen to be similar to the 
pathogenesis observed in tumours. It is possible to identify an ongoing 
inflammatory response characterised by an infiltration of cells of the immune system 
within a tumour and it is possible to identify similar mediators, such as TNFa and 
IFNy, which are also observed at the site of an autoimmune reaction. Like the cells 
at the site of an autoimmune reaction, tumour cells express a number of different 
antigens on their surface, a number of which are presented in the context of the class 
I and class II molecules. Any genetic variation resulting in a difference in the ability 
of a persons cells to process and express these antigens within the MHC could result 
in the immune system failing to see these antigens and therefore failing to initiate an 
immune response against the target tumour cell. It has been clearly documented that 
there is altered MHC expression on colorectal tumour cells (see section 1.2.3 of this 
thesis) and therefore it is possible that any alteration in MHC expression influenced 
by TNF polymorphisms may facilitate in the evasion of malignant or pre-malignant 
cells in the host.
The data presented within this thesis clearly define an association between specific 
alleles of the TNF polymorphisms and the development and progression of 
colorectal adenocarcinoma and although it seems unlikely that the effects seen at the 
TNF polymorphisms in association to disease development are associated with the 
control of TNF production it was still of interest to determine whether these 
polymorphic markers could be associated with either disease severity or disease 
progression. Clinical data, in the form of pathological reports, was obtained for 81 
of the 100 colorectal cancer patients and was used to determine Dukes' staging and
206
metastatic status at time of initial surgery. Dukes' staging was obtained for a further 
11 patients from various other clinical records. The clinical data from the follow up 
clinic of Prof. C.S. McArdle was used to determine the time point at which patients 
either developed metastatic disease or local recurrence and also to identify individual 
patients who had survived over two years free from recurrent disease from the time 
of their initial surgery.
Dukes' staging still represents the most widely used form of clinical grading of 
colorectal malignancies. It provides a system for the classification of tumours into 
four broad groups dependant on the degree of bowel wall infiltration, lymphnode 
involvement and metastatic spread. Since Dukes' staging is essentially a measure of 
the aggressiveness of the tumour then it is possible that a patient's ability to produce 
TNFa could relate to the aggressiveness of their disease and therefore one would 
expect the less aggressive Dukes' A patients to be genetically predisposed to produce 
more TNFa than the more aggressive Dukes' stage B, C or d tumour bearing 
patients. Given this hypothesis it was considered important to ascertain if alleles of 
any of the TNF polymorphisms could be correlated with increased or decreased 
severity of the primary disease.
Analysis of the -308 TNFa RFLP shows a significant association between 
homozygosity for the TNF2 allele and the presence of a Dukes' C tumour however 
no further differences were observed. As previously stated the TNF2 allele has been 
reported to result in an increase in the activity of the promotor region of TNFa by up 
to seven fold, however this work is contradicted. Due to the small number of 
samples within the four Dukes' stage groups it is hard, though still tempting, to 
postulate that Dukes' C tumours could be secreting more TNFa than the other groups 
however a larger cohort of patients would be required to test this hypothesis.
Analysis of the LTa Ncol RFLP genotypes of the same patients failed to show any 
significant difference between the two groups. Examination of the extended
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genotypes of these same patients fails to demonstrate that all of the Dukes' A 
individuals are positive for the common TNF1 and TNFB*2 alleles, however due to 
the small number of Dukes' A patients found in this study it is impossible to suggest 
whether this finding has any real clinical significance. It is therefore impossible to 
concluded that predisposition to either over or under production of TNFa by either 
of the two RFLPs is involved in the aggressiveness of primary colorectal 
adenocarcinoma as determined by Dukes' staging and therefore the hypothesis, in 
terms of the TNF RFLPs, remains unproven.
Analysis of the microsatellite polymorphisms in the Dukes' staged colorectal cancer 
patients shows a clear association with a number of the TNF microsatellite alleles 
and the staging of colorectal adenocarcinoma. The TNFa3, which showed such a 
high frequency in the colorectal cancer patients than compared to the normal 
individuals, also shows an association with Dukes' staging. When compared to the 
other three stages combined, TNFa3 shows an over representation in the Dukes' 
stage A individuals. TNFa8 also shows an association with Dukes' staging in that its 
is found at a higher frequency in the Dukes' stage d, i.e. metastatic tumours. Again 
due to the low numbers of Dukes' staged patients in this study it is impossible to 
predict whether this TNFa3 or the TNFa8 association has any clinical relevance.
Analysis of the other three microsatellite loci fails to demonstrate any further 
significant differences between the Dukes' stage groups and alleles of these loci. 
Although a number of smaller differences are observed at these loci it is difficult to 
predict their significance due to the small number of individuals within each group.
Although there has been much improvement in terms of the treatment of primary 
colorectal adenocarcinoma, generally in terms of diagnosis, surgery and patients 
management the problems associated with secondary disease are still not fully 
resolved. Over 49% of individuals with colorectal cancer will die within two years
208
of initial diagnosis and of these almost 90% will die either from disseminated 
metastatic disease or from local recurrent disease. It can thus been clearly seen that 
this form of secondary disease still represents a major problem for clinicians. Why 
metastatic disease should occur in one patient and not in the other still remains a 
mystery. A number of genes have been suggested to be important in the metastatic 
process such as nm23 (Barnes, R., et. a l , 1991). However it still remains unclear if 
these markers will allow the separation of tumours which will metastasis from those 
which will not.
The data suggest a role for the TNF polymorphisms in the process of metastasis. If 
the polymorphisms are associated with functional changes in the ability to produce 
TNFa then it is possible that an over production of TNFa at either the site of the 
primary tumour or the secondary tumour could facilitate crossing of the endothelium 
by tumour cells.
Having demonstrated associations between alleles of the TNF polymorphisms and 
both the primary development, and possibly the aggressiveness as defined by Dukes' 
staging, of colorectal adenocarcinomas, it was logical to examine whether alleles of 
these polymorphisms could also be used to identify, retrospectively, those cancer 
patients who would develop secondary disease from primary colorectal cancer. 
Development of secondary disease was determined following extensive clinical 
follow up of all of the patients treated by Prof. C.S.M (GRI). Patients were also 
identified who had survived disease free two years from their initial surgery for 
primary disease and these were used as a control population.
Analysis of the two RFLPs demonstrates a difference between the two populations at 
both loci, however statistically significant differences are only observed at the LTa 
Ncol RFLP locus. Analysis of both genotypes and allelotypes of the -308 TNFa 
RFLP shows a slight difference between the frequency of the TNF2/2 genotype, with
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this, homozygous genotype appearing more frequently in the metastatic disease 
group than compared to the non-metastatic group, however this difference is not 
statistically significant.
Analysis of the LTa Ncol RFLP locus demonstrates an association with the 
TNFB*1/B*2 genotype and the presence of secondary disease, whilst there is a 
decrease in the frequency of the TNFB*2/B*2 genotype in the same individuals. If 
the data suggesting that the TNFB*2/B*2 genotype is associated with increased 
ability to secrete TNFa is true then this result does not support the hypothesis that 
TNFa is important in metastasis. Analysis of the allelic usage in these patients 
demonstrates that, as expected from the genotype data, the TNFB*1 allele is over 
represented in the secondary disease population, and the TNFB*2 allele is under 
represented in this same group. There is some evidence to suggest that metastatic 
cells express less MHC antigen on their surface than non-metastatic cells and that 
this allows the cell to evade the host immune system, particularly NK cells 
(Goodrich, K.H., et. al., 1993). TNFa is known to be able to induce MHC 
expression on the surface of a number of cell types, therefore a genetic 
predisposition to under produce TNFa may result in a decreased expression of MHC 
antigens on the surface of metastatic tumour cells there by facilitating their evasion 
of the host immune system.
The clinical relevance of these associations has yet to be ascertained and the true 
relevance of this finding can only be ascertained fully in a large scale, prospective, 
clinical trial carried out over a period of at least five years. This length of time 
would allow for the accumulation of a significant number of individuals and for 
these individuals to be followed up from time of initial diagnosis and treatment for a 
minimum period of two years. This data would then allow for an analysis of the 
potential clinical usefulness of this diagnostic marker in the determination of the
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increased risk in of developing secondary disease in individuals with colorectal 
cancer.
It is therefore clear that polymorphisms within this region of the genome play an 
important part in the development of colorectal adenocarcinoma and progression of 
colorectal adenocarcinoma. The method by which this occurs at each stage still 
remains unclear but may be due to three possible mechanisms. The first mechanism 
is that there is a gene close to this region of the genome which is intimately involved 
in the process of carcinogenesis and that the phenomenon observed within this study 
is simple linkage disequilibrium. This first hypothesis would fit with the 
relationship between the TNFa3 allele and the presence of colorectal cancer, where it 
is hard to envisage such a central role for TNFa. The second mechanism is that 
these markers form part of a very large extended haplotype encompassing the whole 
of the MHC. These polymorphisms are not functional by themselves but instead 
when combined with a number of other polymorphisms are part of a large 
polymorphic region which is involved in altering the specificity of an individuals 
MHC repertoire. This hypothesis would again fit with the association with 
development of colorectal cancer in that it could be envisaged that altered expression 
of MHC antigens would allow a tumour cell to evade the immune system. This 
same hypothesis would also fit with the relationship to progression of colorectal 
cancer, where an ability to evade the immune response would give a tumour an 
advantage at both the primary and secondary sites. The third, and most attractive 
mechanism, is that polymorphisms within this region are involved in the 
transcriptional control of a gene or a number of genes, possibly TNF itself, and that 
the function of these transcriptional regulatory domains are affected due to 
differences in the size of the microsatellites, however it is still controversial as to 
whether the TNF RFLPs play a role in the control of TNFa, LTa or LTp secretion 
and there is even less evidence to support a role for the microsatellite 
polymorphisms in the control of TNF gene activity.
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It is clear that a great deal of further analysis is required to fully explain the 
association between this region of the genome and the development and progression 
of colorectal adenocarcinoma. Studies involving larger numbers of individuals will 
be the key to answering most of the unanswered questions posed by this study and 
thus it remains vital to continue to perform the basic allele association studies whilst 
in parallel endeavouring to ascertain whether these polymorphisms are functional or 
whether they just point to the presence of a tumour associated gene within the region 
of the MHC.
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Future Studies
Given the controversy over the role of the TNF RFLPs and the microsatellites in the 
control of TNF production it is now vital that a study to determine the exact 
relationship that the polymorphisms have on in vivo TNF production is performed.
It is after all the role of these markers in vivo that is important and not their role in 
the artificial tissue culture system that will influence the way that these markers are 
utilised. This study could take a number of forms, including the use of 
immunohistochemical or in situ hybridisation analysis or it could be performed on 
tumour derived cells including T-cells, macrophages and the tumour cells 
themselves.
It would also be important to examine the MHC background of the study 
individuals. Since it is clear that these polymorphisms are intimately associated with 
the MHC then it may prove fruitful to examine whether there is any susceptibility to 
colorectal cancer associated with the MHC. Studies of familial colorectal cancer 
may also provide some help in determining the role of these markers. Since it has 
been demonstrated that the mere presence of a particular allele, particularly of the 
RFLPs, may not be sufficient to infer the susceptibility then these alleles may be 
functioning in a recessive, dominant or codominant manner dependent on the 
particular marker that you look at.
Given the relative ease with which promotor function can be examined by using 
CAT reporter systems it may also be advisable to study the effects of the various 
microsatellites on the promotor activity of the various TNF genes. This would 
require an extensive study in which all of the permutations of TNFa, TNFb, TNFc 
and TNFd alleles would have to be examined to look for both dependent and 
independent associations.
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There are of course five microsatellites within the TNF locus. This study does not 
report any analysis of the TNFb polymorphism. This was due to technical 
difficulties in amplifying the TNFb region. It is therefore imperative that the data be 
completed by performing an analysis of this locus and it may be advisable to use the 
technique of Nedospasov et. a l (1991) where the TNFa and b loci are co-amplified 
and the TNFb haplotye calculated from the size of the PCR product given that the 
corresponding TNFa allele size is already known.
The whole area of disease susceptibility is very complicated and unfortunately the 
role of the TNF polymorphisms in this larger picture is even less clear. It will only 
be with careful analysis and a larger study that any ground will be gain into trying to 
understanding the complex nature of this problem.
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